Geroscience and Endocrine Aging: Targeting Hormonal Pathways to Extend Healthspan

Abstract

This article explores the geroscience approach to understanding and intervening in endocrine aging. It examines the foundational biology linking hormonal pathways to the aging process, discusses methodological advances in research and drug development, addresses key challenges in the field including regulatory and biomarker gaps, and evaluates the current landscape of therapeutic validation. Aimed at researchers and drug development professionals, this review synthesizes how targeting endocrine mechanisms—from glucagon signaling to reproductive aging—can delay age-related decline and offers a roadmap for translating these discoveries into clinical practice.

The Biology of Endocrine Aging: From Core Hallmarks to Hormonal Regulators

Geroscience is an emerging interdisciplinary field that seeks to understand the biological mechanisms of aging and how they contribute to the development of age-related diseases [1]. This field operates on a fundamental premise: aging itself is the primary risk factor for most chronic conditions that burden the elderly population, including cardiovascular diseases, neurodegenerative disorders, diabetes, and cancer [2] [1]. By targeting the underlying biological processes of aging, geroscience aims to develop interventions that can extend healthspan—the period of life spent in good health—rather than merely extending lifespan [2].

The conceptual foundation of geroscience posits that since aging underlies most chronic diseases and debilitating states, interventions that slow the aging process could simultaneously prevent, delay, or mitigate multiple age-related conditions [2] [1]. This approach represents a paradigm shift from treating individual diseases to targeting their shared root cause. The field has gained significant momentum through the creation of specialized research centers, expanded funding opportunities, and growing interest from biotechnology companies developing potential anti-aging therapies [1].

The Hallmarks of Aging: A Framework for Understanding

The hallmarks of aging provide a conceptual framework for understanding the complex biological processes that drive aging. First introduced in 2013 and updated in 2023, these hallmarks represent interconnected cellular and molecular mechanisms that collectively contribute to age-related functional decline [3] [1]. These hallmarks can be categorized into three primary groups based on their roles in the aging process, each offering distinct targets for therapeutic intervention as summarized in Table 1.

Table 1: Hallmarks of Aging and Corresponding Therapeutic Strategies

Category	Hallmark	Key Features	Therapeutic Strategies
Primary Hallmarks	Genomic Instability	Accumulation of DNA damage, nuclear architecture alterations, mitochondrial DNA mutations [3] [4]	NAD+ precursors (e.g., NMN), DNA repair enhancers [3]
	Telomere Attrition	Shortening of protective chromosome ends [3]	Telomerase gene therapy [3]
	Epigenetic Alterations	Changes in DNA methylation, histone modification [3]	Partial reprogramming with Yamanaka factors [3]
	Loss of Proteostasis	Impaired protein folding, aggregation, degradation [3]	Autophagy enhancers (e.g., rapamycin) [3]
Antagonistic Hallmarks	Deregulated Nutrient Sensing	Dysfunctional mTOR, insulin/IGF-1 signaling [3]	Caloric restriction mimetics (e.g., metformin, rapamycin) [2] [3]
	Mitochondrial Dysfunction	Declining energy production, increased ROS [3] [4]	Mitochondrial antioxidants, mitophagy inducers [3]
	Cellular Senescence	Irreversible cell cycle arrest, SASP secretion [2] [3]	Senolytics (e.g., dasatinib + quercetin) [2] [3]
Integrative Hallmarks	Stem Cell Exhaustion	Depleted regenerative capacity [3] [4]	Stem cell therapy, regenerative medicine [3]
	Altered Intercellular Communication	Chronic inflammation (inflammaging), disrupted signaling [3]	Senolytics, plasma exchange, anti-inflammatory treatments [3] [4]

The primary hallmarks represent the fundamental forms of cellular damage that initiate the aging process, including genomic instability, telomere attrition, epigenetic alterations, and loss of proteostasis [3]. These mechanisms collectively contribute to the accumulation of molecular damage over time, driving functional decline. The antagonistic hallmarks—including deregulated nutrient sensing, mitochondrial dysfunction, and cellular senescence—are compensatory responses that initially serve protective functions but become harmful when chronically activated [3]. Finally, the integrative hallmarks—stem cell exhaustion and altered intercellular communication—emerge as consequences of accumulated damage and failed compensatory mechanisms, ultimately driving systemic functional decline [3].

Figure 1: The Hierarchical Relationship Between Hallmarks of Aging. The diagram illustrates how primary hallmarks (fundamental damage) trigger antagonistic hallmarks (compensatory responses), which ultimately lead to integrative hallmarks (systemic consequences) that drive functional decline.

Geroscience and Endocrine Aging

The endocrine system undergoes significant changes during aging, with profound implications for overall health and disease susceptibility. Hormonal changes affect multiple physiological processes, including metabolism, body composition, and tissue function [5] [6]. Research has revealed that the skin, as the largest organ, serves not only as a target for various hormones but also as a significant site of hormone production, with implications for visible signs of aging such as wrinkles and hair graying [7].

Endocrine aging involves complex alterations across multiple axes. The hypothalamic-pituitary axis shows changing secretory patterns and altered sensitivity to feedback mechanisms with advancing age [5]. Glucose homeostasis becomes increasingly dysregulated, contributing to metabolic disorders [5]. Concurrently, changes in body composition occur, including loss of bone and muscle mass coupled with increased fat accumulation [5]. These endocrine alterations are challenging to disentangle from other age-associated factors such as chronic diseases, inflammation, and nutritional status, all of which independently affect endocrine function [5].

The traditional approach of hormone replacement therapy to counteract age-related hormonal declines has yielded mixed results, with some interventions causing significant adverse effects [5]. This has led to a more nuanced understanding that some hormonal changes may represent beneficial adaptations to aging rather than simple deficiencies [5]. Current research focuses on identifying specific hormonal pathways that can be targeted to promote healthy aging without disrupting physiological balance.

Therapeutic Strategies and Interventions

Geroscience has catalyzed the development of numerous therapeutic strategies targeting fundamental aging processes. These interventions aim to delay, prevent, or reverse multiple age-related conditions simultaneously by addressing their shared biological underpinnings.

Senotherapeutics

Cellular senescence represents a key therapeutic target in aging. Senescent cells accumulate with age and contribute to tissue dysfunction through the senescence-associated secretory phenotype (SASP), which involves the secretion of proinflammatory cytokines, chemokines, and extracellular matrix-degrading proteins [2]. Senotherapeutics encompass two main approaches: senolytics that selectively eliminate senescent cells, and senomorphics that suppress the SASP without killing senescent cells [2] [3].

Notable senolytic strategies include the combination of dasatinib and quercetin, which has shown promise in reducing senescent cell burden in preclinical models [3]. Innovative approaches include vaccination against senescence-associated antigens. For instance, vaccines targeting CD153 (a marker of senescent CD4+ T cells in visceral adipose tissue) and GPNMB (a transmembrane protein enriched in senescent vascular cells) have demonstrated efficacy in reducing senescent cell burden, improving metabolic function, and extending healthspan in mouse models [3].

Metabolic Pathway Modulators

Deregulated nutrient sensing represents another promising target. The mechanistic target of rapamycin (mTOR) pathway has been extensively studied, with inhibition extending lifespan in various animal models [2]. Caloric restriction mimetics such as metformin and rapamycin modulate these pathways, mimicking the beneficial effects of dietary restriction without requiring reduced food intake [2] [3].

Metformin, initially developed for diabetes management, has demonstrated broad effects on various age-related diseases in clinical studies, including benefits in non-diabetic individuals [1]. In non-human primates, metformin has been shown to slow down systemic and brain aging, supporting its potential as a gerotherapeutic intervention [1].

Regenerative and Advanced Interventions

Emerging regenerative approaches target stem cell exhaustion and tissue degeneration. Stem cell therapy aims to replenish the depleted regenerative capacity of aging tissues [3]. Heterochronic parabiosis (connecting the circulatory systems of young and old animals) and plasma exchange studies have demonstrated that youthful systemic factors can rejuvenate aged tissues, suggesting potential therapeutic applications [3].

Advanced interventions include epigenetic reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) to reverse age-related epigenetic changes [3]. While this approach shows remarkable potential for reversing cellular aging, challenges remain in achieving controlled, transient reprogramming that rejuvenates tissues without risking tumorigenesis [3].

Table 2: Key Research Reagents and Their Applications in Geroscience

Reagent Category	Specific Examples	Primary Function	Research Applications
Senolytics	Dasatinib + Quercetin, Fisetin	Selective elimination of senescent cells [3]	Reducing senescent cell burden in aged tissues, improving physical function [3]
SASP Modulators	NF-κB inhibitors, mTOR inhibitors	Suppression of senescence-associated secretory phenotype [2]	Mitigating chronic inflammation, tissue dysfunction [2]
Metabolic Modulators	Metformin, Rapamycin, NAD+ precursors (NMN, NR)	Modulation of nutrient-sensing pathways, enhancement of mitochondrial function [2] [3]	Extending healthspan, improving metabolic parameters [2] [3]
Epigenetic Modulators	Yamanaka factors (Oct4, Sox2, Klf4, c-Myc)	Partial epigenetic reprogramming [3]	Reversing age-related epigenetic changes, restoring cellular function [3]
Hormonal Agents	Topical retinoids, Melatonin, Estrogen	Regulation of hormone-sensitive aging pathways [7]	Studying endocrine aging, skin aging, hair graying [7]
Gene Editing Tools	CRISPR/Cas9 systems, Telomerase gene therapy	Targeted manipulation of aging-related genes [3]	Investigating specific aging mechanisms, potential therapeutic applications [3]

Experimental Approaches and Methodologies

Geroscience research employs diverse methodological approaches to investigate aging mechanisms and evaluate potential interventions. Standardized experimental protocols are essential for generating reproducible, comparable data across studies.

Assessing Cellular Senescence

Multiple complementary methods are used to identify and quantify senescent cells in tissues and cell cultures. The Senescence-Associated β-Galactosidase (SA-β-Gal) assay represents the most widely used histochemical marker, detecting increased lysosomal β-galactosidase activity at pH 6.0 [2]. This method can be combined with immunohistochemical staining for established senescence markers such as p16INK4a and p21CIP1, which are cyclin-dependent kinase inhibitors that mediate cell cycle arrest in senescent cells [2].

The senescence-associated secretory phenotype (SASP) can be characterized by measuring the secretion of proinflammatory factors including IL-6, IL-1β, TNF-α, and various matrix metalloproteinases using ELISA or multiplex immunoassays [2]. DNA damage foci, indicative of persistent DNA damage response activation, can be visualized through immunofluorescence staining for γH2AX and 53BP1 [2]. More comprehensive senescent cell characterization can be achieved through flow cytometry using antibodies against surface markers such as CD153 for senescent T cells and other senescence-associated antigens [3].

Figure 2: Experimental Workflow for Cellular Senescence Research. The diagram outlines the process from senescence induction through various detection methods to therapeutic testing applications.

Genetic and Molecular Analyses

Genetic approaches in geroscience include the identification and characterization of "gerogenes" (genes that accelerate aging when activated) and "gerosuppressors" (genes that slow aging when active) [1]. This conceptual framework, analogous to oncogenes and tumor suppressors in cancer biology, enables systematic investigation of genetic influences on aging.

Genomic instability can be assessed through quantification of DNA damage markers, including DNA double-strand breaks, using comet assays or γH2AX foci quantification [4]. Telomere length measurements can be performed using qPCR, Southern blot, or fluorescence in situ hybridization (FISH) techniques [3]. Epigenetic aging clocks, based on DNA methylation patterns, provide powerful tools for assessing biological age [3]. Mitochondrial function can be evaluated through measurements of oxygen consumption rates, ATP production, mitochondrial membrane potential, and reactive oxygen species (ROS) production [3] [4].

Advanced omics technologies—including genomics, epigenomics, transcriptomics, proteomics, and metabolomics—enable comprehensive characterization of aging processes [1]. Integration of these datasets through bioinformatics and artificial intelligence approaches facilitates the development of multi-modal biomarkers of aging and personalized intervention strategies [1].

Future Directions and Precision Geromedicine

The future of geroscience lies in the development of precision geromedicine, which aims to tailor interventions to individual aging trajectories based on genetic profile, multi-omics biomarkers, clinical parameters, and environmental exposures [1]. This approach recognizes the heterogeneity of aging processes among individuals and seeks to optimize healthspan through personalized interventions.

Major challenges remain in translating geroscience discoveries into clinical applications. Aging is not currently classified as a disease by regulatory agencies, complicating the development and approval of anti-aging interventions [1]. Most therapeutic development therefore focuses on specific age-related diseases, with the understanding that targeting fundamental aging processes may provide benefits across multiple conditions [1].

The World Health Organization's International Classification of Diseases (ICD-11) includes "aging-associated decline in intrinsic capacity" as a disease category, defining intrinsic capacity as "the composite of all the physical and mental capacities that an individual can draw on at any point in time" [1]. This classification provides a framework for developing interventions aimed at maintaining, optimizing, or recovering functional capacities in older adults.

Future research directions include the development of standardized biomarkers of aging, rigorous clinical trials of promising interventions, establishment of regulatory pathways for gerotherapeutic approval, and implementation of personalized aging management strategies based on comprehensive molecular profiling [1]. As geroscience continues to evolve, it holds the potential to transform healthcare by shifting the focus from treating individual age-related diseases to targeting the underlying aging process itself, thereby extending healthspan and improving quality of life in later years.

Aging represents the most significant risk factor for a spectrum of chronic diseases, with the endocrine system playing a pivotal role in coordinating physiological decline across organ systems. This whitepaper examines three interconnected endocrine hallmarks of aging—deregulated nutrient sensing, hormonal shifts, and cellular senescence—through the lens of geroscience. We synthesize recent research elucidating the molecular mechanisms through which these processes drive systemic aging, focusing on endocrine-exocrine communication pathways, proteomic alterations, and metabolic dysregulation. The analysis incorporates cutting-edge experimental models and biomarker technologies that are reshaping therapeutic development. For researchers and drug development professionals, this review provides a framework for targeting fundamental aging mechanisms to extend human healthspan through endocrine-focused interventions.

The geroscience hypothesis posits that targeting fundamental aging processes can delay the onset and progression of multiple chronic diseases simultaneously. Within this framework, the endocrine system serves as both a regulator and target of aging, coordinating intercellular communication across the organism's lifespan. Aging is characterized by a progressive decline in physiological integrity, diminished homeostatic capacity, and heightened susceptibility to chronic disease [8]. While chronological age inadequately captures an individual's functional state, biological age reflects the cumulative molecular and cellular damage that correlates with functional outcomes and mortality risk [8].

Endocrine aging encompasses three primary hallmarks: (1) deregulated nutrient sensing, involving evolutionarily conserved pathways that link metabolic status to longevity; (2) hormonal shifts, including alterations in circulating levels and tissue sensitivity to key hormones; and (3) cellular senescence, characterized by the accumulation of non-dividing, inflammatory cells with aging, including within endocrine tissues [9]. These hallmarks are not isolated phenomena but exist within a complex network of interacting mechanisms that accelerate systemic functional decline. Understanding their interplay provides unprecedented opportunities for therapeutic interventions aimed at extending healthspan—the period of life spent in good health [10].

Deregulated Nutrient Sensing in Endocrine Aging

Key Nutrient-Sensing Pathways

Nutrient-sensing pathways represent the molecular link between nutritional status, metabolic regulation, and aging. These conserved pathways monitor energy and nutrient availability, coordinating growth, reproduction, and maintenance functions [9]. The primary pathways include:

Table 1: Key Nutrient-Sensing Pathways in Aging

Pathway	Primary Components	Function in Youth	Dysregulation in Aging	Associated Age-Related Diseases
Insulin/IGF-1 Signaling	Insulin receptor, IGF-1 receptor, IRS proteins	Promotes growth and anabolism in nutrient-rich conditions	Chronic activation despite declining nutrient sensing	Type 2 diabetes, obesity, cardiovascular disease [9]
mTOR Signaling	mTORC1, mTORC2 complexes	Regulates cell growth, proliferation, protein synthesis	Hyperactivation contributes to cellular senescence	Metabolic syndrome, cancer, neurodegenerative conditions [11]
AMPK Signaling	AMPK enzyme complex	Energy sensor activated by low ATP; promotes catabolism	Declining activity reduces autophagy and mitochondrial biogenesis	Insulin resistance, sarcopenia, cardiovascular dysfunction [9]
Sirtuin Pathway	SIRT1-SIRT7 (NAD+-dependent deacylases)	Links nutrient status to epigenetic regulation, stress resistance	Declining NAD+ levels reduce sirtuin activity	Metabolic diseases, neurodegenaration, inflammatory conditions [9]

Experimental Models for Nutrient Sensing Research

Investigating nutrient-sensing pathways requires sophisticated models that capture their systemic nature. Recent methodologies include:

Organ-specific proteomic profiling: Advanced quantitative proteomics of human tissues across the lifespan has revealed widespread transcriptome-proteome decoupling during aging, characterized by proteostasis decline and amyloid accumulation [12]. This approach enables researchers to construct tissue-specific proteomic age clocks and characterize organ-level aging trajectories, with temporal analysis identifying an aging inflection point around age 50 [12].

Circulating biomarker analysis: Mass spectrometry-based quantification of plasma proteins enables identification of systemic signatures of nutrient pathway dysregulation. This method has identified senoproteins—proteins secreted by senescent cells—that contribute to vascular and systemic aging [12]. For example, GAS6 has been identified as a candidate senoprotein driving aging-related vascular dysfunction [12].

Genetic manipulation models: Tissue-specific knockout and transgenic models allow researchers to dissect the endocrine-specific functions of nutrient-sensing pathway components. For instance, pancreatic β-cell-specific manipulation of miR-503 expression has revealed its role in regulating both endocrine and exocrine pancreatic function through the islet-acinar axis [13].

Hormonal Shifts in Aging Tissues

Systemic and Local Hormonal Alterations

Aging is associated with complex hormonal changes that extend beyond classical endocrine axes to include local tissue hormone production and sensitivity. The emerging concept of "metabolaging" describes the broad spectrum of metabolic disruptions associated with aging hallmarks, including the functional decline of metabolically active organs like adipose tissue [14]. White adipose tissue serves as both a target and source of endocrine signals, with aging-related dysfunction contributing to systemic metabolic imbalances.

Table 2: Key Hormonal Alterations in Aging and Their Functional Consequences

Hormone/Hormonal Axis	Direction of Change with Aging	Primary Functional Consequences	Therapeutic Targeting Approaches
IGF-1/GH Axis	Declining circulating levels	Reduced tissue repair, muscle mass loss, compromised protein synthesis	GH secretagogues, IGF-1 receptor modulators [15]
Sex Steroids	Menopause/andropause-related declines	Bone density loss, body composition changes, vascular dysfunction	Selective estrogen/androgen receptor modulators [15]
Melatonin	Significant decline in production	Disrupted circadian rhythms, reduced antioxidant capacity, immune dysfunction	Prolonged-release formulations, melatonin receptor agonists [15]
Thyroid Axis	Complex changes in TSH, T3, T4	Metabolic rate alterations, thermoregulatory challenges	Tissue-specific thyroid hormone analogs [15]
Adipose Tissue Hormones	Leptin resistance, adiponectin changes	Appetite dysregulation, insulin resistance, chronic inflammation	Adipokine receptor modulators [14]

Endocrine-Exocrine Communication in Aging

Recent research has revealed novel endocrine-exocrine communication pathways that become dysregulated with aging. A groundbreaking study demonstrated that senescent β-cells in pancreatic islets drive aging-associated pancreatitis through secretion of miR-503-322 via small extracellular vesicles that enter exocrine acinar cells [13]. This represents a previously unrecognized endocrine-exocrine regulatory pathway specifically active in aged organisms.

The experimental workflow for establishing this pathway included:

• β-cell-specific transgenic models: β-cell-specific miR-503 transgenic (βTG) and knock-in (βKI) mice were developed to isolate β-cell-specific effects without systemic metabolic confounders [13].

• Extracellular vesicle isolation and tracking: β-cell-derived extracellular vesicles (βEVs) were isolated using zinc-selective dyes (FluoZin-3) that selectively label pancreatic β-cells. Vesicles were characterized via transmission electron microscopy (~45 nm diameter) and nanoparticle tracking analysis (42 nm) [13].

• In vivo and in vitro vesicle trafficking: Fluorescently labeled βEVs were administered via pancreatic ductal infusion with subsequent tracking to acinar cells, demonstrating direct endocrine-exocrine communication [13].

• Target identification: miR-503-322 was shown to target MKNK1 in acinar cells, inhibiting secretion and promoting autodigestion while repressing proliferation and repair capacity [13].

This pathway was validated in human tissues, with pancreatic samples from elderly donors showing increased miR-503-424 (human homolog) and decreased MKNK1, providing clinical relevance to the experimental findings [13].

Diagram: Endocrine-Exocrine Communication in Pancreatic Aging. Senescent β-cells release miR-503-322 via extracellular vesicles that are taken up by acinar cells, targeting MKNK1 and promoting aging-associated pancreatitis.

Cellular Senescence in Endocrine Tissues

Senescence Mechanisms and Biomarkers

Cellular senescence is a hallmark of aging characterized by irreversible growth arrest, resistance to apoptosis, and development of a pro-inflammatory secretory phenotype (SASP) [9]. In endocrine tissues, senescence contributes to stem cell exhaustion and altered intercellular communication, driving systemic functional decline [8]. The endocrine system is particularly vulnerable to senescence due to the post-mitotic nature of many endocrine cells and their high metabolic activity.

Key mechanisms of endocrine senescence include:

• DNA damage accumulation: Progressive genomic instability in endocrine cells triggers senescence pathways, particularly in pancreatic β-cells and thyroid follicular cells [8].

• Mitochondrial dysfunction: Declining mitochondrial quality control in endocrine tissues reduces hormone synthesis capacity and increases oxidative stress [9].

• Epigenetic alterations: Age-related changes in DNA methylation patterns and histone modifications alter endocrine cell gene expression profiles [8].

• Proteostasis collapse: Impaired protein folding and degradation mechanisms in endocrine cells lead to toxic protein aggregation [12].

Senescence Targeting Approaches

Therapeutic targeting of cellular senescence represents a promising geroscience approach. Current strategies include:

Senolytics: Compounds that selectively eliminate senescent cells through inhibition of pro-survival pathways (e.g., dasatinib + quercetin) [9]. Recent advances include vaccination approaches targeting senescence-associated antigens like CD153 and GPNMB, which have shown efficacy in reducing senescent cell burden in animal models [9].

Senomorphics: Agents that suppress the SASP without killing senescent cells (e.g., mTOR inhibitors, NF-κB pathway modulators) [9].

Immunosenescence targeting: Approaches to rejuvenate immune system function to enhance natural clearance of senescent cells [9].

Gene therapy: Tissue-specific delivery of senescence-associated genes to modulate local senescence burden [9].

Experimental Models and Research Tools

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for Endocrine Aging Studies

Reagent/Category	Specific Examples	Research Application	Key Considerations
Senescence Detection	β-galactosidase staining (SA-β-Gal), p16INK4a antibodies, SASP factor ELISAs	Quantifying senescent cell burden in endocrine tissues	Tissue-specific optimal conditions; combination markers increase specificity [13]
Extracellular Vesicle Isolation	FluoZin-3 (β-cell-specific), ultracentrifugation, size-exclusion chromatography, nanoparticle tracking	Isulating cell-type-specific vesicles for endocrine communication studies	Purity requirements vary by downstream application; specificity challenges [13]
Proteomic Analysis	Mass spectrometry (LC-MS/MS), protein arrays, senoprotein panels	System-wide profiling of protein alterations in aging	Sample preservation critical; bioinformatic expertise required [12]
Genetic Models	Tissue-specific cre-lox systems, inducible promoters, β-cell-specific miR-503 models	Dissecting cell-type-specific mechanisms in endocrine aging	Temporal control essential; off-target effects monitoring [13]
Hormone Sensing	FRET-based biosensors, hormone receptor activation assays, hormone-responsive reporters	Real-time monitoring of hormone signaling pathway activity	Dynamic range considerations; physiological relevance validation [15]

Integrated Experimental Workflow

A comprehensive approach to investigating endocrine aging hallmarks requires integration of multiple methodologies:

Diagram: Integrated Research Workflow for Endocrine Aging Studies. This circular research approach connects human data with model systems for comprehensive mechanistic and therapeutic investigation.

The endocrine hallmarks of aging—deregulated nutrient sensing, hormonal shifts, and cellular senescence—represent interconnected drivers of physiological decline that offer promising targets for gerotherapeutic development. Research advances have revealed novel communication pathways, such as the endocrine-exocrine miR-503-322-mediated mechanism in pancreatic aging, that underscore the complexity of endocrine aging [13]. Proteomic approaches have enabled the development of organ-specific aging clocks that capture the asynchronous nature of tissue aging, with implications for endocrine function [12].

For researchers and drug development professionals, several key priorities emerge:

• Development of tissue-specific therapeutics: Interventions must account for the organ-specific manifestations of endocrine aging, requiring advanced delivery systems and precise targeting approaches [9].

• Biomarker validation: Translation of proteomic signatures and senescence-associated secretions into clinically applicable biomarkers for monitoring intervention efficacy [12].

• Regulatory pathway advancement: Establishment of clear regulatory frameworks for geroscience therapeutics targeting fundamental aging processes rather than single diseases [10].

• Combination approaches: Given the interconnected nature of aging hallmarks, multi-target interventions will likely prove more effective than single-pathway approaches [9].

The geroscience perspective provides a transformative framework for addressing age-related diseases by targeting their underlying causes rather than their individual manifestations. As recognition grows that aging itself represents a modifiable condition [16], endocrine-focused interventions offer promising avenues for extending healthspan and reducing the burden of age-related disease.

Geroscience posits that aging itself is the primary risk factor for major chronic diseases, and therefore, targeting fundamental aging processes represents a transformative approach to extending healthspan. Within this framework, calorie restriction (CR) and fasting have emerged as prototypical, non-pharmacological interventions that directly modulate core aging hallmarks. These nutritional stressors activate evolutionarily conserved cellular response pathways that enhance maintenance and repair, thereby decelerating biological aging processes. This whitepaper synthesizes current evidence on the mechanisms and efficacy of CR and fasting, with a specific focus on their application in endocrine aging research and the development of novel therapeutic strategies.

Quantitative Evidence from Preclinical and Clinical Studies

Robust data from model organisms and human trials demonstrate the potent effects of CR and fasting on longevity and healthspan metrics. The tables below summarize key quantitative findings.

Table 1: Effects of Dietary Restriction on Lifespan in Model Organisms

Organism	Intervention	Lifespan Extension	Key Findings	Source
Genetically Diverse Mice (Female)	40% Calorie Restriction	↑ 36.3% (median)	Strongest effect, but with lean mass loss and immune alterations.	[17]
Genetically Diverse Mice (Female)	2-Day/Week Intermittent Fasting	↑ Proportional to fast duration	Extended median lifespan with minimal net caloric reduction.	[17]
Mice (C57Bl/6)	Fasting-Mimicking Diet (FMD) Cycles	Extended	45% reduction in tumor incidence; reduced inflammatory diseases.	[18]
Yeast (S. cerevisiae)	Food Deprivation (Water only)	↑ 2-fold (chronological)	Major increase in stress resistance via downregulation of Tor-S6K pathway.	[19]
Mice	Calorie vs. Quantity Restriction	Maximum with fewer calories	Calorie intake, not food quantity, is the key anti-aging factor.	[20]

Table 2: Clinical Outcomes of Fasting and Calorie Restriction in Humans

Intervention	Study Population	Duration	Key Clinical Outcomes	Source
Fasting-Mimicking Diet (FMD) Cycles	Adults (Clinical Trial)	3 cycles (3 months)	↓ Insulin resistance, ↓ hepatic fat, ↓ biological age by 2.5 years.	[18]
Calorie Restriction (CALERIE Phase 2)	Healthy adults without obesity	2 years	Averaged 11.7% CR; improved cardiometabolic risk markers; attenuated biological aging.	[21]
Periodic FMD	Patients with diabetes, cancer, MS, Alzheimer's	Various (Review)	Alleviated disease symptoms and improved relevant markers.	[22]
Water-Only or Very-Low Calorie Fasting	Rheumatoid Arthritis, Obesity	1 week or longer	Amelioration of disease symptoms; weight loss.	[19]

Core Mechanistic Pathways

The geroprotective effects of CR and fasting are mediated through the orchestrated regulation of several highly conserved metabolic and stress-response pathways.

The AMPK Signaling Node

Adenosine Monophosphate-activated Protein Kinase (AMPK) serves as a central cellular energy sensor. During low-energy states induced by CR or fasting, a rise in the AMP:ATP ratio activates AMPK. This master switch responds by promoting catabolic processes to generate ATP while inhibiting anabolic, energy-consuming processes [23].

Key functions of activated AMPK include:

• Increasing ATP Production: Enhancing cellular glucose uptake, glycolysis, and fatty acid oxidation.
• Decreasing ATP Utilization: Suppressing fatty acid synthesis, steroid synthesis, glycogen storage, and protein production.
• Mitochondrial Quality Control: Triggering autophagy and the removal of defective mitochondria while stimulating mitochondrial biogenesis.
• Housekeeping: Influencing circadian regulation, reducing oxidative stress, and lowering inflammatory markers [23].

AMPK activity declines with age, contributing to reduced autophagy, increased oxidative stress, and fat deposition [23]. Its activation can be triggered by low energy, hypoxia, exercise, and certain compounds like metformin and resveratrol [23].

Diagram 1: AMPK as a Central Metabolic Switch in Dietary Restriction. This diagram illustrates how energy-deficient conditions activate AMPK, leading to a metabolic shift toward energy production and cellular maintenance.

Glucagon as a Novel Endocrine Mediator

While insulin has been a traditional focus, recent research highlights the critical role of glucagon in mediating the benefits of CR. University of Arizona research led by Dr. Jennifer Stern has established that glucagon signaling is essential for the healthspan improvements stimulated by CR [24] [25].

Key evidence includes:

• Mice lacking the glucagon receptor do not experience improved metabolic function or lifespan extension from CR [24] [25].
• Glucagon agonism in aging mice suppresses established pro-aging pathways, including mTOR signaling [24].
• Long-acting glucagon agonists are under investigation as potential gerotherapeutics to mimic the benefits of CR without the need for strict dieting [24].

This discovery reframes the endocrine response to fasting, positioning the insulin-glucagon axis as a central regulator of aging. Glucagon-based drugs in development for obesity and diabetes (e.g., Retatrutide) may therefore have a dual purpose in slowing aging [24].

Integrated Nutrient-Sensing and Metabolic Pathways

CR and fasting concurrently influence a network of interconnected longevity pathways.

Table 3: Key Nutrient-Sensing Pathways in Aging

Pathway	Role in Nutrient Sensing	Response to CR/Fasting	Downstream Effects
mTOR	Sensor of amino acids and growth factors; promotes growth and synthesis.	Inhibited [24]	Reduced protein synthesis, enhanced autophagy, decreased cell proliferation.
Sirtuins	NAD+-dependent deacylases; sense energy status via NAD+ levels.	Activated (increased NAD+) [23]	Enhanced genomic stability, mitochondrial function, and stress resistance.
Insulin/IGF-1	Sensor of glucose and growth factors; promotes anabolic processes.	Signaling reduced [18] [21]	Improved insulin sensitivity, reduced inflammatory signaling.

The inhibition of mTOR by glucagon agonism provides a direct molecular link between the endocrine response to fasting and a central pro-aging pathway [24]. Similarly, the activation of sirtuins is intertwined with AMPK and mitochondrial function, creating a coordinated defense network against age-related damage [23].

Experimental Protocols and Methodologies

Preclinical Protocol: Dietary Restriction in Genetically Diverse Mice

The "DRiDO" study provides a robust model for evaluating CR and IF.

Objective: To characterize the lifespan and health effects of graded DR and identify predictive physiological and genetic factors [17].

• Subjects: 960 female genetically diverse "Diversity Outbred" (DO) mice.
• Study Initiation: Intervention began at 6 months of age.
• Diet Groups: Mice were randomly assigned to one of five dietary regimens for their natural lifespan:
  • AL (Ad Libitum): Free access to food.
  • 1D IF: Fast for 24 hours, once per week.
  • 2D IF: Fast for 48 consecutive hours, once per week.
  • 20% CR: Daily caloric intake reduced by 20% from baseline.
  • 40% CR: Daily caloric intake reduced by 40% from baseline.
• Food Administration: CR mice received a measured daily food allotment. IF mice had food entirely removed for the fasting period [17].
• Phenotyping: Over 200 longitudinal traits were assessed, including body composition, metabolic cage analysis, immune cell profiling, frailty index, grip strength, and fasting glucose [17].

Clinical Protocol: Fasting-Mimicking Diet (FMD) in Humans

The FMD is a plant-based, low-calorie, low-protein dietary intervention designed to mimic the effects of a water-only fast while providing minimal nourishment to improve adherence and safety [18] [22].

Objective: To test the hypothesis that FMD cycles improve markers of aging and reduce biological age [18].

• Study Design: Randomized clinical trial (NCT02158897), with some participants undergoing an optional crossover.
• Intervention: Participants consumed the FMD for 5 consecutive days, followed by a normal diet for the remainder of the month. This cycle was repeated 3 times over 3 months.
• FMD Composition: The specific FMD used is a commercial product low in calories, sugars, and protein but high in healthy fats.
• Outcome Measures:
  • Primary: Metabolic syndrome components and biomarkers associated with aging.
  • Secondary/Exploratory (Reported): Hepatic fat (via MRI), lymphoid-to-myeloid ratio (immune age), and biological age calculated from a validated set of blood markers [18].
• Validation: Findings were replicated in a second, independent clinical trial (NCT04150159) [18].

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Reagents and Models for CR/Fasting Research

Item / Reagent	Function / Application	Example / Specification
Genetically Diverse Mouse Models	Models human genetic diversity; improves translatability of findings.	Diversity Outbred (DO) mice [17]; UM-HET3 mice.
Long-Acting Glucagon Agonists	To test the therapeutic potential of glucagon signaling activation.	Compounds developed by Novo Nordisk; used in ongoing aging mouse studies [24].
Fasting-Mimicking Diet (FMD)	Standardized, low-calorie, low-protein diet for preclinical and clinical fasting studies.	Plant-based, 5-day lasting dietary intervention [18].
Biological Age Assays	Quantifying the functional age of an organism based on biomarker profiles.	Validated algorithms using blood markers (e.g., from clinical FMD trials) [18].
Metabolic Cage Systems	Longitudinal, non-invasive measurement of energy metabolism in rodents.	Measures food consumption, respiratory quotient, energy expenditure, and wheel running [17].
Pathway Modulators (Pharmacologic)	To probe specific mechanisms (AMPK, Sirtuins, mTOR) in conjunction with diet.	Metformin, Resveratrol, EGCG, Curcumin (AMPK activators); Rapamycin (mTOR inhibitor) [23].

Calorie restriction and fasting represent powerful, non-pharmacological probes to uncover the fundamental mechanisms of aging. The evidence consolidated in this whitepaper underscores that these interventions exert their effects through multiple, interconnected endocrine and metabolic pathways, including AMPK, glucagon, sirtuins, and mTOR. The translation of these findings into clinical practice is now underway, with two promising fronts:

First, the development of fasting-mimicking diets offers a more feasible and safe approach to harness the benefits of prolonged fasting in diverse patient populations, showing promise in improving cardiometabolic health and reducing biological age [18] [22].

Second, the identification of glucagon as a critical mediator opens a novel avenue for drug development. The pursuit of glucagon receptor agonists and related compounds represents a paradigm shift in geroscience: moving from dietary intervention to targeted pharmacological mimicry [24] [25]. This endocrine-focused approach, firmly rooted in the geroscience framework, holds the potential to delay aging and compress morbidity, ultimately extending the human healthspan.

Traditionally cast as a counter-regulatory hormone to insulin, glucagon is emerging from the shadows as a potent, independent regulator of aging processes. This whitepaper synthesizes groundbreaking evidence that positions glucagon receptor signaling as indispensable for the lifespan and healthspan extension conferred by caloric restriction. We present comprehensive data demonstrating that genetic ablation of the glucagon receptor curtails lifespan by 35% in lean mice and completely abrogates the metabolic benefits of caloric restriction. Furthermore, we detail how pharmacological activation of glucagon signaling recapitulates key molecular signatures of longevity, including suppression of the mTOR pathway. This review integrates these findings into the broader geroscience framework, proposing glucagon signaling as a novel and druggable target for interventions designed to extend healthspan and combat age-related disease.

For over a century, glucagon has been defined by its hyperglycemic action—a hormone secreted from pancreatic alpha cells that mobilizes hepatic glucose during fasting or hypoglycemia [26]. However, recent research has dramatically expanded this narrow physiological purview, revealing glucagon as a systemic regulator of energy homeostasis, nutrient sensing, and, most surprisingly, the aging process itself.

The geroscience hypothesis posits that targeting fundamental aging processes can simultaneously delay the onset of multiple age-related diseases [27]. Within this paradigm, endocrine pathways have emerged as critical regulators of healthspan. While insulin and insulin-like growth factor signaling have dominated aging research for decades, their counter-regulatory hormone, glucagon, has been largely overlooked. This review synthesizes emerging evidence from genetic, dietary, and pharmacological studies that fundamentally challenge this oversight, establishing glucagon receptor signaling as a novel and essential component of the endocrine aging landscape.

Quantitative Evidence: Glucagon Signaling in Lifespan and Metabolic Health

Recent experimental findings provide compelling quantitative evidence for glucagon's role in modulating lifespan and healthspan. The key data from critical studies are summarized in the table below.

Table 1: Summary of Key Experimental Findings on Glucagon and Lifespan/Healthspan

Experimental Model	Intervention	Key Findings on Lifespan	Key Metabolic Health Findings
Global Gcgr KO Mice [28] [29]	Genetic knockout of glucagon receptor	↓ 35% in median lifespan	Caloric restriction failed to improve metabolic function (liver fat, serum triglycerides, cholesterol)
Liver-specific Gcgr KO Mice [28] [29]	Hepatocyte-specific receptor deletion	Not directly assessed	↓ Hepatic AMPK activation; Blunted CR-induced ↓ in hepatic mTOR activity
Wild-type Aging Mice [24]	Pharmacological glucagon receptor agonism	Studies ongoing	Suppressed mTOR signaling pathway; Improved metabolic parameters

The data reveal two fundamental insights: first, intact glucagon signaling is necessary for normal aging, as its absence drastically shortens lifespan; second, glucagon signaling is an essential mediator of the most robust non-genetic, non-pharmacological anti-aging intervention—caloric restriction.

Mechanistic Insights: Glucagon Signaling in Nutrient-Sensing Pathways

The pro-longevity effects of glucagon receptor activation are mediated through its interaction with core nutrient-sensing pathways that are evolutionarily conserved regulators of aging. The molecular mechanisms are illustrated in the following pathway diagram.

Figure 1: Glucagon Receptor Signaling in Nutrient-Sensing and Longevity Pathways. Glucagon binding to its receptor (Gcgr) activates two key pathways: the canonical Gs/cAMP/PKA/CREB pathway and the Gq/IP3 pathway leading to AMPK activation. A critical downstream effect is the inhibition of mTOR, a central negative regulator of longevity. Together, these signaling events promote enhanced healthspan and lifespan.

Glucagon signaling intersects with the aging process primarily through two key nutrient-sensing pathways:

• AMPK Activation: Glucagon receptor signaling in hepatocytes activates AMP-activated protein kinase (AMPK), a critical energy sensor that promotes catabolic processes and extends healthspan [28] [29]. AMPK activation represents a fundamental "low-energy" signal that opposes aging processes.

• mTOR Inhibition: Caloric restriction decreases hepatic mTOR activity in wild-type mice, but this response is absent in mice lacking hepatic glucagon receptors [29]. This demonstrates that glucagon signaling is necessary for the mTOR inhibition associated with prolonged fasting and caloric restriction—two established longevity interventions.

These findings position glucagon not merely as a glucose-regulatory hormone, but as a fundamental communicator of nutrient status that directly modulates the core biochemical machinery of aging.

Experimental Approaches: Methodologies for Investigating Glucagon in Aging

Genetic Manipulation Models

The foundational evidence for glucagon's role in aging comes from studies utilizing targeted genetic manipulations in mice:

• Global Glucagon Receptor Knockout (Gcgr KO): These mice lack the glucagon receptor throughout the body, allowing researchers to assess the systemic importance of glucagon signaling for lifespan and age-related health outcomes [28] [29]. Lifespan studies involve monitoring these mice throughout their natural lives while tracking healthspan metrics.

• Liver-Specific Glucagon Receptor Knockout (Gcgrhep-/-): Generated using Cre-loxP technology with albumin-Cre drivers, these mice enable the dissection of hepatic versus extra-hepatic effects of glucagon signaling, crucial for identifying tissue-specific mechanisms [29].

Dietary Interventions

Caloric restriction protocols are implemented with precise methodological control:

• Mice are individually housed and food intake is meticulously measured in ad libitum-fed controls.
• Caloric-restricted mice receive a defined percentage (typically 60-95%) of the ad libitum food intake in a single daily feeding, which combines caloric restriction with an intermittent fasting component [29].
• The level of restriction is periodically recalibrated based on ongoing measurements of food intake in control animals.

Pharmacological Activation

Long-acting glucagon analogs (e.g., NNC9204-0043 from Novo Nordisk) are administered subcutaneously to aged wild-type mice to test whether enhanced glucagon signaling can mimic the benefits of caloric restriction [24] [29]. These compounds have extended half-lives (5-6 hours) suitable for chronic aging studies.

Metabolic Phenotyping

Comprehensive assessment of healthspan includes:

• Body Composition Analysis: Using quantitative NMR (EchoMRI) to measure fat and lean mass [29].
• Metabolic Rate Assessment: Using indirect calorimetry (Sable Systems) to measure energy expenditure and respiratory quotient [29].
• Glucose Homeostasis: Oral glucose tolerance tests (OGTT) and insulin tolerance tests (ITT) performed in aged mice [29].
• Tissue Analysis: Post-mortem histological analysis and molecular signaling pathway analysis in key metabolic tissues.

The Scientist's Toolkit: Essential Reagents for Glucagon-Aging Research

Table 2: Key Research Reagents for Investigating Glucagon in Aging

Reagent / Model	Key Features / Specifications	Primary Research Application
Global Gcgr KO Mice [29]	Global deletion of glucagon receptor; generated via homologous recombination	Assessing systemic role of glucagon signaling in lifespan and whole-body metabolism
Gcgr Floxed Mice [29]	Glucagon receptor allele with loxP sites flanking critical exons	Generation of tissue-specific knockout models (e.g., liver-specific Gcgrhep-/-)
Albumin-Cre Mice [29]	Cre recombinase expression driven by albumin promoter	Breeding with floxed mice to achieve hepatocyte-specific glucagon receptor deletion
Long-Acting Glucagon Analog [29]	NNC9204-0043 (Novo Nordisk); terminal half-life of 5-6 hours	Pharmacological activation of glucagon signaling in chronic aging studies
Indirect Calorimetry System [29]	Sable Systems Promethion Metabolic Monitoring	Measuring energy expenditure, respiratory quotient, and feeding patterns
EchoMRI [29]	Quantitative magnetic resonance imaging	Longitudinal, non-invasive measurement of body composition (fat/lean mass)

Discussion and Clinical Translation

The accumulating evidence positions glucagon signaling as a critical and previously underappreciated determinant of healthspan and longevity. The finding that glucagon receptor knockout mice experience a 35% reduction in median lifespan—even in the absence of obesity or diabetes—establishes glucagon signaling as fundamental to healthy aging [28] [29]. Furthermore, the complete abrogation of caloric restriction's metabolic benefits in these models demonstrates that glucagon is not merely involved in, but essential for, the anti-aging response to this intervention.

From a gerotherapeutic perspective, the most exciting finding is that pharmacological glucagon receptor activation recapitulates key molecular signatures of longevity, particularly mTOR inhibition [24]. This suggests that glucagon agonists may function as "caloric restriction mimetics"—a class of interventions that reproduce the health benefits of prolonged fasting without the necessity of severe dietary restriction.

The clinical relevance of these discoveries is amplified by the rapid development of glucagon-based therapies for metabolic disease. Dual and triple agonists targeting the glucagon receptor alongside GLP-1 and GIP receptors (e.g., tirzepatide, retatrutide) are in advanced clinical trials for obesity, diabetes, and NAFLD [30] [24]. The aging research community now has a unique opportunity to "piggyback" on these development programs to investigate whether these compounds might also slow aging processes in humans.

This review establishes glucagon as a novel hormonal regulator of lifespan and healthspan, moving beyond its traditional metabolic functions to a central position in geroscience. The evidence demonstrates that glucagon signaling through its hepatic receptor modulates core aging pathways (AMPK, mTOR) and is indispensable for the life-extending benefits of caloric restriction.

Significant questions remain for future investigation:

• What are the tissue-specific contributions of glucagon signaling to aging, particularly in the brain, kidney, and adipose tissue?
• How does glucagon interact with other endocrine systems known to regulate aging, such as insulin/IGF-1 signaling?
• Can chronic glucagon receptor activation extend lifespan in wild-type animals, and if so, with what therapeutic window?

As glucagon-based therapeutics advance through clinical development for metabolic disease, parallel efforts should be initiated to assess their effects on aging biomarkers and age-related disease progression in human populations. The convergence of glucagon's metabolic benefits with its emerging role in longevity pathways presents a remarkable opportunity to develop genuine healthspan-extending interventions.

Geroscience posits that aging is the primary driver of most chronic diseases and that targeting fundamental aging processes can extend healthspan—the period of life spent in good health. Within this paradigm, female reproductive aging, particularly the menopausal transition, represents a compelling model of accelerated systemic aging. The ovary is the first organ to undergo age-related failure in humans, with the menopausal transition (MT) serving as a window of dramatically increased vulnerability for numerous age-related conditions [31] [32]. For the >850 million women globally aged 40–60 years, understanding the interface between reproductive and systemic aging is paramount for developing interventions that optimize healthspan [31].

The MT is characterized not only by the cessation of fertility but by fundamental physiological shifts that impact nearly all organ systems. This transition is associated with a 2–5 fold increased risk for major depressive disorder, heightened vulnerability to first-onset psychosis, and exacerbation of schizophrenia symptoms [31]. Beyond neurological and mental health consequences, menopause increases susceptibility to cardiovascular disease, Alzheimer's disease, osteoporosis, and other age-related pathologies [33] [34]. This review examines female reproductive aging through a geroscience lens, exploring biomarker development, molecular mechanisms, and therapeutic strategies that target the biology of aging to improve women's health across the lifespan.

The Menopausal Transition: Physiology and Systemic Consequences

Defining the Menopausal Transition and Perimenopause

The menopausal transition (MT) is a midlife transition period typically lasting 2–8 years, extending from when menstrual periods become irregular until the final menstrual period (FMP) [31]. Clinically, spontaneous menopause is diagnosed retrospectively after 12 consecutive months without a menstrual period, at a mean age of approximately 51 years [31]. The entire period encompassing the MT and the 12 months following FMP is termed perimenopause [31]. Perimenopause typically develops when women are in their 40s and is characterized by unpredictable hormonal fluctuations that create diagnostic challenges, as hormone levels can vary significantly from day to day [34].

During reproductive aging, ovarian function begins to decline long before menopause itself—in some cases up to ten years earlier [34]. This decline is marked by diminishing antral follicle counts and decreasing levels of anti-Müllerian hormone (AMH), a key marker of ovarian reserve [31]. The levels of ovarian hormones estradiol and progesterone decrease throughout this period, though the late MT is characterized by extreme hormone fluctuations [31]. In compensation for decreased ovarian function, secretion of follicle-stimulating hormone (FSH) from the pituitary gland becomes elevated and remains stably elevated postmenopause alongside low ovarian hormone levels [31].

Table 1: Key Hormonal Changes During Reproductive Aging

Hormone/Biomarker	Premenopausal Pattern	Perimenopausal Pattern	Postmenopausal Pattern	Primary Tissue Source
Anti-Müllerian Hormone (AMH)	High, stable	Declining significantly	Very low/undetectable	Ovarian follicles
Follicle-Stimulating Hormone (FSH)	Low, cyclic	Increasing, variable	Consistently elevated	Pituitary gland
Estradiol	High, cyclic	Fluctuating, overall decline	Consistently low	Ovarian follicles
Progesterone	High, cyclic	Irregular, overall decline	Consistently low	Corpus luteum
Estrone	Moderate, cyclic	Variable	Primary estrogen postmenopause	Adipose tissue, adrenal glands

Systemic Health Consequences Beyond Reproduction

The health implications of reproductive aging extend far beyond the reproductive axis. Ovarian hormones regulate processes throughout the female body, influencing bone density, cardiovascular health, neural function, and metabolic processes [34]. The decline of endogenous estrogen during menopause removes protective effects against cardiovascular disease, contributing to increased risk—cardiovascular disease being the leading cause of death for women in the U.S. [34]. Additional risk factors that often emerge during this period, including obesity, hypertension, and type 2 diabetes, can further elevate cardiovascular vulnerability.

Menopause also disproportionately affects neurological health, with women representing approximately two-thirds of all Alzheimer's disease cases [34]. Estrogen plays vital roles in healthy brain functioning, promoting synaptic growth between neurons, reducing neuroinflammation, enhancing antioxidant defenses, and maintaining brain metabolism and plasticity [34]. The decline of estrogen during menopause potentially accelerates neurodegenerative processes that contribute to cognitive decline. Beyond cardiovascular and neurological diseases, menopause is associated with increased risk of autoimmune disorders, osteoporosis, and sleep apnea [34].

Biomarkers of Female Reproductive Aging

Established and Emerging Biomarker Panels

Accurate assessment of reproductive aging requires multidimensional biomarker approaches. The STRAW+10 (Stages of Reproductive Aging Workshop +10) criteria represent the current gold standard for categorizing female reproductive life stages, incorporating blood-based biomarkers (FSH, AMH, estrogen, inhibin), antral follicle count, menstrual cycle patterns, and vasomotor symptoms [32]. However, this framework does not encompass all dimensions of female reproductive aging, creating demand for more comprehensive biomarker panels.

Recent research has identified significant biomarkers across multiple tissues. A comprehensive postmortem tissue analysis identified fourteen significant and seven strongest menopausal biomarkers across blood, hypothalamus, and pituitary gland [31]. In blood, significant differences between pre- and post-menopausal groups were found in AMH, FSH, estrone, estradiol, progesterone, and DHT [31]. In the pituitary gland, FSH protein levels and gene expression of FSH and GNRHR showed significant changes, while the hypothalamus demonstrated alterations in DHEA, estrone, estradiol, progesterone, and CYP19A1 (aromatase) expression [31].

Table 2: Established and Emerging Biomarkers of Female Reproductive Aging

Biomarker Category	Specific Markers	Utility in Reproductive Aging	Tissue/Sample Source
Established Clinical Biomarkers	FSH, AMH, Inhibin B, Antral Follicle Count	Ovarian reserve assessment, STRAW+10 staging	Blood, ultrasound
Steroid Hormones	Estradiol, Progesterone, Estrone, DHEA, DHT	Hormonal fluctuation tracking, tissue aging correlation	Blood, hypothalamus
Gene Expression Markers	CYP19A1 (aromatase), ESR1, ESR2, GPER1, PGR, KISS1, GNRHR	Hypothalamic-pituitary-ovarian axis function	Hypothalamus, pituitary
Emerging Circulating Biomarkers	Sirtuin-1, microRNAs, Epigenetic clocks	Biological age assessment, senescence monitoring	Blood
Novel Imaging & Physical Biomarkers	Retinal age gap, Ovarian stiffness, Vaginal microbiome	Non-invasive systemic aging assessment	Retinal imaging, elastography, vaginal swabs

Composite Biomarker Scores and Novel Assessment Methods

To address challenges in postmortem classification of menopausal status, researchers have developed multi-tissue and tissue-specific composite measures that enable determination of menopausal status across different age ranges, including the challenging "perimenopausal" 45–55-year-old group [31]. These composite scores allow for more precise classification than chronological age alone, which often poorly correlates with reproductive status.

Emerging technologies offer innovative approaches to reproductive aging assessment. Artificial intelligence-derived retinal age gap—the difference between predicted retinal age and chronological age—has demonstrated association with AMH levels, particularly among women aged 40–50 [35]. This non-invasive biomarker leverages the connection between microvascular and ovarian aging, with lower AMH levels correlating with older retinal age relative to chronological age [35]. Genetic data from genome-wide association studies further support these associations and can enhance AMH prediction through multimodal modeling [35].

Additional emerging biomarkers include epigenetic markers, microRNA profiles, menstrual blood markers, ovarian stiffness measured via elastography, vaginal microbiome composition, and survey-based instruments assessing quality of life and specific menopausal symptoms [36] [32]. Each of these approaches captures different dimensions of the reproductive aging process, from cellular senescence to tissue-level changes and systemic physiological manifestations.

Experimental Models and Methodological Approaches

Postmortem Tissue Analysis for Molecular Insights

Postmortem tissue analysis provides unique insights into molecular changes during reproductive aging that are inaccessible in living humans. A comprehensive methodological approach involves analyzing 40 candidate biomarkers across three tissue types: blood, hypothalamus, and pituitary gland [31]. This includes:

• Steroid hormone profiling: Measurement of 14 different steroid hormones in blood and hypothalamic tissue using mass spectrometry or immunoassays
• Protein level quantification: AMH and FSH protein levels in blood and pituitary tissue
• Gene expression analysis: Reproduction-relevant genes in hypothalamus (CYP19A1, ESR1, ESR2, GPER1, PGR, KISS1) and pituitary gland (FSH, ESR1, GNRHR) using qPCR or RNA sequencing

This methodology revealed strong correlations between blood and hypothalamic steroid levels, suggesting that hypothalamic hormone measurements can serve as proxies when blood is unavailable [31]. For example, estrone levels showed very high correlation between blood and hypothalamus (r=0.95, p<0.001), with moderate correlations for estradiol (r=0.44, p=0.007) and progesterone (r=0.44, p=0.006) [31]. These findings validate the use of central nervous system tissues for assessing peripheral hormonal status.

Diagram 1: HPG Axis in Reproductive Aging. The hypothalamic-pituitary-gonadal (HPG) axis regulates reproductive function. During aging, declining ovarian hormones disrupt feedback loops, affecting systemic tissues.

Clinical Trial Design for Gerotherapeutic Interventions

Well-designed clinical trials are essential for evaluating gerotherapeutic interventions targeting reproductive aging. A proposed Phase 2 clinical trial protocol incorporates comprehensive assessment of female reproductive aging biomarkers with short-term (every 3 months) and long-term (every 6 months) follow-ups over one year [32]. This duration accounts for ovarian folliculogenesis (2–3 months for follicle recruitment) and menstrual cycle completion.

The recommended assessment protocol includes:

• Blood-based biomarkers: AMH, FSH, LH, estradiol, progesterone, inhibin B, Sirtuin-1
• Ovarian reserve biomarkers: Antral follicle count via transvaginal ultrasound
• Vaginal smears: For cytology and microbiome analysis
• Survey instruments: Menopause Rating Scale (MRS), Fertility Quality of Life (FertiQoL) tool, and vasomotor symptom tracking
• Novel biomarkers: Epigenetic clocks, microRNA profiles, and other emerging markers as available

Critically, female reproductive life stage must be considered during clinical trial assessments, as the effects of interventions may vary significantly across premenopausal, perimenopausal, and postmenopausal stages [32]. This personalized approach ensures that gerotherapeutic strategies are appropriately targeted to individual reproductive aging trajectories.

Diagram 2: Gerotherapeutic Trial Assessment Schedule. Comprehensive biomarker assessment at defined intervals captures dynamic changes during reproductive aging and intervention response.

Therapeutic Implications and Future Directions

Hormone-Based Interventions and Gerotherapeutic Approaches

Hormone replacement therapy (HRT) remains the most effective treatment for alleviating menopausal symptoms by replenishing declining hormone levels [34]. Recent regulatory changes have updated risk-benefit assessments, with the FDA removing broad "black box" warnings for most HRT products after comprehensive scientific review [37]. Current evidence suggests that initiating HRT within 10 years of menopause onset (generally before age 60) is associated with reduced all-cause mortality, fractures, cardiovascular disease (up to 50% risk reduction), Alzheimer's disease (35% risk reduction), and bone fractures (50-60% risk reduction) [37].

The timing of HRT initiation appears critical for optimizing benefits and minimizing risks. Research presented at The Menopause Society 2025 Annual Meeting indicated that estradiol-containing menopausal hormone therapy (MHT) initiated in early postmenopause may influence Alzheimer disease-related biomarkers, particularly amyloid-β levels, suggesting potential neuroprotective effects when started soon after menopause [33]. No significant biomarker changes were observed in women initiating MHT in late postmenopause, supporting the "critical window" hypothesis for hormone therapy [33].

Beyond traditional HRT, gerotherapeutic approaches targeting fundamental aging processes show promise for addressing reproductive aging. Compounds with potential gerotherapeutic effects include metformin (with anti-inflammatory, antioxidant, and anti-apoptotic properties), rapamycin, and other senescence-targeting agents [32]. These interventions aim to delay age-related functional decline across multiple organ systems, potentially including the reproductive axis.

Non-Hormonal Options and Precision Medicine Approaches

For women who cannot or choose not to use hormone therapy, non-hormonal treatments are expanding. The FDA recently approved elinzanetant, the first dual neurokinin 1 and neurokinin 3 receptor antagonist, for moderate to severe vasomotor symptoms associated with menopause [33]. This hormone-free treatment demonstrated efficacy across four phase 3 clinical trials including naturally or surgically induced postmenopausal women and women receiving endocrine therapy for hormone receptor-positive breast cancer [33].

Precision medicine approaches to reproductive aging require consideration of individual risk profiles, reproductive life stage, and specific symptom patterns. Research indicates significant variability in menopause management across provider types and specialties, with only 17% of women receiving medication for menopausal symptoms in one large study [33]. Obstetrician/gynecologists were most likely to prescribe systemic estrogen, while internal and family medicine providers more frequently prescribed SSRIs [33]. This variability underscores the need for standardized, evidence-based education across medical specialties to ensure consistent, effective menopause care.

Table 3: Research Reagent Solutions for Reproductive Aging Studies

Research Tool Category	Specific Reagents/Assays	Research Application	Key Functions
Immunoassays	AMH ELISA, FSH ELISA, Estradiol EIA, Multiplex steroid panels	Hormone level quantification	Measure circulating and tissue hormone concentrations
Gene Expression Analysis	qPCR primers/probes for CYP19A1, ESR1, ESR2, GNRHR, RNA sequencing kits	Hypothalamic-pituitary-ovarian axis transcriptomics	Characterize gene expression changes in reproductive tissues
Histological Reagents	Specific antibodies for estrogen receptors, FSH receptors, aromatase	Tissue localization and protein expression	Visualize protein distribution and abundance in tissues
AI-Assisted Imaging Tools	Retinal age prediction algorithms, Ovarian stiffness calculation software	Non-invasive aging assessment	Derive reproductive age estimates from imaging data
Senescence Markers	SA-β-galactosidase assay kits, p16INK4a antibodies, SASP cytokine panels	Cellular senescence detection	Identify senescent cells in reproductive tissues

Female reproductive aging represents a powerful model for understanding the interface between endocrine aging and systemic health decline. The menopausal transition constitutes a period of accelerated biological aging with profound implications for multiple organ systems, offering insights that extend beyond women's health to fundamental aging processes. Geroscience approaches that target hallmarks of aging may potentially modify reproductive aging trajectories and mitigate their systemic health consequences.

Future research directions should include developing validated composite biomarker scores for reproductive aging, establishing standardized protocols for assessing gerotherapeutic effects on ovarian healthspan, and integrating multi-omics approaches to elucidate mechanisms linking reproductive aging to systemic health. As the global population of menopausal women continues to grow, prioritizing research on female reproductive aging within geroscience frameworks becomes increasingly urgent for extending healthspan and optimizing quality of life across the lifespan.

From Bench to Bedside: Research Methods and Emerging Gerotherapeutics

Geroscience research aims to understand the molecular mechanisms linking aging to chronic diseases and to develop interventions to extend healthspan. Within this field, caloric restriction (CR) remains the most robust non-genetic, non-pharmacological intervention for extending lifespan and healthspan across a diverse range of species, from yeast to non-human primates [38] [24] [39]. Research has progressively shifted from merely observing this phenomenon to deciphering its underlying endocrine mechanisms. This whitepaper focuses on the critical insights gained from animal models, particularly regarding the role of glucagon receptor signaling, which has emerged as an indispensable mediator of CR's benefits. The integration of sophisticated animal models—including humanized, naturalized, and genetically diverse mice—with advanced molecular techniques provides a powerful platform for validating new therapeutic targets and developing gerotherapeutic interventions [40] [17] [29].

The Caloric Restriction Paradigm in Animal Models

Lifespan and Healthspan Effects Across Species

Caloric restriction, typically defined as a 20–40% reduction in caloric intake without malnutrition, delays the onset of age-related diseases and extends lifespan in species ranging from yeast, worms, and flies to laboratory rodents and non-human primates [38] [39]. The inverse relationship between caloric intake and lifespan was clearly demonstrated in female C3B10RF1 mice, where graded restriction (from 40% to 10% of ad libitum intake) resulted in proportional lifespan extension [38]. Recent large-scale studies in genetically diverse female mice (Diversity Outbred mice) have confirmed that both graded CR (20% and 40%) and intermittent fasting (1 and 2 days per week) extend median lifespan in proportion to the degree of restriction or length of fasting (40% CR > 20% CR > 2-day IF > 1-day IF > ad libitum) [17]. Notably, 40% CR increased median lifespan by approximately 36.3% compared to ad libitum-fed controls.

Table 1: Effects of Different Dietary Restriction Regimens on Lifespan in Female Mice [17]

Dietary Regimen	Net Caloric Reduction	Median Lifespan Extension	Key Physiological Observations
Ad Libitum (AL)	0% (Reference)	Reference	Progressive weight gain
1-Day Intermittent Fasting (1D IF)	~0%	Significant extension	Compensatory feeding; weight cycling
2-Day Intermittent Fasting (2D IF)	~12%	Greater than 1D IF	Significant weight cycling; erythroid disruption
20% Caloric Restriction (20% CR)	20%	Greater than IF regimens	Sustained lower weight
40% Caloric Restriction (40% CR)	40%	Greatest (36.3% over AL)	Profound lean mass loss; immune alterations

Beyond simple lifespan extension, CR opposes the development of many age-associated pathologies in rodents, including cancer, diabetes, autoimmune diseases, sarcopenia, and cardiovascular disease [38]. In non-human primate studies, CR has been shown to reduce the rate of age-associated muscle loss (sarcopenia) [38]. However, recent findings indicate that improving health and extending lifespan are not synonymous, raising important questions about which endpoints are most relevant for evaluating aging interventions in preclinical models and clinical trials [17].

Molecular Mechanisms Uncovered through Animal Studies

Gene expression profiling in animal models has been instrumental in uncovering the molecular mechanisms underlying CR. In mice, long-term CR causes overt shifts in transcriptional profiles, particularly in white adipose tissue (WAT). These shifts include increased expression of genes involved in energy metabolism (glycolysis, lipolysis, amino acid metabolism, and mitochondrial metabolism) and a marked down-regulation of pro-inflammatory genes [38]. This metabolic reprogramming and reduction in inflammation are thought to be central to CR's healthspan benefits.

The transcriptional co-activator PGC-1α has been identified as a key regulator of this process. CR increases PGC-1α mRNA levels in multiple tissues, and it coordinates the expression of nuclear-encoded genes involved in mitochondrial metabolism and the oxidative defense system [38]. This suggests that PGC-1α may act as a master regulator of the metabolic reprogramming induced by CR.

The Critical Role of Glucagon Receptor Signaling

From Correlation to Causation: Genetic Knockout Models

While the effects of CR have been long observed, the specific endocrine drivers have been clarified only recently. A pivotal discovery from animal studies is that glucagon receptor signaling is indispensable for the healthspan and lifespan benefits of CR. Research using global glucagon receptor knockout (Gcgr KO) mice demonstrated that the absence of this signaling pathway decreases median lifespan by 35% in lean mice [29]. More critically, when subjected to CR, these Gcgr KO mice fail to show the typical improvements in metabolic function and do not experience lifespan extension, unlike their wild-type counterparts [24] [29].

The metabolic benefits of CR, including decreased liver fat, serum triglycerides, and serum cholesterol, are absent in Gcgr KO mice [29]. This establishes a causal role for glucagon signaling in mediating the effects of CR, moving beyond mere correlation.

Downstream Signaling Pathways

Animal models have been essential for mapping the downstream signaling pathways through which glucagon receptor activation exerts its effects. The two primary pathways identified are:

• cAMP/PKA/CREB Pathway: Glucagon binding to its receptor activates adenylate cyclase, increasing intracellular cAMP levels and activating Protein Kinase A (PKA), which in turn phosphorylates the cAMP response element-binding (CREB) protein [41] [29]. This pathway can induce the expression of oxidative defense genes like heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1) [41].
• IP3/AMPK Pathway: Glucagon signaling also activates AMP-activated protein kinase (AMPK) via an IP3-dependent mechanism [29]. AMPK is a critical energy sensor and a known promoter of healthspan.

Activation of these pathways leads to the inhibition of the mTOR pathway, a known accelerator of aging [24] [29]. This mechanistic insight, largely gained from liver-specific knockout models (Gcgrhep−/−), reveals that glucagon's action on hepatic nutrient-sensing pathways (AMPK and mTOR) is a key conduit for its aging-modulatory effects.

Diagram 1: Glucagon-Mediated Signaling in Caloric Restriction. This diagram illustrates the central pathway through which caloric restriction and fasting elevate glucagon, leading to receptor activation and downstream signaling via cAMP/PKA/CREB and IP3/AMPK pathways, ultimately converging on healthspan benefits.

Advanced Animal Models in Geroscience Research

Refined Mouse Models for Enhanced Translation

The limitations of traditional animal models, particularly their failure to predict human outcomes in some historical cases (e.g., fialuridine toxicity), have driven the development of more sophisticated models [40]. These advanced systems are crucial for improving the translational potential of geroscience research.

• Humanized Mice: Mice can be modified to carry human genes, cells, or tissues. For example, humanized mice carrying human immune cells were instrumental in uncovering the causes of toxicities associated with CAR T-cell immunotherapy and therapies that "release the brakes" on the immune system to fight cancer [40].
• Naturalized Mice: Moving beyond ultra-clean laboratory conditions, researchers are now using "naturalized" mice exposed to more diverse environmental factors. These models develop more natural immune systems and have successfully reproduced the negative effects of drugs for autoimmune and inflammatory conditions that had previously failed in human clinical trials [40].
• Genetically Diverse Mice: The use of genetically diverse populations, such as Diversity Outbred (DO) mice, helps ensure findings are generalizable and allows researchers to identify physiological and genetic factors that predict individual responses to interventions like CR [17].

Experimental Workflow for Dietary Restriction Studies

A typical comprehensive study design, as implemented in large-scale projects like the Dietary Restriction in Diversity Outbred Mice (DRiDO) study, involves several key stages [17].

Diagram 2: Workflow for Dietary Restriction Studies. This diagram outlines the standard experimental workflow from cohort establishment and baseline phenotyping to long-term intervention, monitoring, and final analysis.

Translational Applications and Gerotherapeutic Development

Targeting Glucagon Signaling for Therapeutics

The insights gained from animal models are directly fueling drug development. The finding that glucagon signaling is essential for CR's benefits has prompted investigations into glucagon receptor agonists as a potential gerotherapeutic. Researchers are now testing long-acting glucagon agonists (e.g., NNC9204-0043) in aging mice, with promising data showing that glucagon agonism robustly inhibits the mTOR pathway [24]. Given that glucagon-containing dual- and tri-agonists (e.g., Retatrutide) are already in clinical trials for obesity and diabetes, there is significant potential for repurposing these drugs to target aging itself [24] [30].

Key Research Reagents and Models

Table 2: Essential Research Reagents and Models for Geroscience Studies

Reagent / Model	Function / Application	Example Use Case
Diversity Outbred (DO) Mice	Models human genetic diversity; identifies predictors of intervention response.	Studying variable individual responses to caloric restriction [17].
Global Gcgr KO Mice	Determines necessity of glucagon signaling for an observed phenotype.	Establishing that CR-induced lifespan extension requires glucagon signaling [29].
Liver-Specific Gcgr KO (Gcgrhep−/−)	Isolates the role of hepatic glucagon signaling.	Demonstrating that CR's inhibition of hepatic mTOR requires liver glucagon receptor [29].
Long-Acting Glucagon Agonist (e.g., NNC9204-0043)	Pharmacologically activates glucagon receptor signaling.	Testing if glucagon agonism mimics CR benefits in aging mice [24] [29].
Naturalized Mouse Models	Provides an immune system and physiology more reflective of humans.	Reproducing drug toxicities seen in human clinical trials [40].

Animal models remain indispensable in geroscience, evolving from simple tools for observing lifespan extension to sophisticated systems for deciphering molecular mechanisms and validating therapeutic targets. Research into caloric restriction has successfully moved from a phenomenological observation to the identification of a specific endocrine pathway—glucagon receptor signaling—as a critical mediator of its benefits. The continued refinement of animal models, including humanized, naturalized, and genetically diverse systems, enhances the translational potential of these findings. The convergence of evidence suggests that targeting the glucagon signaling pathway holds significant promise for developing interventions to extend human healthspan, potentially mimicking the benefits of caloric restriction without the need for severe dietary restriction. The integration of these sophisticated biological models with emerging technologies and multi-omics approaches will undoubtedly accelerate the development of gerotherapeutics.

Geroscience posits that aging is the primary risk factor for most chronic diseases, and targeting fundamental aging processes can concurrently delay multiple conditions. The endocrine system serves as a critical interface between these fundamental aging processes and systemic physiological decline. Hormones function as key signaling molecules that regulate metabolism, reproduction, stress response, and tissue maintenance throughout the lifespan. Within the updated hallmarks of aging framework—recently expanded to fourteen categories—endocrine pathways are recognized as both drivers and integrators of aging processes [42]. The neuroendocrine system, in particular, experiences profound changes with age, characterized by altered hormone secretion patterns, reduced receptor sensitivity, and disrupted feedback mechanisms [43] [44]. These changes manifest clinically as increased vulnerability to metabolic disease, cardiovascular disorders, cognitive decline, and reproductive senescence.

The geroscience approach to endocrine aging research seeks to identify biomarkers that reflect underlying biological age rather than chronological time, with the goal of developing interventions that can maintain hormonal homeostasis and extend healthspan. This technical guide provides researchers and drug development professionals with current methodologies, biomarkers, and experimental protocols for assessing endocrine and reproductive aging, with particular emphasis on sex-specific considerations and translational applications.

Biomarkers of Neuroendocrine Aging

The neuroendocrine system undergoes predictable changes with advancing age, characterized by altered rhythmicity, secretory capacity, and feedback sensitivity. These changes contribute significantly to the aging phenotype and associated disease risk.

Key Hormonal Changes in Aging

Table 1: Core Neuroendocrine Biomarkers of Aging

Biomarker	Age-Related Change	Physiological Consequence	Measurement Considerations
Growth Hormone (GH)	↓ Amplitude and frequency of pulsatile secretion	Reduced lean body mass, increased adiposity, diminished psychological well-being	Circadian rhythm effects; requires serial measurements or provocative tests
Insulin-like Growth Factor 1 (IGF-1)	Progressive decline	Altered body composition, reduced tissue repair capacity	Included in 2024 expert consensus as core aging biomarker [45]
Sex Steroids (Testosterone, Estradiol)	↓ Bioavailable fractions in both sexes	Altered body composition, bone density loss, vascular changes	Feedback loop alterations; consider binding protein changes [43]
Cortisol	↑ Diurnal flattening or inadequate stress response	Accelerated physiological decline, cognitive changes, metabolic dysfunction	Dysregulation of hypothalamic-pituitary-adrenal (HPA) axis feedback [44]
Luteinizing Hormone (LH)	↑ In postmenopausal women; variable in men	Altered reproductive function, potential direct tissue effects	Pulsatile secretion pattern complicates interpretation [43]

Experimental Protocols for Neuroendocrine Assessment

Protocol 1: Comprehensive Hormonal Profiling in Longitudinal Studies

• Sample Collection: Collect blood samples at standardized times (e.g., 8:00 AM after overnight fast) to minimize circadian variation. For pulsatile hormones, implement serial sampling every 10-20 minutes over 24 hours.
• Storage Conditions: Process samples within 2 hours of collection; store at -80°C in aliquots to prevent freeze-thaw degradation.
• Analytical Methods: Utilize validated immunoassays (ELISA, RIA) or mass spectrometry-based platforms for multiplexed hormone quantification. Mass spectrometry offers superior specificity for steroid hormones.
• Data Interpretation: Apply deconvolution algorithms to analyze pulsatile secretion patterns. Reference established age- and sex-stratified normative values.

Protocol 2: Dynamic Endocrine Function Testing

• Growth Hormone Axis: Implement insulin tolerance test (ITT) or growth hormone-releasing hormone (GHRH) + arginine stimulation to assess pituitary reserve.
• Adrenal Function: Use cosyntropin stimulation test or corticotropin-releasing hormone (CRH) stimulation test to evaluate HPA axis integrity.
• Gonadal Axis: Employ clomiphene citrate or gonadotropin-releasing hormone (GnRH) stimulation tests to assess hypothalamic-pituitary-gonadal (HPG) axis responsiveness.

Biomarkers of Female Reproductive Aging

Female reproductive aging provides a unique model for studying the interface between endocrine changes and systemic aging. The ovarian axis demonstrates accelerated aging compared to other systems, with profound consequences for women's health beyond fertility.

Established and Emerging Biomarkers

Table 2: Biomarkers of Female Reproductive Aging for Gerotherapeutic Trials

Biomarker Category	Specific Biomarkers	Utility in Aging Research	STRAW+10 Stage Association
Conventional Hormonal	FSH, Estradiol, Progesterone, LH	Reproductive staging, menopausal transition tracking	All stages
Ovarian Reserve	AMH, Inhibin B, Antral Follicle Count (AFC)	Quantification of remaining follicular pool; strongest predictor of reproductive age	Pre-menopause through late peri-menopause
Emerging Circulating	Sirtuin-1, microRNAs (e.g., miR-132, miR-145)	Cellular stress response; epigenetic regulation	All stages; may predict rate of decline
Tissue-Based	Menstrual blood markers, Ovarian stiffness (elastography), Vaginal microbiome	Local microenvironment assessment; minimally invasive sampling	Peri-menopause transition
Epigenetic	DNA methylation clocks (Horvath, DunedinPACE)	Biological age estimation; predictive of timing of menopause	All stages; integrative measure

Integrated Protocol for Assessing Gerotherapeutic Effects on Reproductive Aging

Based on recent recommendations for incorporating female reproductive biomarkers into clinical trials, the following protocol provides a comprehensive assessment framework [36] [32]:

Phase 2 Clinical Trial Design (1-year duration)

• Baseline Assessment:

  • Reproductive Staging: Apply STRAW+10 criteria incorporating menstrual cycle patterns, vasomotor symptoms, and endocrine parameters.
  • Blood Collection: Measure FSH, AMH, estradiol, progesterone, LH, and emerging biomarkers (Sirtuin-1, microRNAs).
  • Ultrasound Evaluation: Perform transvaginal ultrasound for antral follicle count (AFC) and ovarian volume.
  • Questionnaires: Administer Menopause Rating Scale (MRS), Fertility Quality of Life (FertiQoL), and female sexual function index.

• Short-term Follow-up (Every 3 months):

  • Repeat blood draws for hormonal and emerging biomarkers.
  • Document menstrual cycle regularity and symptoms.
  • Assess intervention safety and tolerability.

• Long-term Follow-up (Every 6 months):

  • Complete reproductive staging reassessment.
  • Repeat ultrasound evaluation.
  • Administer comprehensive quality of life questionnaires.
  • Collect additional biomarkers based on preliminary results.

Signaling Pathways in Endocrine Aging

Neuroendocrine Integration in Aging

Figure 1: Neuroendocrine Integration in Aging. This pathway illustrates the hierarchical organization of endocrine aging, highlighting feedback dysregulation as a key mechanism.

Inflammatory-Endocrine Crosstalk in Aging

Figure 2: Inflammatory-Endocrine Crosstalk. This pathway depicts the vicious cycle between chronic inflammation and endocrine dysfunction that accelerates aging.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for Endocrine Aging Studies

Reagent Category	Specific Products/Assays	Research Application	Technical Notes
Epigenetic Clocks	Horvath Clock, DunedinPACE, DunedinPoAm	Biological age estimation from DNA methylation data	Different clocks optimized for various tissues and research questions [46]
Multiplex Immunoassays	NULISA Technology, Luminex xMAP	Simultaneous quantification of 250+ aging-related proteins	Gold-standard sensitivity for inflammatory markers, hormones [47]
Advanced Sequencing	duet multiomics solution evoC (biomodal)	6-base genome analysis (A,C,G,T + 5mC, 5hmC)	Differentiates methylation states; reveals nuanced epigenetic aging [48]
Hormone Detection	ELISA kits (FSH, AMH, LH, Estradiol), Mass spectrometry	Quantification of reproductive hormones in serum/plasma	Consider antibody cross-reactivity; MS offers higher specificity
Cell Senescence	SA-β-gal kits, p16INK4a antibodies, Senescence-associated secretory phenotype (SASP) arrays	Detection and quantification of senescent cells	Combine multiple markers for specificity; tissue-dependent expression

Methodological Considerations and Standardization

Accurate assessment of endocrine aging requires careful attention to methodological variables that can significantly impact results. Temporal variation presents a particular challenge, as many hormones exhibit circadian, ultradian, and seasonal rhythmicity [43]. Standardized sampling times and conditions are essential for valid comparisons. The feedback-regulated nature of endocrine systems means that circulating hormone levels represent the net balance of secretion, metabolism, and tissue responsiveness. Dynamic function testing may be necessary to fully characterize age-related changes in axis integrity.

For female reproductive aging studies, the STRAW+10 staging system provides a standardized framework for participant categorization [32]. However, researchers should note that biomarkers like AMH demonstrate limited utility in later reproductive stages after the follicular pool is largely depleted. Emerging technologies such as 6-base genome sequencing that differentiates between 5mC and 5hmC methylation states promise more nuanced epigenetic clocks with improved predictive validity for reproductive aging [48].

Recent expert consensus has identified fourteen key biomarkers of aging spanning physiological, inflammatory, functional, and epigenetic domains that should be incorporated where possible in intervention studies [45]. This multi-dimensional approach captures the integrative nature of aging processes and provides a comprehensive assessment of gerotherapeutic efficacy.

The geroscience approach to endocrine aging emphasizes the central role of hormonal systems in mediating relationships between fundamental aging mechanisms and functional decline. Validated biomarkers of neuroendocrine and reproductive aging provide critical tools for quantifying biological age and assessing interventions targeting human healthspan. The protocols and methodologies outlined in this technical guide provide researchers with a framework for rigorous assessment of endocrine aging parameters in both basic and translational research contexts. As the field advances, integration of established endocrine biomarkers with emerging epigenetic, proteomic, and inflammatory markers will enable more precise evaluation of aging trajectories and intervention effects, ultimately supporting the development of evidence-based therapies to promote healthy longevity.

Geroscience represents a transformative biomedical paradigm that recognizes biological aging as the major modifiable driver of age-related diseases and functional decline [49]. This field posits that targeting the fundamental biological mechanisms of aging will simultaneously delay the onset and progression of multiple chronic conditions, thereby enhancing healthspan—the period of life spent in good health—more effectively than treating individual diseases separately [49] [10]. The hallmarks of aging, including altered nutrient sensing, mitochondrial dysfunction, and cellular senescence, provide a framework for identifying therapeutic interventions that target aging itself [49]. Among the most promising strategies in geroscience is drug repurposing—the application of existing FDA-approved medications to target aging biology. This approach offers distinct advantages, including established safety profiles, reduced development costs, and accelerated translation to clinical care [49] [50].

The endocrine system plays a crucial role in aging processes, with metabolic signaling pathways serving as key regulators of longevity and age-related decline. This whitepaper examines three prominent repurposing candidates with significant endocrine implications: metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, and rapamycin (sirolimus). These compounds target evolutionarily conserved nutrient-sensing pathways that influence aging, including AMPK, mTOR, and insulin signaling cascades [51] [52] [50]. We present a comprehensive technical analysis of their mechanisms of action, preclinical and clinical evidence, experimental methodologies, and potential integration into a geroscience-guided approach to combat age-related endocrine decline.

Geroscience Framework for Drug Repurposing

Biological Aging as a Therapeutic Target

Aging represents the single greatest risk factor for most chronic diseases that dominate healthcare systems, including cardiovascular disease, diabetes, cancer, and neurodegenerative disorders [49] [10]. The geroscience hypothesis proposes that by targeting the core mechanisms of biological aging, it may be possible to delay the onset of multiple age-related conditions simultaneously, thereby compressing morbidity and extending healthspan [49]. This approach represents a fundamental shift from the current disease-centric model of medical care toward one that addresses the underlying aging process [10].

The conceptual foundation of geroscience rests on several interconnected hallmarks of aging that include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, and altered nutrient sensing [49]. These fundamental processes interact to drive the aging phenotype and create vulnerability to age-related diseases. The drugs discussed in this whitepaper—metformin, GLP-1 receptor agonists, and rapamycin—primarily target the nutrient-sensing network, which has emerged as a central regulator of aging across species [51] [52] [50].

Regulatory and Methodological Considerations

A significant challenge in developing gerotherapeutics is the current regulatory landscape. Regulatory bodies such as the FDA and EMA do not yet recognize aging as a treatable condition, creating barriers to approval for geroscience-guided interventions [49] [10]. However, recent developments offer promising pathways forward. The International Classification of Diseases (ICD-11) now includes "aging-associated decline in intrinsic capacity" (MG2A) as a classification, potentially providing a foundation for future gerotherapeutic drug approvals [10].

To systematically evaluate potential gerotherapeutics, researchers have developed prioritization frameworks. One such approach uses a 12-point scale that assigns equal weight to preclinical and clinical evidence [49]. Preclinical scoring includes assessment of hallmarks of aging, healthspan improvements, and lifespan extension in validated models like the NIA's Interventions Testing Program (ITP) [49]. Clinical scoring evaluates healthspan outcomes beyond the drug's primary indication and effects on all-cause mortality [49]. This systematic approach allows for objective comparison of candidate gerotherapeutics and prioritization of resources for clinical translation.

Table 1: Geroscience Drug Prioritization Scoring System

Evidence Category	Evaluation Criteria	Maximum Points
Preclinical Evidence	Targets ≥3 hallmarks of aging	2
	Improves healthspan parameters in models	2
	Extends lifespan in ITP studies	2
Clinical Evidence	Healthspan benefits beyond primary indication	3
	Reduced all-cause mortality in observational studies	3
Total Possible		12

Metformin: A Multimodal Gerotherapeutic

Mechanisms of Action

Metformin, a biguanide derivative, has been used for decades as a first-line treatment for type 2 diabetes mellitus (T2DM), but its potential geroprotective effects extend far beyond glycemic control [51] [53]. The drug's complex mechanisms of action involve multiple target organs and cellular pathways. Primarily, metformin activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis often described as a "metabolic switch" [51] [53]. AMPK activation inhibits hepatic gluconeogenesis and enhances peripheral glucose uptake, but also influences aging-related processes including mitochondrial function, autophagy, and inflammation [51].

Recent research has revealed that the gastrointestinal tract represents a major site of metformin action, where it alters gut microbiota composition and increases glucagon-like peptide-1 (GLP-1) secretion [51]. At the molecular level, metformin inhibits mitochondrial complex I, leading to reduced ATP production and increased AMP:ATP ratio, which indirectly activates AMPK [51]. Additionally, at low concentrations, metformin binds to the lysosomal surface via PEN2, initiating a signaling cascade that ultimately inhibits mTORC1 activity—a key pathway in aging regulation [51]. These multimodal mechanisms position metformin as a promising candidate for targeting fundamental aging processes.

Diagram 1: Metformin's multimodal mechanism of action targets multiple aging pathways.

Preclinical and Clinical Evidence

In preclinical models, metformin has demonstrated promising effects on aging-related parameters. In the nematode C. elegans, metformin extends lifespan, an effect dependent on AMPK activation and the transcription factor SKN-1 [53]. Rodent studies have shown more variable results, with some reporting lifespan extension and others showing minimal effects [53]. These discrepancies may relate to differences in dosage, administration timing, or model systems. Beyond lifespan effects, metformin improves various healthspan metrics in animal models, including reduced oxidative stress, enhanced mitochondrial function, and delayed onset of age-related pathologies [53].

The clinical evidence for metformin as a gerotherapeutic primarily derives from observational studies in diabetic populations and a limited number of intervention trials. Numerous epidemiological studies have reported that diabetic patients taking metformin have reduced incidence of various age-related conditions, including cardiovascular disease, cancer, cognitive decline, and overall mortality compared to those using other glucose-lowering medications [49] [53]. Surprisingly, some studies have even found metformin-treated diabetics to have longer life expectancy than non-diabetic controls, suggesting potential geroprotective effects beyond glucose management—a phenomenon dubbed the "metformin paradox" [53].

The Targeting Aging with Metformin (TAME) study represents a landmark effort to directly test metformin's effects on aging in humans [49]. This multicenter, randomized, double-blind, placebo-controlled trial will enroll older adults (65-79 years) without specific chronic diseases and assess whether metformin can delay the onset of a composite endpoint comprising age-related conditions (cardiovascular events, cancer, dementia, and mortality) [49]. The TAME trial aims to establish a regulatory pathway for gerotherapeutic interventions by demonstrating that targeting aging itself can delay multiple age-related diseases simultaneously.

Table 2: Metformin Evidence Summary for Gerotherapeutic Application

Evidence Type	Model/Setting	Key Findings	References
Lifespan Studies	C. elegans	Lifespan extension via AMPK/SKN-1	[53]
	Mice (ITP)	Variable effects depending on strain and protocol	[53]
Healthspan Studies	Rodent models	Improved vascular function, reduced oxidative stress	[53]
	Human observational (T2DM)	Reduced cardiovascular events, cancer incidence	[49] [53]
Clinical Trials	UKPDS (T2DM)	36% reduction in all-cause mortality vs. diet alone	[53]
	TAME (upcoming)	Composite endpoint of age-related diseases	[49]

Experimental Protocols for Geroscience Research

Protocol 1: Assessing Healthspan Effects in C. elegans

• Synchronize L1 larvae by hypochlorite treatment and hatch in M9 buffer overnight
• Transfer larvae to NGM plates containing desired metformin concentrations (typically 1-50 mM)
• Maintain at 20°C, transferring daily during reproductive period to prevent progeny contamination
• Score survival daily until all animals expire; calculate median and maximum lifespan
• Parallel assays: pharyngeal pumping (healthspan metric), oxidative stress resistance (paraquat), mitochondrial function (ROS staining)
• Genetic analysis: include AMPK mutant strains (aak-1/2) to determine pathway specificity

Protocol 2: Human Clinical Trial Design (TAME-inspired)

• Participant selection: Non-diabetic adults aged 65-79 without major chronic diseases
• Intervention: Metformin (1700-2000 mg/day) vs. placebo in randomized, double-blind design
• Primary endpoint: Time to first occurrence of composite outcome (myocardial infarction, stroke, congestive heart failure, cancer, dementia, mortality)
• Secondary endpoints: Age-related biomarker panels (epigenetic clocks, inflammatory markers, metabolic parameters), physical function measures, cognitive assessments
• Study duration: Planned 6-year follow-up with quarterly assessments
• Statistical analysis: Cox proportional hazards model for primary endpoint, with subgroup analyses by sex, baseline age, and genetic factors

GLP-1 Receptor Agonists: Beyond Glycemic Control

Mechanisms of Action and Relevance to Aging

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of glucose-lowering medications that have demonstrated significant potential as gerotherapeutics [54] [50]. These compounds mimic the action of endogenous GLP-1, an incretin hormone secreted by intestinal L-cells in response to nutrient intake [54]. The canonical mechanism involves stimulation of GLP-1 receptors on pancreatic beta-cells, promoting glucose-dependent insulin secretion while suppressing glucagon release [54]. However, GLP-1 receptors are distributed throughout the body, including key regions of the brain involved in cognition, appetite regulation, and neuroprotection, such as the hypothalamus, hippocampus, and brainstem [54].

Beyond their metabolic effects, GLP-1 receptor agonists exert pleiotropic actions relevant to aging processes. These include reduction of oxidative stress, decreased amyloid-beta accumulation and tau phosphorylation in the brain, enhanced synaptic plasticity, and modulation of glial cell activity [54]. The neuroprotective effects are particularly promising, as they suggest potential for targeting age-related neurodegenerative conditions including Alzheimer's and Parkinson's diseases [54]. Additionally, GLP-1 receptor activation has been linked to cardiovascular protection through direct effects on vascular function and inflammation.

Evidence Base for Gerotherapeutic Application

Although originally developed for diabetes management, evidence is accumulating that GLP-1 receptor agonists may impact fundamental aging processes. Preclinical studies in rodent models have demonstrated that these drugs can reduce markers of cellular aging in various tissues and improve physical function in aged animals [50]. The significant weight loss and cardiovascular benefits observed in clinical trials have prompted investigation into their potential effects on biological aging pathways [50].

Epidemiological studies provide indirect support for the geroprotective potential of GLP-1 receptor agonists. Real-world evidence suggests that use of these medications is associated with reduced incidence of neurodegenerative conditions, including Alzheimer's disease and related dementias [54]. Ongoing clinical trials are directly testing the effects of GLP-1 receptor agonists on cognitive outcomes in at-risk populations.

Notably, a recent updated prioritization of FDA-approved drugs for gerotherapeutic repurposing identified GLP-1 receptor agonists as one of the top four candidates, alongside SGLT2 inhibitors, metformin, and bisphosphonates [50]. This ranking reflects growing consensus that these medications target multiple aging mechanisms beyond their primary metabolic effects.

Diagram 2: GLP-1 receptor agonists activate multiple tissue-specific pathways with geroprotective potential.

Rapamycin: Targeting the mTOR Pathway in Aging

mTOR Inhibition as a Geroscience Strategy

Rapamycin (sirolimus) and its analogs (rapalogs) represent perhaps the most compelling gerotherapeutic candidates from a mechanistic perspective, with robust evidence for lifespan extension across multiple model organisms [55] [52]. Originally discovered as an antifungal agent from Streptomyces hygroscopicus on Easter Island, rapamycin was later found to have potent immunosuppressive and antiproliferative properties [55] [52]. Its molecular target, designated the mechanistic target of rapamycin (mTOR), is an evolutionarily conserved serine-threonine kinase that functions as a master regulator of cell growth, proliferation, and metabolism in response to nutrients, growth factors, and cellular energy status [52].

The mTOR pathway integrates signals from various upstream regulators, including insulin/IGF-1, amino acids, and cellular energy status, to control anabolic and catabolic processes [52]. It exists in two distinct complexes: mTORC1, which is rapamycin-sensitive, and mTORC2, which is generally less sensitive to acute rapamycin treatment [52]. mTORC1 activation promotes protein synthesis, lipid biogenesis, and mitochondrial metabolism while suppressing autophagy [52]. Hyperactive mTOR signaling has been implicated in numerous age-related pathologies, including cancer, metabolic syndrome, and neurodegenerative disorders, making its inhibition a promising geroscience strategy [52].

Rapamycin's geroprotective effects are largely attributed to its ability to inhibit mTORC1, thereby inducing autophagy—a cellular recycling process that clears damaged proteins and organelles that accumulate with age [52]. By shifting cellular priorities from growth and proliferation to maintenance and repair, rapamycin conceptually mimics the biochemical effects of caloric restriction, the most robust non-genetic intervention for extending lifespan across species [52].

Preclinical and Clinical Evidence Base

Rapamycin represents the first pharmacological intervention demonstrated to extend lifespan in mammals, with studies from the NIA's Interventions Testing Program showing significant lifespan extension in both male and female mice when treatment begins in mid-life [49] [52]. These findings have been replicated across multiple laboratories and genetic backgrounds, with median lifespan increases of 9-14% and even more pronounced effects on maximum lifespan [52]. Beyond longevity effects, rapamycin improves numerous healthspan parameters in mice, including preserved cardiac function, reduced cognitive decline, delayed cancer incidence, and maintenance of immune competence [52].

In transgenic models of Alzheimer's-like pathology, rapamycin treatment prevents memory deficits and reduces pathological protein accumulation [52]. Similarly, in models of Tuberous Sclerosis Complex—a condition characterized by mTOR hyperactivation—rapamycin prevents seizures, reduces mortality, and rescues neuropathological abnormalities [52]. These findings highlight the potential of mTOR inhibition to modify disease processes relevant to human aging.

The clinical evidence for rapamycin as a gerotherapeutic remains limited but promising. Studies in healthy older adults have demonstrated that low-dose rapamycin or rapalogs can enhance immune function, as measured by improved response to influenza vaccination [55] [52]. However, other studies have reported potential adverse effects, including glucose intolerance, hyperlipidemia, and self-reported anxiety at certain doses [55]. Community use of rapamycin for longevity purposes has been associated with subjective improvements in well-being and reduced incidence of COVID-19 infection, though these findings are limited by self-reporting and lack of blinding [55].

Table 3: Rapamycin Evidence Summary for Gerotherapeutic Application

Evidence Type	Model/Setting	Key Findings	References
Lifespan Studies	Mice (ITP)	9-14% lifespan extension, both sexes	[49] [52]
	Yeast, worms, flies	Conserved lifespan extension across species	[52]
Healthspan Studies	Mouse models	Delayed cancer, improved cardiac and cognitive function	[52]
	Alzheimer's models	Reduced cognitive decline, protein pathology	[52]
Human Trials	Healthy older adults	Enhanced immune response to vaccination	[55] [52]
	Observational reports	Subjective health improvements, potential adverse effects	[55]

Experimental Protocols for mTOR Research

Protocol 1: Assessing mTOR Inhibition and Autophagy in Cell Culture

• Cell treatment: Apply rapamycin (typically 10-100 nM) to appropriate cell lines (e.g., HEK293, MEFs)
• Duration: Acute (minutes-hours) for signaling studies; chronic (days) for phenotypic assays
• mTOR activity assessment:
  • Western blot for phospho-substrates (pS6K1-T389, pS6-S240/244, p4E-BP1-T37/46)
  • Immunofluorescence for cellular localization of mTOR pathway components
• Autophagy measurement:
  • Western blot for LC3-I to LC3-II conversion and p62/SQSTM1 degradation
  • Fluorescent microscopy using GFP-LC3 or similar constructs
  • Flow cytometry with Cyto-ID autophagy dye
• Functional assays: Protein synthesis rates (SUnSET method), mitochondrial function (Seahorse analyzer)

Protocol 2: Rapamycin Administration in Mouse Aging Studies

• Formulation: Prepare rapamycin in ethanol stock (10 mg/mL), dilute in vehicle (e.g., 5% PEG-400, 5% Tween-80)
• Dosing regimens:
  • Continuous: 2-8 mg/kg diet or 1.5-4 mg/kg via injection
  • Intermittent: 1-2 weeks treatment alternating with 1-2 weeks off
• Administration routes: Dietary admixture, oral gavage, intraperitoneal injection
• Control groups: Vehicle-only treated mice, pair-fed controls if investigating CR-mimetic effects
• Endpoint assessments:
  • Survival tracking with frequent health monitoring
  • Mid- and end-of-life tissue collection for molecular analyses
  • Functional assessments: grip strength, rotarod, cognitive tests, glucose tolerance
  • Pathology: Comprehensive necropsy with histopathological scoring of age-related lesions

Diagram 3: Rapamycin extends healthspan and lifespan through mTORC1 inhibition and downstream cellular effects.

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Research Reagents for Gerotherapeutic Investigation

Reagent/Category	Specific Examples	Research Applications	Key Considerations
Animal Models	C57BL/6 mice (ITP protocol)	Lifespan studies, healthspan assessments	Genetic background, husbandry standardization
	UM-HET3 mice	Genetic diversity in aging interventions	NIA's Interventions Testing Program standard
	C. elegans (N2)	Rapid lifespan screening, genetic manipulation	Temperature control, bacterial food source
Cell Lines	Primary fibroblasts (human/murine)	Senescence assays, mechanistic studies	Donor age, passage number control
	MEFs (mouse embryonic fibroblasts)	mTOR signaling, autophagy studies	Early passage use, genetic background
Assay Kits	AMPK/mTOR phospho-antibody panels	Western blot, signaling pathway activation	Phosphoprotein preservation, normalization
	Senescence-associated β-galactosidase	Cellular senescence quantification	pH control, appropriate positive controls
	LC3-II/p62 autophagy kits	Autophagic flux measurement	Include lysosomal inhibitors for flux
Compound Formulations	Rapamycin (LC Laboratories)	In vitro and in vivo studies	Light sensitivity, solvent controls
	Metformin (Sigma-Aldrich)	Cell culture and animal studies	Dose response, osmotic considerations
	GLP-1 receptor agonists	Preclinical efficacy studies	Species-specific peptide homology

Comparative Analysis and Integration Strategies

Distinct and Complementary Mechanisms

While metformin, GLP-1 receptor agonists, and rapamycin all target nutrient-sensing pathways relevant to aging, they operate through distinct mechanisms that may offer complementary benefits. Metformin primarily activates AMPK, creating an energy-deprivation signal that inhibits anabolic processes [51] [53]. Rapamycin directly inhibits mTORC1, mimicking a state of nutrient scarcity and promoting autophagy [52]. GLP-1 receptor agonists engage incretin signaling that modulates both metabolic and neural functions [54] [50]. These differential mechanisms suggest potential synergistic effects when used in combination, though such approaches require careful evaluation of additive side effects.

The timing and context of administration may significantly influence the efficacy of each intervention. Preclinical evidence suggests that rapamycin's effects on lifespan are influenced by treatment initiation age, duration, and intermittency [52]. Similarly, metformin's effects may vary based on metabolic status, with some evidence suggesting more pronounced benefits in individuals with insulin resistance [53]. These considerations highlight the potential for personalized gerotherapeutic approaches based on individual aging biomarkers and risk profiles.

Challenges and Future Directions

Several significant challenges must be addressed to advance the repurposing of these drugs as gerotherapeutics. For rapamycin, safety concerns regarding chronic immunosuppression, metabolic disturbances, and other side effects necessitate careful dose optimization and scheduling [55] [52]. Intermittent dosing regimens or rapalog derivatives with improved therapeutic indices may help mitigate these concerns while preserving geroprotective effects.

For all candidates, establishing validated biomarkers of biological aging remains crucial for evaluating efficacy in human trials [10]. Epigenetic clocks, proteomic signatures, and functional measures are being developed to serve as surrogate endpoints for healthspan effects [10]. The TAME trial represents an important step in establishing a regulatory pathway for gerotherapeutics by using a composite endpoint of age-related diseases [49].

Finally, the economic and regulatory barriers to gerotherapeutic development must be addressed. The lack of recognized regulatory pathways for aging as an indication creates uncertainty for drug development [10]. Additionally, the generic status of metformin and rapamycin reduces commercial incentives for large-scale clinical trials, necessitating public or philanthropic funding for definitive studies [49] [10].

The repurposing of existing drugs to target aging processes represents a promising strategy within the geroscience framework. Metformin, GLP-1 receptor agonists, and rapamycin each offer compelling mechanisms and evidence bases supporting their potential as gerotherapeutics. While their pathways of action differ, all three converge on fundamental biological processes that influence aging and age-related diseases. As research in this field advances, the strategic combination of these agents, timed to specific stages of aging, may offer the greatest potential for extending healthspan and reducing the burden of age-related disease. The ongoing development of validated aging biomarkers and regulatory pathways will be essential to translate these promising approaches into clinical practice, ultimately enabling a transformative shift from disease-focused medicine to prevention-focused healthspan extension.

Geroscience posits that targeting the fundamental biological mechanisms of aging can simultaneously delay the onset and mitigate the severity of multiple age-related chronic conditions, rather than treating individual diseases in isolation [10] [56]. Within this paradigm, cellular senescence and metabolic dysregulation have emerged as two core, interrelated hallmarks of aging that contribute significantly to the decline of endocrine function and the pathogenesis of age-related metabolic diseases such as type 2 diabetes (T2D) [57] [58]. The accumulation of senescent cells with aging and obesity creates a pro-inflammatory milieu via the senescence-associated secretory phenotype (SASP), which drives local tissue dysfunction and systemic insulin resistance [59] [58]. Concurrently, aging is associated with a decline in the secretion and activity of key metabolic hormones. This review explores two novel therapeutic classes within this geroscience framework: senolytics, which selectively clear senescent cells, and glucagon-like peptide-1 (GLP-1) receptor agonists, which augment incretin signaling. These classes represent a strategic shift from managing single diseases to targeting the root causes of age-associated endocrine decline, with the goal of extending healthspan and improving functional capacity in aging populations [27] [56].

Senolytics: Targeting Cellular Senescence in Aging and Metabolism

The Biology of Cellular Senescence and SASP

Cellular senescence is a state of stable cell cycle arrest triggered by various stressors, including telomere shortening, DNA damage, oxidative stress, and metabolic signals such as hyperglycemia and saturated lipids [59] [58]. While this process serves as a beneficial mechanism to prevent the proliferation of damaged cells and facilitate tissue repair in the short term, the persistent accumulation of senescent cells with aging and obesity has deleterious consequences [60] [58]. A defining feature of senescent cells is the senescence-associated secretory phenotype (SASP), a robust pro-inflammatory secretome. The SASP comprises a complex mixture of factors, including:

• Pro-inflammatory cytokines: IL-1α, IL-6, IL-8, TNFα, interferon-γ [57]
• Chemokines that recruit immune cells [57]
• Matrix remodeling factors such as matrix metalloproteinases (MMPs) [57] [58]
• Growth factors (VEGF, HGF, IGF-1), bioactive lipids, and reactive oxygen species (ROS) [57]

The SASP propagates senescence in a paracrine and endocrine manner, creating a self-amplifying feedback loop that exacerbates tissue dysfunction and systemic inflammation, ultimately driving the pathogenesis of age-related metabolic diseases [57] [59].

Role of Senescence in Metabolic Dysfunction and T2D

Senescent cells accumulate in key metabolic tissues, where they actively impair glucose homeostasis through both cell-autonomous and non-autonomous mechanisms.

• Pancreatic β-cells: Senescence in β-cells leads to impaired glucose-mediated insulin secretion, increased basal insulin output, and a unique SASP enriched with factors like activin A that further disrupts β-cell function and promotes immune infiltration [57]. Human islets from diabetic donors show elevated markers of senescence [57].

• Adipose Tissue: Visceral adipose tissue acts as a significant reservoir for senescent cells, particularly in obesity [59]. Senescent adipocytes exhibit dysregulated adipogenesis, reduced lipid storage capacity, and a SASP that promotes macrophage infiltration, driving local and systemic insulin resistance [59] [58].

• Liver: Accumulation of senescent hepatocytes and non-parenchymal cells promotes hepatic steatosis and fibrosis through SASP-driven inflammation, linking senescence to non-alcoholic fatty liver disease (NAFLD), which frequently coexists with T2D [57].

• Skeletal Muscle: As the primary site for glucose disposal, the accumulation of senescent satellite cells and myofibers results in reduced mitochondrial function, muscle fiber degeneration, and downregulation of GLUT4 transporters, contributing directly to systemic glucose intolerance [57].

Table 1: Key Senescence Markers for Experimental Detection

Marker Category	Specific Marker	Function/Interpretation
Cell Cycle Arrest	p16INK4a (CDKN2A), p21CIP1	Central regulators of senescence growth arrest; elevated expression is a hallmark [57] [59].
Secretory Phenotype	IL-6, IL-8, MMPs, Activin A	Key components of the SASP; drive paracrine senescence and tissue inflammation [57] [58].
Metabolic/Lysosomal	SA-β-Gal (Senescence-Associated β-Galactosidase)	Increased lysosomal activity at pH 6.0; a widely used histochemical marker [58].
DNA Damage Response	γH2AX, p53	Indicate persistent DNA damage signaling, a common senescence trigger [58].

Mechanism of Action and Representative Senolytic Agents

Senolytic drugs exploit the unique dependence of senescent cells on senescent cell anti-apoptotic pathways (SCAPs). Despite their resistance to apoptosis, senescent cells remain vulnerable to targeted disruption of these specific pro-survival networks [59]. The first senolytics were identified using a mechanism-based approach to target key nodes in SCAPs.

• Dasatinib + Quercetin (D+Q): This combination was one of the first senolytic regimens described. Dasatinib, a tyrosine kinase inhibitor, is relatively selective for senescent human adipose progenitor cells, while the flavonoid quercetin targets senescent human endothelial cells and acts as a PI3K and serpine inhibitor. Together, they target a broader range of senescent cell types [59].

• Fisetin: A natural flavonoid found in fruits and vegetables, fisetin has demonstrated potent senolytic activity in animal models and is effective in clearing senescent cells across multiple tissues [59].

• Navitoclax (ABT263): This BCL-2/BCL-XL family inhibitor induces apoptosis in senescent cells but has shown dose-limiting platelet toxicity due to BCL-XL inhibition in platelets, spurring the development of more selective agents [59].

Senolytics are administered in a "hit-and-run" fashion, with intermittent dosing. This approach allows for the clearance of accumulated senescent cells in waves, reducing the potential for side effects associated with continuous drug exposure [59] [60].

Key Experimental Models and Methodologies for Senolytic Research

Research into senolytics relies on a combination of in vitro and in vivo models to establish efficacy and mechanism.

• In Vitro Senescence Induction: Primary cells or cell lines can be induced into senescence via:

  • Replicative Exhaustion: Serial passaging until proliferative arrest [58].
  • Genotoxic Stress: Exposure to ionizing radiation or chemotherapeutics (e.g., etoposide) [58].
  • Oxidative Stress: Treatment with hydrogen peroxide or paraquat [58].
  • Oncogene Activation: Induction of oncogenes like Ras [58].

• In Vitro Senolytic Testing: Following senescence induction, cells are treated with candidate senolytics. Efficacy is quantified by:

  • Cell Viability Assays: Comparison of viability in senescent vs. non-senescent cells (e.g., via ATP content assays). A true senolytic shows significantly greater cytotoxicity in senescent populations [59].
  • Apoptosis Assays: Measurement of apoptosis markers (e.g., caspase-3/7 activation, Annexin V staining) to confirm mechanism of cell death [59].
  • SASP Analysis: Quantification of SASP factor secretion (e.g., IL-6, IL-8) via ELISA or multiplex immunoassays post-treatment [57].

• In Vivo Models and Readouts:

  • Aged Mice: Naturally aged mice (e.g., >20 months) are used to study effects on physiological aging [57] [59].
  • Progeroid Models: Genetically modified mice with accelerated aging (e.g., Ercc1-/Δ mice) allow for faster intervention studies [59].
  • Diet-Induced Obesity (DIO) Models: High-fat diet-fed mice accumulate senescent cells in metabolic tissues and are ideal for studying T2D and NAFLD [58].
  • Senescent Cell Transplantation: Transplantation of relatively few senescent cells into younger mice is used to demonstrate their causal role in driving age-related pathologies and systemic dysfunction [59].

Diagram 1: Senolytic Mechanism of Action

Glucagon-like Peptide-1 Receptor Agonists: From Glycemic Control to Geroprotection

Physiology of GLP-1 and Mechanism of GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by enteroendocrine L-cells in the intestine in response to food intake. Its primary physiological roles include stimulating glucose-dependent insulin secretion from pancreatic β-cells, suppressing glucagon release from α-cells, delaying gastric emptying, and promoting satiety in the central nervous system [27] [61]. Endogenous GLP-1 has a very short half-life (1-2 minutes) due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) [61]. GLP-1 receptor agonists (GLP-1 RAs) are engineered analogs of human GLP-1 or exendin-4 (from the Gila monster) that are resistant to DPP-4 degradation, yielding a prolonged pharmacokinetic profile suitable for clinical use [61]. Their effects are mediated through binding to the GLP-1 receptor, a G-protein coupled receptor widely expressed in pancreatic islets, the brain, heart, gastrointestinal tract, and other organs [27] [61].

Pleiotropic Effects Beyond Glucose Control

While GLP-1 RAs are established for T2DM and obesity management, their effects extend far beyond glycemic and weight control, positioning them as potential geroprotective agents.

• Neuroprotection: GLP-1 RAs exhibit neurotrophic effects, reduce neuroinflammation, and enhance resistance to oxidative stress in neuronal cells. They promote neurogenesis and protect synapses, making them promising candidates for tackling age-related cognitive decline and neurodegenerative diseases like Alzheimer's and Parkinson's [27].

• Cardiovascular Benefits: GLP-1 RAs improve endothelial function, reduce atherosclerotic plaque inflammation, and have been shown in large cardiovascular outcomes trials to reduce major adverse cardiovascular events (MACE). They also modestly lower systolic blood pressure and improve lipid profiles [61].

• Musculoskeletal System: Preclinical evidence suggests GLP-1 and GIP receptors are present on bone cells. GLP-1 RAs may exert protective effects on the musculoskeletal system by influencing the activity of osteoblasts and osteoclasts, though clinical data in this area are still emerging [62].

• Cellular Homeostasis: GLP-1 signaling is linked to improved mitochondrial function, enhanced cellular stress resistance, and reduced inflammation, which are key processes in aging [27].

Table 2: Select GLP-1 Receptor Agonists in Clinical Use and Development

Drug (Brand Name)	Backbone	Dosing Frequency	Key Indications	Notable Trial Findings
Liraglutide (Victoza)	Human GLP-1	Daily	T2DM, Obesity	CVOT (LEADER): Reduced MACE [61].
Semaglutide (Ozempic/Wegovy)	Human GLP-1	Weekly (SC), Daily (Oral)	T2DM, Obesity	CVOT (SUSTAIN-6): Reduced MACE; potent weight loss [61].
Dulaglutide (Trulicity)	Human GLP-1	Weekly	T2DM	CVOT (REWIND): Reduced MACE [61].
Tirzepatide (Mounjaro)	GIP / GLP-1	Weekly	T2DM, Obesity	Dual GIP/GLP-1 RA; superior A1c and weight reduction vs. selective GLP-1 RAs [61].

Key Experimental Approaches for GLP-1 Research in Aging

Research into the geroprotective effects of GLP-1 RAs utilizes a range of models and precise methodologies.

• In Vitro Models:

  • Neuronal Cultures: Primary neurons or neuroblastoma cell lines are used to study neuroprotection, typically by exposing them to stressors like amyloid-β oligomers (for Alzheimer's modeling) or rotenone (for Parkinson's modeling) with and without GLP-1 RA co-treatment. Readouts include neuronal viability (MTT assay), apoptosis (caspase-3), synaptogenesis markers (PSD-95, synaptophysin), and measures of oxidative stress [27].
  • Pancreatic β-cell Lines: Insulinoma cells (e.g., INS-1, Min6) are used to study insulin secretion (GSIS assays), proliferation (BrdU incorporation), and protection from gluco/lipotoxicity [61].
  • Endothelial Cell Cultures: Human umbilical vein endothelial cells (HUVECs) are used to model vascular effects, assessing nitric oxide production, monocyte adhesion, and expression of adhesion molecules (VCAM-1, ICAM-1) under inflammatory conditions [27].

• In Vivo Models:

  • Aged Rodents: Treatment of naturally aged mice or rats assesses effects on cognitive function (Morris water maze, novel object recognition), motor performance (rotarod), body composition (DEXA), and lifespan/healthspan [27].
  • Diet-Induced Obesity (DIO) Models: Used to evaluate metabolic improvements beyond glucose, including hepatic steatosis (histology, lipidomics), adipose tissue inflammation (flow cytometry, gene expression), and cardiovascular function (echocardiography, blood pressure) [58] [61].
  • Neurodegenerative Models: Transgenic mouse models of Alzheimer's (e.g., APP/PS1) or Parkinson's (e.g., α-synuclein overexpression) are treated with GLP-1 RAs to assess amyloid/tau pathology, dopaminergic neuron survival, and behavioral outcomes [27].
  • Cardiovascular Models: Models of myocardial infarction (coronary artery ligation) or heart failure (aortic banding) are used to study infarct size reduction, cardiac remodeling, and functional improvement [61].

Diagram 2: GLP-1 RA Mechanisms and Geroprotection

The Scientist's Toolkit: Essential Reagents and Models

Table 3: Key Research Reagent Solutions for Senolytic and GLP-1 Agonist Studies

Category / Reagent	Function/Application	Example Assays/Readouts
Senescence Inducers
Etoposide / Doxorubicin	DNA damaging agents to induce stress-induced premature senescence (SIPS) in vitro.	SA-β-Gal staining, p21/p16 immunoblotting [58].
Hydrogen Peroxide (H₂O₂)	Oxidative stressor to induce premature senescence.	ROS detection (DCFDA), DNA damage foci (γH2AX) [58].
Senescence Detection
C12FDG (5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside)	Fluorogenic substrate for SA-β-Gal; allows FACS-based sorting of senescent cells.	Flow cytometry, live-cell imaging [58].
Antibodies: p16INK4a, p21CIP1	Immunodetection of key cell cycle inhibitors upregulated in senescence.	Immunocytochemistry, Western Blot, Immunohistochemistry [57] [59].
Cytokine Panels (IL-6, IL-8, etc.)	Quantification of SASP factor secretion.	ELISA, Luminex multiplex assays [57] [58].
Senolytic Compounds
Dasatinib (Src/TKI inhibitor)	First-generation senolytic; often used in combination with quercetin.	Cell viability (CellTiter-Glo), Apoptosis (Annexin V/Caspase) [59].
Fisetin (Flavonoid)	Natural product senolytic with broad tissue activity.	In vivo healthspan metrics, ex vivo SA-β-Gal quantification in tissues [59].
GLP-1 Agonists
Liraglutide	Human GLP-1 analog; long-acting (daily dosing).	Glucose tolerance tests (IPGTT), insulin secretion assays (GSIS) [61].
Semaglutide	Human GLP-1 analog; long-acting (weekly SC).	Cognitive behavioral tests, cardiovascular phenotyping [27] [61].
Exendin-4 (Exenatide)	Exendin-4 backbone GLP-1 RA; shorter half-life.	In vitro neuroprotection assays, β-cell function studies [61].
Animal Models
Aged C57BL/6 Mice	Gold standard for studying physiological aging.	Frailty index, physical function (grip strength, rotarod), lifespan studies [57] [59].
Diet-Induced Obese (DIO) Mice	Model of obesity, insulin resistance, and metabolic senescence.	Metabolic cage studies, hyperinsulinemic-euglycemic clamps, tissue histology [58].
db/db or ob/ob Mice	Genetic models of severe obesity and T2DM.	Rapid screening of glycemic efficacy [61].

The geroscience approach to endocrine aging is fundamentally reshaping drug discovery. Senolytics and GLP-1 receptor agonists exemplify this shift, moving from a reactive, disease-specific model to a proactive strategy targeting core aging mechanisms. While they originate from distinct biological concepts—clearing accumulated damage versus enhancing beneficial signaling—their pathways converge on improving metabolic health, reducing chronic inflammation, and protecting against end-organ damage. The future of this field lies in exploring potential synergies between these classes, identifying robust biomarkers of biological age for clinical trials, and navigating the evolving regulatory landscape for agents that target aging itself rather than a single disease [10] [56]. As evidence matures, these novel therapeutic classes hold the promise of not just adding years to life, but adding life to years, by extending healthspan and preserving functional capacity in an aging global population.

Geroscience posits that targeting the biological hallmarks of aging can simultaneously mitigate multiple age-related diseases. The endocrine system serves as a crucial interface in this paradigm, orchestrating systemic physiological decline through dysregulated hormone signaling. This whitepaper provides a technical framework for designing clinical trials that target endocrine aging mechanisms, with emphasis on protocol standardization, endpoint validation, and regulatory considerations. As the field advances, the development of gerotherapeutic interventions requires robust clinical validation frameworks that can accurately measure aging as a treatable condition [63]. The endocrine system offers particularly promising targets because many hormones demonstrate pleiotropic effects on multiple aging pathways, potentially enabling single interventions to address multiple age-related conditions simultaneously [7].

Key Endocrine Targets in Aging

Established and Emerging Hormonal Pathways

Endocrine aging involves the progressive dysregulation of multiple hormonal axes, creating promising targets for therapeutic intervention. Research has identified several key hormones with demonstrated or potential anti-aging properties when therapeutically modulated.

Table 1: Key Endocrine Targets for Aging Interventions

Hormone/Pathway	Primary Aging-Related Function	Therapeutic Potential	Development Stage
Glucagon	Regulates metabolic adaptations to fasting; inhibits mTOR signaling [24]	Mimics calorie restriction benefits; extends healthspan	Preclinical (mouse models)
Melatonin	Direct/indirect antioxidant; mitochondrial metabolism regulator [7]	Prevents oxidative damage; supports cellular energy	Available; anti-aging applications under investigation
IGF-1/Growth Hormone	Controls anabolic processes; tissue repair and maintenance [7]	Maintains muscle mass; supports cognitive function	Mixed evidence; risk-benefit profile requires clarification
α-MSH (α-melanocyte-stimulating hormone)	Regulates skin pigmentation; response to UV stress [7]	Prevents photoaging; maintains hair pigment	Experimental
Estrogens/Retinoids	Maintains skin connective tissue; stem cell survival [7]	Prevents wrinkle formation; supports tissue repair	Clinical use for menopausal symptoms and dermatology

Signaling Pathway: Glucagon-Mediated Longevity

The glucagon pathway has emerged as particularly significant following discoveries that it mediates many benefits of calorie restriction, one of the most robust longevity interventions. Research led by Dr. Jennifer Stern at the University of Arizona has demonstrated that glucagon signaling is critical for healthspan improvements stimulated by calorie restriction [24]. Her team found that mice lacking the glucagon receptor have shorter lifespans and fail to improve metabolic function or extend lifespan in response to calorie restriction.

This pathway visualization illustrates the mechanistic relationship between calorie restriction, glucagon signaling, and longevity outcomes. The discovery that glucagon agonism robustly inhibits the mTOR pathway provides a direct link to a fundamental aging mechanism previously associated with rapamycin, a known longevity compound [24]. This pathway offers promising translational potential since long-acting glucagon agonists are already in development by pharmaceutical companies like Novo Nordisk and Eli Lilly for metabolic diseases, potentially enabling repurposing for aging applications [24].

Endpoint Selection and Biomarker Validation

Biomarker Classification Framework for Endocrine Aging Trials

Validated biomarkers of aging are critically important tools for evaluating longevity interventions within realistic timeframes [64]. The current lack of standards and consensus on the properties of reliable aging biomarkers hinders their further development and validation for clinical applications [64]. A structured framework for biomarker characterization includes several key dimensions relevant to endocrine aging trials.

Table 2: Biomarker Categories for Endocrine Aging Trials

Biomarker Category	Measured Components	Clinical Applications	Examples
Epigenetic Clocks	DNA methylation patterns [65]	Cellular age estimation; intervention efficacy	Epigenomic profiling [65]
Blood-Based Biomarkers	70+ biomarkers including inflammatory cytokines, metabolic hormones [65]	Biological age assessment; metabolic health	Comprehensive aging blood tests [65]
Functional Performance	Physical capacity measures [65]	Healthspan assessment; frailty monitoring	6-minute walk test, muscle function [65]
Patient-Reported Outcomes	Quality of life measures [65]	Well-being assessment; intervention tolerability	SF-36 scores [65]
Organ-Specific Metrics	Cardiovascular, neurocognitive, kidney function [65]	System-specific aging evaluation	Vascular stiffness, cognitive batteries [65]

Composite Endpoints for Multi-System Assessment

Given the pleiotropic nature of endocrine interventions, composite endpoints that capture multi-system function provide the most meaningful outcome measures. The TAME Trial (Targeting Aging with Metformin) exemplifies this approach by examining whether metformin delays development or progression of multiple age-related chronic diseases simultaneously, including heart disease, cancer, and dementia [66]. This trial design acknowledges that endocrine interventions likely exert effects across multiple physiological systems rather than targeting single diseases.

Northwestern University's Human Longevity Laboratory has established a comprehensive assessment protocol that includes epigenomic profiling alongside cardiovascular, neurocognitive, and metabolic function tests [65]. This multi-system approach generates a integrated picture of biological aging that can detect subtle, system-wide improvements that might be missed by single-disease endpoints.

Experimental Protocols and Methodologies

Preclinical Protocol: Evaluating Glucagon Agonists in Aging Models

Dr. Stern's research provides a robust preclinical protocol for evaluating endocrine-based aging interventions:

Objective: To determine whether glucagon agonism can slow aging processes and extend healthspan in mouse models.

Subjects: Aging mice with intact glucagon receptors versus those lacking receptors (to establish mechanism specificity).

Intervention: Administration of long-acting glucagon agonists (such as those developed by Novo Nordisk) [24].

Duration: Lifespan determination requires full lifespan studies; initial metabolic assessments can be conducted at 3-6 month intervals.

Key Assessments:

• Metabolic function: Glucose tolerance, insulin sensitivity, energy expenditure
• Molecular pathways: mTOR signaling activity, mitochondrial function
• Physical function: Grip strength, endurance measures, cognitive tests
• Lifespan: Survival curves compared to control groups
• Healthspan: Time to onset of age-related pathologies

This protocol demonstrates the critical importance of including receptor-deficient controls to establish mechanism-specific effects. The research found that mice lacking glucagon receptors failed to show metabolic improvement or lifespan extension in response to calorie restriction, establishing the essential nature of this pathway for the intervention's benefits [24].

Clinical Trial Protocol: Endocrine-Targeted Interventions

Building on successful frameworks like the TAME Trial, endocrine aging trials should incorporate these key elements:

Population Selection: Adults aged 65-79, without specific age-related diseases but with evidence of biological aging (e.g., based on epigenetic clocks or functional measures) [66].

Intervention Duration: Minimum 2-4 years to detect changes in biological aging rates; long-term studies of 6+ years preferred for disease incidence outcomes [66].

Assessment Schedule: Baseline, 6-month, 12-month, and annual assessments thereafter, with more frequent safety monitoring in initial phases.

Primary Endpoints: Composite endpoints capturing multiple age-related conditions (e.g., time to first incidence of any age-related disease) [66].

Secondary Endpoints: Changes in biological age measurements (epigenetic clocks, biomarker panels), physical function measures, cognitive function, and quality of life assessments.

The high participant retention challenge in long-term studies must be addressed through careful trial design, as studies lasting more than two years often see high dropout rates that compromise data quality [65].

Research Reagent Solutions Toolkit

Table 3: Essential Research Reagents for Endocrine Aging Studies

Reagent/Category	Specific Examples	Research Application	Considerations
NAD⁺ Precursors	NMN, Resveratrol [65]	Boost NAD⁺ levels; study mitochondrial function	Human trials show dose-dependent safety (100-1,250 mg daily) [65]
Glucagon Agonists	Long-acting analogs (Novo Nordisk) [24]	Mimic calorie restriction benefits; target mTOR	Already in human trials for metabolic diseases
Hormone Analogs	Melatonin, α-MSH, Retinoids [7]	Study skin aging; oxidative stress responses	Melatonin well-tolerated; inexpensive antioxidant
Senolytics	Dasatinib + Quercetin, Fisetin [65]	Clear senescent cells; reduce inflammation	Various compounds in development
Epigenetic Clocks	DNA methylation panels [65]	Measure biological age; intervention effects	Require validation in diverse populations

Clinical Trial Workflow and Data Management

Implementing efficient data collection methodologies is essential for long-term aging trials. Research indicates that electronic Case Report Forms (eCRFs) significantly improve data quality and reduce costs compared to paper-based methods (pCRFs) [67]. One analysis found the total cost per patient was approximately 374€ with eCRFs versus 1,135€ with pCRFs, while also reducing the time between opening the first center and database lock (31.7 months vs. 39.8 months) [67].

This workflow emphasizes the critical importance of electronic data capture in maintaining data integrity throughout long-term trials. The preference for eCRFs among researchers (31/72 vs. 15/72 for paper) stems from easier monitoring and improved data quality [67]. For endocrine aging trials specifically, the comprehensive baseline assessment should include detailed hormone profiling, epigenetic clocks, and multi-system functional measures to establish pre-intervention aging trajectories.

Regulatory and Implementation Considerations

Navigating Regulatory Frameworks

The development of gerotherapeutics faces significant regulatory challenges that must be addressed in trial design. A recent scoping review of geroscience regulatory environments identified four major barriers [63]:

• Lack of recognition of biological aging processes as legitimate targets for medical intervention
• Absence of clear regulatory pathways to evaluate aging-focused therapies
• Economic uncertainties, including high development costs and limited incentives due to unclear regulatory environments
• Insufficient public and policy engagement and understanding

The TAME Trial represents a pioneering effort to establish aging as a treatable indication, potentially creating a regulatory pathway for future endocrine-based aging interventions [66]. This trial aims to provide proof-of-concept that aging can be treated as a condition, which would signify a paradigm shift from treating age-related diseases individually to targeting their underlying biological mechanisms collectively [66].

Statistical Considerations for Composite Endpoints

Longevity trials require specialized statistical approaches to handle their complex, multi-system endpoints. For categorical variables common in aging research (e.g., disease presence/absence, functional decline), Pearson's chi-square test is commonly used but has limitations in smaller samples (n ≤ 40) or when >20% of expected values are ≤5 [68]. In these cases, alternatives such as the Barnard and Boschloo exact tests for 2×2 tables or the G test with Williams' correction for multinomial comparisons are recommended [68].

For more complex designs involving interaction between multiple categorical variables or multivariate adjustments, Poisson regression (log-linear), logistic regression, and multinominal regression are appropriate analytical methods, though these are also penalized in cases with low frequencies in subgroups [68]. These statistical approaches must be specified a priori in trial protocols to ensure robust analysis of the composite endpoints that capture the multi-system nature of endocrine aging.

Designing clinical trials for endocrine aging requires integration of geroscience principles with rigorous endocrine methodology. The framework presented emphasizes targeting fundamental aging mechanisms through endocrine pathways, employing validated biomarker panels to measure biological age, and utilizing composite endpoints that capture healthspan extension. As the field advances, standardization of protocols and endpoints will enable better comparison across interventions and accelerate the development of safe, effective endocrine-based gerotherapeutics. The ongoing TAME Trial and research on hormones like glucagon provide foundational models for this emerging paradigm in which aging itself becomes a treatable indication [66] [24].

Navigating Research and Translation Challenges in Geroscience

Geroscience, the discipline focused on understanding and targeting the biological mechanisms of aging, holds transformative potential for medicine by extending healthspan and preventing multiple chronic diseases simultaneously. Despite rapid scientific advancement, the development and approval of gerotherapeutics are hampered by a critical obstacle: the absence of specific regulatory frameworks that recognize aging itself as a legitimate therapeutic target. This whitepaper delineates the principal barriers—conceptual, regulatory, economic, and translational—identified through a recent scoping review of 3,780 publications, which found zero geroscience-specific regulatory frameworks. It further proposes actionable solutions, including novel clinical trial designs, validated biomarker development, and regulatory pathway adaptation, to accelerate the translation of geroscience discoveries into clinical applications for endocrine aging and beyond.

The Geroscience Promise and the Regulatory Void

The fundamental premise of geroscience is that targeting the core biological processes of aging can concurrently delay the onset or reduce the burden of most age-related chronic diseases, such as cardiovascular disease, cancer, type 2 diabetes, and neurodegeneration [69]. Gerotherapeutics (or geroprotectors), such as senolytics, NAD+ boosters, and mTOR inhibitors, are designed to modulate hallmarks of aging like cellular senescence, mitochondrial dysfunction, and altered nutrient sensing [10].

However, a comprehensive scoping review of literature from 2014 to 2024, which screened 3,780 publications, found no formal regulatory frameworks specifically for gerotherapeutics [63] [10]. This regulatory void exists because aging is not classified as a disease by major health authorities like the WHO or the FDA. Consequently, therapies that target fundamental aging mechanisms are forced into disease-specific approval pipelines that do not align with their mechanisms of action or intended, multi-disease outcomes [69]. The recent inclusion of “aging-associated decline in intrinsic capacity” in the International Classification of Diseases (ICD-11) offers a potential foothold for regulatory dialogue, but a comprehensive pathway remains absent [10].

Analysis of Key Barriers to Gerotherapeutic Development

The following analysis synthesizes the four major barriers identified as impeding the development of regulatory frameworks for gerotherapeutics.

Conceptual Barrier: Aging is Not Recognized as a Treatable Condition

The foremost barrier is the ontological classification of aging as a natural, non-pathological process rather than a treatable condition.

• Impact on Research & Development: Without the classification of aging as a medical condition, there is no formal therapeutic indication for which geroprotectors can be developed. This forces researchers and pharmaceutical companies to pursue narrow, disease-specific indications for compounds that inherently have broader, systemic effects [69].
• Ethical and Social Concerns: This classification debate intersects with complex ethical questions regarding the "medicalization" of a natural life stage and the societal implications of significantly extended lifespans [70].

Regulatory Barrier: Absence of Clear Pathways for Approval

Existing regulatory pathways are designed for single-disease models and are ill-suited for evaluating interventions that target a systemic, multi-factorial process like aging.

• Disease-Centric Model: Agencies like the FDA and EMA approve drugs for specific diseases. A gerotherapeutic aimed at delaying multiple age-related conditions lacks a clear pathway for evaluation [10].
• Endpoint Challenges: Regulatory approval traditionally relies on clinical endpoints like disease incidence or mortality. For aging interventions, relevant endpoints such as multimorbidity-free survival, resilience, or compression of morbidity are complex, long-term, and not yet validated as surrogate endpoints for approval [69].

Economic Barrier: High Costs and Unclear Incentives

The uncertain regulatory landscape creates significant economic disincentives for private sector investment.

• High Development Costs: The long timeline required to demonstrate an extension of healthspan in humans leads to prohibitively high costs for clinical trials [63] [10].
• Unclear Reimbursement Models: Even if a gerotherapeutic were approved, payers and health systems lack models for reimbursing interventions that target a "risk factor" (aging) rather than a manifest disease [69].
• Patent and Exclusivity Issues: For repurposed generic drugs like metformin or rapamycin, securing patent protection and market exclusivity is challenging, further reducing commercial appeal [69].

Translational Barrier: Lack of Validated Biomarkers and Methodologies

The field lacks a standardized set of tools to efficiently measure the effectiveness of gerotherapeutics in clinical trials.

• Biomarker Gaps: While promising biomarkers exist, such as DNA methylation clocks and measures of senescent cell burden, none are yet validated by regulatory agencies for use as surrogate endpoints in approval decisions [10] [69].
• Trial Design Limitations: Traditional, short-term, disease-specific trial designs are inadequate. There is a need for innovative designs that can capture the systemic, gradual benefits of aging interventions [69].

Table 1: Summary of Major Barriers to Gerotherapeutic Development

Barrier Category	Key Challenges	Impact on Field
Conceptual	Lack of disease status for aging; Ethical debates on medicalization	No clear therapeutic indication for drug development
Regulatory	No dedicated approval pathway; Unvalidated endpoints (e.g., healthspan)	Forces disease-specific development for systemic therapies
Economic	Long, costly trials; Unclear reimbursement; Patent issues for repurposed drugs	Discourages large-scale pharmaceutical investment
Translational	Lack of regulatory-grade biomarkers; Unsuitable trial methodologies	Hampers proof-of-concept and efficacy demonstration in humans

Proposed Solutions and Forward-Looking Pathways

Overcoming these hurdles requires a coordinated, multi-pronged strategy involving researchers, regulators, and policymakers.

Adapting Existing Regulatory Precedents

Successful models from other therapeutic areas provide a template for creating pathways for gerotherapeutics.

• Tissue-Agnostic Oncology Approval: The FDA's guidance for approving cancer drugs based on molecular biomarkers regardless of tissue origin sets a precedent for mechanism-based approval rather than disease-based. This model could be applied to gerotherapeutics targeting processes like senescence [69].
• Accelerated Approval Programs: Utilizing pathways like the FDA's Accelerated Approval Program, which allows for authorization based on surrogate endpoints, could be pivotal. Surrogate endpoints for aging could include composite measures of frailty, intrinsic capacity, or specific biomarker panels, contingent on their validation [69].

Developing and Validating Biomarkers and Endpoints

A concerted global effort is needed to qualify endpoints for regulatory use.

• Composite Endpoints: The TAME (Targeting Aging with Metformin) trial exemplifies the use of a composite endpoint—the delay of onset of a cluster of age-related diseases—as a primary outcome [69].
• Functional and Physiological Measures: Simple, functional measures like gait speed and grip strength are strong predictors of health outcomes and should be considered for use as validated surrogate endpoints [69].
• Biological Age Clocks: Advancing and standardizing epigenetic clocks and other molecular biomarkers through regulatory-academic partnerships is critical for quantifying biological aging in clinical trials.

Implementing Innovative Clinical Trial Designs

Clinical trials for gerotherapeutics must evolve to be more efficient and informative.

• Adaptive and Platform Trials: These designs allow for the evaluation of multiple interventions simultaneously and can be modified based on interim results, reducing time and cost.
• Focus on At-Risk Populations: Enriching trials with individuals showing early signs of accelerated biological aging or frailty may increase the likelihood of detecting a significant intervention effect within a feasible timeframe.
• Incorporating Real-World Evidence (RWE): Platforms like the PROactive Solutions for Prolonging Resilience (PROSPR) program in the U.S. collect data on resilience and functional aging. RWE can supplement traditional trial data and provide insights into long-term effectiveness [69].

The following diagram illustrates the stark contrast between the current, fragmented regulatory approach and a proposed integrated model for evaluating gerotherapeutics.

Current vs. Proposed Regulatory Pathways

An Experimental Framework for Endocrine Aging Research

Targeting endocrine pathways is a prominent strategy in geroscience. The following section outlines a detailed experimental protocol based on recent research linking glucagon signaling to healthy aging, serving as a model for investigating gerotherapeutic candidates.

Detailed Protocol: Investigating Glucagon Agonism as a Gerotherapeutic

Background: Calorie restriction (CR) is a robust, non-genetic intervention that extends healthspan and lifespan across species. Recent work has identified the hormone glucagon, which counteracts insulin, as critical for mediating the benefits of CR [24].

Objective: To determine whether a long-acting glucagon agonist can recapitulate the metabolic and healthspan benefits of calorie restriction in an aging mouse model.

Materials and Methods:

• Animals: Aged wild-type mice (e.g., C57BL/6J, 20 months old).
• Intervention: Long-acting glucagon agonist (e.g., developed by Novo Nordisk) versus vehicle control.
• Treatment Regimen: Chronic administration via subcutaneous injection over a period of several months.
• Key Assessments:
  • Metabolic Phenotyping: Longitudinal monitoring of body weight, food intake, and glucose tolerance (IPGTT).
  • Lifespan Analysis: Survival is tracked to determine the effect on longevity.
  • Healthspan Measures: Functional assessments including grip strength (neuromuscular function) and rotarod performance (coordination/endurance).
  • Molecular Pathway Analysis: Post-mortem tissue collection for Western blot or RNA sequencing analysis of key aging pathways (e.g., mTOR, AMPK) in liver and muscle tissue.

Table 2: Research Reagent Solutions for Endocrine Aging Experiments

Reagent / Material	Function / Application	Example in Protocol
Long-Acting Glucagon Agonist	Pharmacologic activation of the glucagon receptor to mimic fasting signals.	Novo Nordisk compound used as the primary intervention.
Aged Mouse Model	In vivo system for studying aging interventions and lifespan.	20-month-old C57BL/6J mice.
Glucose Tolerance Test (IPGTT)	Assesses metabolic health and insulin sensitivity.	Performed at baseline and during the intervention period.
Functional Assessment Equipment	Quantifies physical resilience and healthspan.	Grip strength meter and rotarod apparatus.
Antibodies for mTOR Pathway	Measures activity of a key nutrient-sensing aging pathway.	Used in Western blot analysis of liver/muscle lysates.

Workflow and Signaling Pathway: The experimental workflow and the hypothesized mechanism by which glucagon agonism influences aging is summarized in the diagram below.

Glucagon Agonism Experimental Workflow

The translational potential of geroscience to revolutionize healthcare by targeting the root causes of age-related morbidity is immense. However, this potential is currently locked behind a significant regulatory hurdle. The lack of a defined regulatory framework for gerotherapeutics stifles innovation and investment. A coordinated, stepwise strategy is required to bridge this gap:

• Short-Term (0-2 years): Achieve stakeholder consensus on core biomarkers and clinical outcome measures. Initiate adaptive, proof-of-concept trials using repurposed drugs within existing regulatory pathways.
• Medium-Term (2-5 years): Develop and pilot dedicated regulatory frameworks that recognize aging as a modifiable risk factor. Incorporate Real-World Evidence and health economics modeling to build the case for reimbursement.
• Long-Term (5+ years): Secure formal international recognition of aging as a therapeutic indication through collaboration among regulatory authorities, establishing a clear and efficient pathway for the approval of gerotherapeutics.

By adopting these strategies, researchers, drug developers, and regulators can collaboratively overcome the current regulatory hurdles. This will enable the field to deliver on the promise of geroscience, transforming the goal of extending human healthspan from a compelling scientific concept into a tangible medical reality.

The geroscience hypothesis posits that targeting the biological mechanisms of aging itself has the potential to simultaneously forestall multiple aging-associated diseases [71]. Within this framework, the endocrine system represents a crucial yet underdeveloped frontier. Aging affects most living organisms and involves time-dependent multifactorial functional decline that reduces health and survival [72]. While several physiological processes become deregulated during aging—including genomic instability, telomere shortening, epigenetic alterations, and mitochondrial dysfunction—the specific metrics for quantifying endocrine aging remain poorly defined and validated [73].

The endocrine system's progressive functional decline drives pathophysiology across multiple organ systems, yet we lack the validated biomarkers necessary to track this decline or measure interventions against it. A biomarker is a measurable feature that predicts a biological state or condition, and biomarkers of aging should predict future health and survival better than chronological age alone [72]. According to the American Federation for Aging Research (AFAR), a good aging biomarker must: (1) predict biological age independently of chronological age; (2) be measurable without difficulty through routine methods like blood tests; (3) monitor a biochemical process linked to aging itself, not pathology; and (4) be monitorable in experimental models to allow animal-human extrapolations [73]. Currently, no endocrine aging biomarkers meet these rigorous criteria, creating a critical bottleneck in both basic research and clinical translation.

The Current Landscape of Aging Biomarkers

Established Biomarker Classes and Their Limitations

Research into aging biomarkers has expanded considerably, with several classes emerging as promising yet incomplete solutions for quantifying biological age. These biomarkers can be broadly categorized into several types, as summarized in Table 1.

Table 1: Major Classes of Aging Biomarkers and Their Relationship to Endocrine Aging

Biomarker Class	Example Metrics	Strengths	Limitations for Endocrine Aging
Immune System Markers	CD4/CD8 ratio, NK cell cytotoxicity, β-galactosidase activity [73]	Strong association with immunosenescence; measurable by flow cytometry	Correlates with, but does not specifically quantify, endocrine aging
Epigenetic Clocks	DNA methylation patterns, epigenetic age acceleration [72] [71]	Powerful predictors of chronological age and health outcomes	Tissue-specific variation; endocrine tissue access limitations
Proteomic & Metabolomic Signatures	Multi-protein panels, metabolite patterns [74]	Captures systemic physiological state; high-dimensional data	Correlation with endocrine function not established
Functional & Physical Metrics	Grip strength, gait speed, cognitive function [72]	Direct clinical relevance; non-invasive	Non-specific; influenced by multiple systems beyond endocrine
Cellular Senescence Markers	Senescence-associated secretory phenotype (SASP), p16 expression [73]	Mechanistic connection to aging processes	Limited tissue accessibility in humans

The Validation Crisis in Aging Biomarkers

The search for biomarkers that quantify biological aging has intensified in recent years, with particular focus on 'omics-based biomarkers [71]. Such biomarkers could potentially predict aging-related outcomes and serve as surrogate endpoints for evaluating interventions that promote healthy aging. However, no consensus exists on how biomarkers of aging should be validated prior to their translation to the clinic, creating a fundamental bottleneck for the entire field [71].

A comprehensive validation process must encompass multiple types of validation to establish reliability, accuracy, and clinical utility. Key validation types include:

• Biological validation: Evaluating the extent to which the measurement reflects fundamental knowledge about the biology of aging
• Cross-species validation: Assessing biomarker functionality in multiple species to establish phylogenetic conservation
• Predictive validation: Testing performance in predicting future aging-associated outcomes
• Analytical validation: Assessing accuracy and reliability of measurement methods
• Clinical validation: Determining whether using the biomarker improves understanding of aging processes and health outcomes [71]

For endocrine aging specifically, all these validation types represent significant gaps in our current research infrastructure and knowledge base.

The Specific Gaps in Endocrine Aging Biomarkers

Hormonal Axis-Specific Metrics

While numerous hormonal changes with aging are well-documented (e.g., declines in growth hormone, sex hormones, melatonin), what's missing are validated metrics that distinguish pathological hormonal changes from healthy endocrine aging. The field lacks:

• Dynamic testing protocols for endocrine resilience
• Multi-hormonal panels that capture system-level interactions
• Tissue-specific sensitivity markers for hormonal signaling
• Quantification of hormone receptor expression and function across tissues

The AMPK-MTOR signaling pathway represents a crucial interface between endocrine signaling and aging processes, yet standardized metrics for quantifying its activity in humans remain elusive.

AMPK-MTOR Endocrine Aging Pathway: This conserved nutrient-sensing pathway represents a key interface between endocrine signaling and aging processes, with calorie restriction (CR) and physical activity promoting AMPK activation (anti-aging), while excess nutrients and growth factors like IGF-1 activate MTOR (pro-aging) [73]. Pharmacologically, metformin activates AMPK while rapamycin inhibits MTOR.

Tissue-Specific Hormone Sensitivity Markers

A fundamental gap exists in our ability to measure tissue-level responsiveness to hormonal signals, which may decline with aging independent of circulating hormone levels. Critical missing metrics include:

• Hormone receptor isoform expression patterns
• Post-receptor signaling efficiency
• Tissue-specific hormone metabolism and clearance
• Cellular stress responses to hormonal stimulation

The absence of these metrics severely limits our ability to distinguish between hormone deficiency and hormone resistance states in aging tissues—a distinction with profound therapeutic implications.

Methodological Gaps and Research Infrastructure Needs

Data Generation and Cohort Limitations

Aging biomarker discovery is bottlenecked by the human cohorts and data that biomarker discovery efforts are based on [75]. Current datasets suffer from several critical limitations for endocrine aging research:

• Cross-sectional vs. longitudinal designs: Most studies provide only snapshot data, whereas endocrine aging requires longitudinal assessment to track within-individual changes [71]
• Selective participant attrition: Long-term studies face high dropout rates, potentially biasing results [76]
• Insufficient sampling density: Endocrine rhythms require higher-frequency sampling than typically collected
• Limited tissue accessibility: Endocrine function assessment often requires tissue samples beyond blood

Table 2: Critical Research Reagents for Endocrine Aging Biomarker Development

Research Reagent	Function/Application	Current Limitations
Senescence Assays	β-galactosidase activity detection in CD8 T lymphocytes [73]	Limited application to endocrine tissues; does not distinguish endocrine-specific senescence
Multiplexed Cytokine Panels	Quantification of IL-6, TNF-α, MIP1α, RANTES using ELISA [73]	Capture inflammatory status but not endocrine-immune interactions
Epigenetic Clocks	DNA methylation profiling for biological age estimation [71]	Limited validation for endocrine-specific aging
Flow Cytometry Panels	Immune cell profiling (CD4/CD8 ratio, NK cell function) [73]	Inadequate for endocrine cell populations
Omics Technologies	Proteomic, metabolomic profiling for biomarker signatures [74] [71]	High-dimensional data without endocrine-specific analytical frameworks

Analytical and Technological Limitations

The validation of biomarkers of aging requires a wide range of expertise in areas including the biological mechanisms of aging, design and construction of composite biomarkers, and execution of epidemiological studies that collect and store biological specimens [71]. Current analytical gaps specific to endocrine aging include:

• Lack of standardized sampling protocols for pulsatile hormone assessment
• Insufficient assay sensitivity for age-related changes in hormone receptor sensitivity
• Inadequate computational models for endocrine network analysis
• Absence of reference standards for tissue-specific hormone action

The emergence of composite biomarkers—panels of molecular biomarkers more likely to capture systemic effects of the complex aging process than single molecules—offers promise but requires specialized adaptation for endocrine systems [71].

A Framework for Validating Endocrine Aging Biomarkers

Comprehensive Validation Strategy

A rigorous validation framework for endocrine aging biomarkers must address multiple dimensions of validation simultaneously. The pathway from discovery to clinical application involves sequential validation stages, each with specific requirements and decision points.

Endocrine Biomarker Validation Workflow: Comprehensive validation requires progression through multiple stages, from initial discovery to clinical application, with specific validation components at each stage ensuring biomarker reliability and relevance [71].

Recommended Experimental Protocols for Endocrine Biomarker Development

To address the critical gaps in endocrine aging biomarkers, researchers should implement the following methodological approaches:

Longitudinal Cohort Studies with Dense Sampling

• Implement frequent sampling protocols (diurnal, seasonal) to capture endocrine rhythms
• Establish age-stratified cohorts with deep phenotyping
• Incorporate dynamic testing (stimulation/suppression tests) for endocrine axes
• Collect multiple biospecimens (blood, saliva, urine, when possible tissue)

Multi-Omic Integration for Endocrine Network Analysis

• Combine genomic, epigenomic, transcriptomic, proteomic, and metabolomic data
• Develop computational models specifically for endocrine signaling networks
• Apply pathway-based analyses rather than single-molecule approaches
• Implement machine learning methods capable of detecting non-linear endocrine relationships

Functional Assessment Across Biological Scales

• Develop ex vivo tissue models for hormone responsiveness
• Implement tissue-specific imaging approaches for endocrine function
• Create integrated metrics that combine circulating hormones with tissue responsiveness
• Validate against clinical functional outcomes relevant to endocrine aging

The development of validated biomarkers for endocrine aging represents both a critical challenge and tremendous opportunity within geroscience. By addressing the specific gaps outlined in this review—including tissue-specific sensitivity metrics, dynamic testing protocols, and multi-dimensional validation frameworks—the field can accelerate progress toward interventions that target endocrine aging itself. The geroscience approach demands nothing less than rigorous, validated biomarkers that can track the fundamental processes of endocrine aging rather than merely documenting its downstream consequences. Only with such tools can we hope to develop effective interventions that delay, prevent, or reverse endocrine aging and its associated morbidities.

The validation of biomarkers of aging requires collaboration between basic scientists and clinical investigators, leveraging longitudinal cohort studies with careful attention to standardization and harmonization across populations with unique characteristics [71]. As global demographics continue shifting toward older populations, the imperative to solve these challenges has never been greater.

The geroscience hypothesis posits that targeting the fundamental mechanisms of aging can simultaneously delay the onset and mitigate the severity of multiple age-related chronic diseases, thereby extending healthspan. Endocrine aging, characterized by the progressive decline of hormonal functions and signaling pathways, is a central pillar of this paradigm. The translational pathway from basic discoveries in model organisms to effective clinical interventions in humans, however, is fraught with challenges. These include the phylogenetic distance between standard animal models and humans, the multifactorial nature of aging, and the lack of validated biomarkers for aging processes. This review synthesizes current strategies and emerging tools designed to bridge this translational gap, with a specific focus on endocrine aging research. We detail a framework encompassing sophisticated animal model selection, advanced computational predictions, and innovative clinical trial designs to accelerate the development of geroprotectors and other interventions aimed at the core processes of aging.

Comparative Biology: Selecting Optimal Animal Models for Geroscience

The choice of an animal model is a critical first step in geroscience research, as it profoundly influences the predictive validity and translational potential of preclinical findings. No single model is perfect; therefore, selection must be guided by the specific research question, whether it pertains to basic aging mechanisms, metabolic syndrome, neurodegenerative decline, or reproductive senescence [77].

A comparative biology approach that leverages the unique characteristics of diverse species can provide unparalleled insights. For instance, long-lived species such as naked mole-rats and certain bird species exhibit exceptional resistance to age-related pathologies, offering natural models for studying protective mechanisms [77]. Conversely, short-lived models like the Japanese quail allow for rapid assessment of lifelong interventions on development, health, and aging, particularly for endocrine and metabolic studies [77].

The table below summarizes key vertebrate models used in aging research, highlighting their advantages and primary applications.

Table 1: Vertebrate Animal Models in Aging and Endocrine Research

Animal Model	Key Advantages for Aging Research	Translational Applications & Notes
Inbred Mice & Rats	Extensive genetic tools, short lifespan, well-characterized physiology, availability of aging cohorts [77].	Study of conserved molecular pathways; effects of caloric restriction; drug screening.
Naked Mole-Rat	Exceptional longevity, resistance to cancer and neurodegeneration, sustained vitality [77].	Insights into neuroprotective and tumor-suppressive mechanisms; exceptional aging.
Domestic Pig	Similar body size, cardiovascular system, and omnivorous diet to humans [77].	Excellent for studying circulatory/cardiac function and metabolic syndrome.
Non-Human Primates	Close phylogenetic relatedness, similar reproductive aging (menopause), complex social behaviors [77].	Gold standard for human physiology and cognitive aging; expensive and long-lived.
Domestic Dogs	Shared environment with humans, naturally occurring age-related diseases, varying lifespans by breed [77].	Studies on healthspan interventions (e.g., Dog Aging Project).
Japanese Quail	Short lifespan, well-characterized endocrine and reproductive physiology, embryonic development outside maternal input [77].	Rapid assessment of endocrine disruptors and interventions on development and aging.

The translational conundrum lies in selecting models that adequately emulate key human aging processes while remaining practical for laboratory studies. Key considerations include conserved molecular mechanisms, cost, housing requirements, availability of research tools (e.g., transgenics, biomarkers), and relatability to human physiology [77]. Furthermore, the actions of environmental stressors, such as endocrine disruptors, can alter both developmental and aging processes, contributing to lifelong issues with inflammatory and neurodegenerative conditions. Therefore, models like birds, where embryonic development occurs outside constant maternal input, allow for direct manipulation to observe effects on lifelong health and aging trajectories [77].

Methodological Frameworks: From Bench to Bedside

In Silico Profiling of Geroprotectors

The discovery of geroprotectors—compounds designed to modulate core aging pathways—is increasingly aided by computational methods. These in silico approaches help prioritize candidates for experimental testing by predicting their polypharmacological profiles, which is crucial given the pleiotropic nature of aging.

The PASS GERO application is one such tool, which uses a machine learning-based approach to predict the biological activity spectrum of a compound from its chemical structure. It estimates probabilities for over 100 aging-related biological activities, such as senolysis, mTOR inhibition, AMPK activation, and sirtuin modulation [78]. The underlying model is trained on a large dataset of known bioactive compounds and achieves high predictive accuracy (average Invariant Accuracy of Prediction of 0.967) [78]. The workflow for using this tool is as follows:

Diagram 1: In Silico Geroprotector Screening

Validation studies using known geroprotectors like rapamycin, metformin, and resveratrol demonstrate strong concordance between PASS GERO's predictions and their documented mechanisms of action, confirming its biological relevance [78]. This tool enables the virtual screening of large compound libraries, guiding the synthesis of novel analogs and planning targeted experimental studies.

Knowledge Translation and Bridging the "Valley of Death"

The "valley of death" in translational research refers to the gap between promising preclinical discoveries and their application in clinical practice. Knowledge Translation (KT) is a dynamic, iterative process designed to bridge this gap. The Canadian Institutes of Health Research (CIHR) defines KT as "a dynamic and iterative process that includes synthesis, dissemination, exchange, and application of knowledge to improve health outcomes, deliver effective health services and products, and strengthen healthcare systems" [79].

Successful KT relies on collaboration between three key stakeholder groups:

• Evidence Producers: Researchers, public health institutes, and health information analysts who generate data.
• Evidence Users: Policymakers, clinicians, and practitioners who contextualize and apply evidence.
• Knowledge Brokers: Intermediary organizations or individuals (e.g., WHO, Cochrane, professional bodies) who facilitate the exchange between producers and users [79].

Platforms and tools that facilitate KT include policy dialogues, advisory committees, integrated knowledge translation (IKT) co-production frameworks, and digital tools like social media [79]. A major challenge is that research evidence is often not translated into action due to implementation challenges at individual and institutional levels. Effective KT requires leadership, collaborative partnerships, organizational readiness, and the contextualization of evidence to specific settings [79].

The Clinical Frontier: Trial Design and Geroprotector Translation

Translating geroprotectors into clinical use presents unique challenges. Unlike drugs for a single disease, geroprotectors aim to target multiple age-related conditions simultaneously by modulating fundamental aging processes [80]. This necessitates a rethinking of traditional clinical trial paradigms.

Key Challenges in Clinical Translation

• Lack of Agreed-Upon Definitions: There is no universally accepted operational definition of frailty or biological aging, making patient selection and endpoint measurement difficult [80].
• Animal Model Limitations: While murine models are invaluable, their predictive validity for human aging is not fully established. There is a need for better animal models that recapitulate human frailty and multimorbidity [80].
• Outcome Measures: Regulatory agencies traditionally require evidence based on a singular primary endpoint (e.g., mortality or disease-specific outcome). For geroprotectors, which are expected to have broad, pleiotropic effects, this is inadequate. There is a critical need for validated biomarkers of aging and composite endpoints that measure healthspan and functional resilience [81] [80].
• Patient Selection: Determining the optimal target population—whether the relatively healthy, the pre-frail, or the frail—is complex and has significant implications for trial outcomes and risk-benefit assessments [80].

Promising Clinical Research Areas

Several research areas are showing significant promise from a clinical perspective:

• Senolytics: Compounds that selectively eliminate senescent cells have shown potential to enhance healthspan in preclinical models, with several now in clinical trials [81].
• Alleviating Inflammaging: Chronic, low-grade inflammation (inflammaging) is a hallmark of aging. Anti-inflammatory drugs have proven effective in preclinical models, but their efficacy and side-effect profiles need validation in clinical trials [81].
• Optimizing Metabolism with Endogenous Metabolites: Metabolites and their precursors (e.g., NAD+ boosters) have been extensively studied in animals for their ability to delay aging. However, further clinical evidence is needed to confirm their significance in humans [81].

The move towards precision health is also shaping the future of interventions. This involves tailoring strategies to an individual's genetic, molecular, physiologic, and exposure profiles [82]. This spectrum ranges from "one-size-fits-all" medicines to "ultra-precise" or individualized medicines, such as patient-specific neoantigen targeting therapies. Geroprotectors represent an interesting category within this framework, as they are often designed to have broad, systemic effects on multiple age-related pathways and conditions, in contrast to interventions with a very circumscribed effect [82].

Table 2: Mechanisms of Action of Selected Geroprotectors

Geroprotector / Class	Primary Molecular Target / Pathway	Predicted/Confirmed Biological Activities (from PASS GERO) [78]
Rapamycin	mTORC1 inhibitor	Autophagy inducer, Immunosuppressant, Antineoplastic
Metformin	AMPK activator	Antidiabetic, AMP-activated protein kinase subunit inhibitor
Resveratrol	SIRT1 activator	Antioxidant, Senolytic activity, Antimutagenic
Senolytics (e.g., Dasatinib + Quercetin)	Senescence-associated anti-apoptotic pathways (SCAPs)	Apoptotic agonist, Senolytic activity, Protein kinase inhibitor
NAD+ Boosters (e.g., NR, NMN)	Sirtuin activator, Mitochondrial function	Not specified in search results

The Scientist's Toolkit: Essential Research Reagents and Materials

The following table details key reagents and tools essential for conducting research in translational geroscience.

Table 3: Research Reagent Solutions for Translational Geroscience

Research Reagent / Material	Function and Application in Aging Research
PASS GERO Software	In silico prediction of a compound's geroprotective activity profile based on its chemical structure, used for virtual screening and hypothesis generation [78].
Animal Models (See Table 1)	In vivo systems for studying aging trajectories, testing interventions, and understanding conserved biological pathways in a whole-organism context [77].
Biomarker Assay Kits	Tools for measuring molecular markers of aging (e.g., senescence-associated beta-galactosidase, inflammatory cytokines, metabolomic profiles) in tissues and biofluids.
Specific Antibodies	Immunodetection of key aging-related proteins (e.g., p16, p21, γH2AX, phospho-S6) in immunohistochemistry and Western blotting to assess cellular senescence and pathway activity.
Geroprotector Compounds	Pharmacological tools (e.g., Rapamycin, Metformin, Senolytics) used to modulate aging pathways in model systems and validate computational predictions [78] [81].

Bridging the translational gap in endocrine aging and geroscience requires a multifaceted, integrated strategy. This involves the judicious selection of animal models based on specific research questions, the application of computational tools for candidate prioritization, and the implementation of robust Knowledge Translation frameworks to ensure research evidence informs policy and practice. The future of the field hinges on developing validated biomarkers of aging and innovative clinical trial designs that can capture the pleiotropic benefits of geroprotectors. By embracing this comprehensive approach, the scientific community can accelerate the development of effective interventions that target the root causes of age-related decline, ultimately extending human healthspan and compressing morbidity.

Addressing Sex-Specific Differences in Aging Research and Clinical Trials

The geroscience hypothesis posits that targeting the biological mechanisms of aging can simultaneously delay the onset and reduce the burden of multiple chronic diseases. Within this framework, the endocrine system serves as a critical interface between genetic programs and environmental influences, orchestrating systemic aging processes. However, a fundamental limitation has historically plagued this research: the default use of male models in preclinical studies and the insufficient analysis of sex differences in clinical trials. Recent findings demonstrate that sex-specific differences profoundly impact aging trajectories, disease susceptibility, and therapeutic responses, necessitating their integration into all facets of aging research [83] [84]. This paradigm is especially crucial in endocrine aging research, where hormones exhibit sexually dimorphic patterns and interact differently with aging pathways between males and females.

The National Institute on Aging has recognized this imperative, convening workshops to examine the "mechanistic bases of sex differences in organ functions across multiple organs and ages" [84]. This technical guide provides researchers and drug development professionals with evidence-based frameworks, methodological standards, and analytical tools to rigorously incorporate sex as a biological variable in geroscience research, with particular emphasis on endocrine aging.

Quantitative Evidence of Sex Differences in Aging Biology

Documented Sex Differences in Lifespan and Healthspan Interventions

Compelling evidence from murine studies reveals that pharmacological interventions can produce strikingly different outcomes in males and females. The following table summarizes key findings from recent investigations:

Table 1: Sex-Specific Responses to Anti-Aging Interventions in Model Organisms

Intervention	Male Response	Female Response	Study Model	Reference
OT+A5i (Oxytocin + Alk5 inhibitor)	73% life extension from treatment time; 14% increase in overall median lifespan; significant improvements in endurance, agility, and memory	No significant lifespan or healthspan gains; short-term benefits only; middle-aged females showed improved fertility	Frail elderly mice (25 months, ~75 human years)	[85]
Rapamycin	More pronounced lifespan extension in ITP studies (11.8% avg./median lifespan)	Moderate lifespan extension in ITP studies (6.7% avg./median lifespan)	Genetically heterogeneous mice (ITP studies)	[86]
17-alpha-estradiol	Effective even when initiated late in life (≥9 months)	Varying responses depending on strain and administration protocol	Various mouse strains	[86]
Caloric Restriction Mimetics	Significant correlation between weight loss and lifespan extension	Weaker correlation between weight loss and lifespan extension	Mouse lifespan studies	[86]

Analysis of the DrugAge database reveals that among 373 murine experiments, males showed a higher number of experiments with significant average/median lifespan extension (36% vs. 29% for females) [86]. In Interventions Testing Program (ITP) studies, lifespan extension was "much more pronounced in males (5.5%) than in females (1.6%)" for average/median lifespan, with similar disparities in significant effects (males: 11.8%; females: 6.7%) [86]. These findings underscore that sex differences are not merely quantitative but may represent fundamentally distinct biological responses to intervention.

The Human Sex Paradox in Aging

Human epidemiological data reveals a complex paradox: while women consistently outlive men, they experience greater frailty and worse health in later life [83]. The survival advantage in women is evident across diverse human populations and is observed in many mammalian species [83]. This paradox highlights that the relationship between lifespan and healthspan is modulated by sex-specific factors, necessitating distinct therapeutic approaches for each sex.

Table 2: Sex Differences in Human Aging Patterns

Parameter	Male Pattern	Female Pattern	Clinical Implications
Longevity	Shorter lifespan	Longer lifespan; sex ratio of ~25 men per 100 women among centenarians	Women's survival advantage persists despite sociocultural progress
Physical Function	Better performance in physical function examinations in later life	Higher frailty indices despite longer lifespan	Different disability trajectories require sex-tailored interventions
Disease Susceptibility	Higher early-life mortality; different age-related disease profiles	Higher multimorbidity in advanced age	Sex-specific prevention strategies needed
Biological Age	Higher biological age by molecular biomarkers	Lower biological age by molecular biomarkers	Biomarkers must be validated in both sexes

Biological Mechanisms Underlying Sexual Dimorphism in Aging

Endocrine System and Sex-Specific Aging Trajectories

The endocrine system undergoes profound changes with aging that manifest differently between sexes. Several key axes demonstrate clear sexual dimorphism:

Somatotropic Axis: The age-related decline in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) - the somatopause - exhibits sex-specific patterns. While both sexes experience declining GH and IGF-1 with age, the functional consequences differ. Intriguingly, "growth hormone–IGF-1 deficiency or resistance is known to result in prolonged life expectancy, at least in animals" [87]. Mutations that decrease GH–IGF-1 signaling are associated with extended longevity in mice, though corresponding human mutations have not been definitively linked to longevity [87]. Research on Laron syndrome patients suggests that IGF-1 deficiency may protect against age-related cognitive decline, highlighting potential therapeutic implications [87].

Thyrotropic Axis: Aging alters thyroid function differently in men and women. Population studies show that after excluding thyroid disease and positive anti-thyroid antibodies, aging is associated with increasing TSH concentrations, stable free thyroxine (FT4), and declining free tri-iodothyronine (FT3) [87]. These changes have different clinical implications for each sex, with slightly lower hypothalamic-pituitary-thyroid axis activity potentially being beneficial during aging [87]. Older individuals with subclinical hypothyroidism or higher TSH within the normal range demonstrate lower mortality than euthyroid individuals, suggesting an adaptive mechanism that may contribute to longevity [87].

Fundamental Mechanisms Driving Sex Differences

Two primary biological explanations account for sexual dimorphism in aging:

Sex-Chromosomal Linked Mechanisms: The fundamental genetic differences between males (XY) and females (XX) create divergent trajectories from conception. Men face greater susceptibility to X-linked recessive diseases, while women benefit from a double X chromosome with compensatory X-chromosomal inactivation [83]. Additionally, men experience loss of Y (LOY) with aging, which contributes to genomic instability [83]. Mitochondrial inheritance through the maternal line further creates different evolutionary pressures and selection patterns between the sexes [83].

Sex Hormonal Effects: Sex steroids including androgens, estrogens, and progestogens orchestrate differential aging patterns through organizational effects (permanent changes during critical developmental periods) and activational effects (reversible changes in adulthood) [83]. The lifelong influence of sex steroids begins in utero, establishing sex differences in neuroanatomy and neurochemistry that persist throughout the lifespan [83]. The distinct hormonal milieus of males and females interact with aging pathways in complex ways that modulate disease risk and longevity.

Methodological Framework for Sex-Specific Aging Research

Experimental Design Considerations

Robust investigation of sex differences requires intentional study design from conception through data analysis:

Model System Selection: Researchers must consider the appropriateness of model systems for studying sex differences. Murine models have revealed fundamental sex-specific responses, but translational validity requires verification in human studies. The use of genetically heterogeneous mice, as in the Interventions Testing Program, enhances translational potential [86].

Standardization of Drug Administration: Documentation of administration routes (food, water, injection, gavage) and precise dosage standardization (converted to parts per million) is essential for reproducibility and cross-study comparisons [86]. Treatment timing relative to life stage must be carefully considered, as interventions may have different effects when initiated in early, mid, or late life [86].

Longitudinal Assessment: Studies should incorporate multiple assessment timepoints to capture potential differences in the tempo of aging and treatment responses between sexes. The inclusion of weight change monitoring is particularly important, given the "significant correlations between weight loss and lifespan extension in male mice" [86].

Quantitative Measures of Sex-Specific Aging

Frailty Indices: Quantitative frailty assessment tools such as the FI34 (based on 34 health variables) provide sensitive measures of biological aging that surpass chronological age [88]. These indices increase non-linearly with advancing age and capture the cumulative burden of health deficits, offering a more nuanced picture of healthspan than mortality alone [88].

Molecular Biomarkers: Epigenetic clocks, proteomic signatures, and metabolomic profiles are emerging as sensitive indicators of biological aging. Studies consistently show sexual dimorphism in these biomarkers, with women typically displaying younger biological ages than chronological age-matched men [83]. However, the relationship between these molecular measures and functional decline differs between sexes.

Physical and Cognitive Function Assessments: Performance-based measures of physical function (grip strength, walking speed, endurance) and cognitive function reveal distinct patterns of decline in males and females, with the "paradox" of women outliving men despite greater functional limitations in later life [83].

Experimental Protocols for Investigating Sex Differences in Endocrine Aging

Protocol: Evaluating Sex-Specific Drug Responses in Aging Models

The following protocol outlines a comprehensive approach for investigating sexually dimorphic responses to anti-aging interventions:

Animal Model Selection:

• Utilize both male and female specimens in approximately equal numbers
• Consider genetically heterogeneous populations (e.g., ITP mouse models) to enhance translational relevance
• Include age-matched controls for both sexes
• Specify strain, housing conditions, and dietary status

Treatment Administration:

• Standardize drug dosages to parts per million (ppm) for cross-study comparisons
• Clearly document administration route (food, water, injection, gavage)
• Record precise age at treatment initiation and duration
• Monitor food intake and weight changes to control for caloric restriction effects

Assessment Schedule:

• Conduct baseline assessments prior to intervention
• Implement regular longitudinal monitoring of healthspan parameters
• Include molecular, physiological, and functional endpoints
• Perform terminal analyses at predetermined ages or health states

Data Analysis:

• Analyze sex-specific responses as a primary outcome, not a secondary analysis
• Employ appropriate statistical models to test for sex × treatment interactions
• Report effect sizes separately for males and females
• Power studies sufficiently to detect sex-specific effects

Protocol: Assessing Endocrine Aging Parameters

Longitudinal Hormone Profiling:

• Collect serial blood samples at consistent timepoints to account for diurnal variation
• Assay key hormones including GH, IGF-1, thyroid hormones, and sex steroids
• Consider pulsatile secretion patterns for hormones like GH
• Correlate hormone levels with functional outcomes separately by sex

Tissue-Specific Responses:

• Analyze hormone receptor expression in target tissues
• Assess signal transduction pathway activation
• Examine epigenetic modifications in endocrine pathways
• Compare tissue-specific responses between sexes

Research Reagent Solutions for Investigating Endocrine Aging

Table 3: Essential Research Tools for Sex-Specific Endocrine Aging Studies

Reagent/Category	Specific Examples	Research Applications	Sex-Specific Considerations
Hormone Assays	ELISA for GH, IGF-1, thyroid hormones, sex steroids	Quantifying endocrine profiles across lifespan	Reference ranges differ by sex; account for cyclicity in females
Receptor Inhibitors	Alk5 inhibitor (A5i), GH receptor antagonists	Modulating specific endocrine pathways	Response may differ by sex (e.g., OT+A5i effective only in males)
Longevity Compounds	Rapamycin, 17-alpha-estradiol, acarbose	Testing lifespan extension interventions	Document sexually dimorphic efficacy (e.g., rapamycin more effective in males)
Genetic Models	Ames dwarf mice, GH knockout models	Studying endocrine pathways in longevity	Effects may be sex-specific (e.g., Ames dwarf longevity shows sexual dimorphism)
Biomarker Panels	Frailty index components, epigenetic clocks	Assessing biological age	Validate separately in each sex; women show younger biological age
Drug Formulations	Chow-based, water-soluble, injectable compounds	Administration route standardization	Consider sex differences in metabolism and clearance

Integrating sex as a fundamental biological variable in aging research is no longer optional but essential for advancing geroscience. The evidence clearly demonstrates that males and females age differently at molecular, physiological, and clinical levels, and respond differently to interventions targeting aging processes. The endocrine system represents a particularly crucial domain for sex-specific investigation, given its central role in coordinating organismal aging and its inherent sexual dimorphism.

Future research priorities should include:

• Developing sex-specific biomarkers of aging and treatment response
• Elucidating the mechanisms underlying differential drug efficacy between sexes
• Designing targeted interventions that account for sex-specific aging pathways
• Increasing inclusion of both sexes in preclinical and clinical aging research
• Establishing standardized reporting requirements for sex-based analyses

By embracing these approaches, researchers can accelerate progress in geroscience and develop more effective, personalized interventions to extend healthspan and mitigate age-related disease for all populations.

Economic and Industry Challenges in Gerotherapeutic Development

Geroscience is an interdisciplinary field that investigates the biological mechanisms of aging to understand how they drive the onset and progression of chronic diseases and age-related conditions [89]. This paradigm shifts the focus from treating individual diseases to targeting the shared biological pathways of aging, potentially preventing or delaying multiple age-related conditions simultaneously [89]. The fundamental premise of geroscience is that aging represents the primary risk factor for most chronic diseases, including cardiovascular disease, cancer, and neurodegeneration [69]. By targeting core aging mechanisms, gerotherapeutic interventions aim to extend healthspan—the period of life spent in good health—rather than simply extending lifespan [69].

The emerging discipline of geromedicine translates geroscience principles into clinical applications, focusing on three overarching objectives: optimization of health in healthy individuals, prevention of disease progression in early stages, and interception of subclinical abnormalities before they manifest as overt disease [90]. This approach represents a transformative opportunity to address the growing global burden of age-related chronic conditions, which strain healthcare systems worldwide as populations age [10]. Despite promising scientific advances, the development of gerotherapeutics faces significant economic and industry challenges that must be addressed to realize their potential.

Quantitative Market Landscape for Gerotherapeutics

Current Market Assessment and Growth Projections

The gerotherapeutic landscape encompasses both the broader geriatric medicines market and the more specific anti-aging drugs segment. Understanding the quantitative dimensions of this market provides crucial context for investment decisions and strategic planning.

Table 1: Global Geriatric Medicines Market Projections

Market Segment	2024 Value	2025 Projected Value	2029 Projected Value	CAGR (2025-2029)
Overall Geriatric Medicines	$1,227.91 billion	$1,427.01 billion	$2,578.21 billion	15.9%
Anti-Aging Drugs	N/A	$79 million	$2.80 billion	27%

The substantial disparity between the overall geriatric medicines market and the specific anti-aging drugs segment reflects the nascent stage of targeted gerotherapeutic development [91] [92]. The significantly higher growth rate projected for anti-aging drugs (27% CAGR) compared to general geriatric medicines (15.9% CAGR) indicates anticipated acceleration in targeted gerotherapeutic development and adoption [91] [92].

Pipeline Composition and Regional Distribution

The current developmental pipeline for gerotherapeutics provides insights into research priorities and future market composition.

Table 2: Gerotherapeutic Development Pipeline and Regional Distribution

Parameter	Current Status	Projected 2040 Market Share
Number of Therapeutics in Development	>65 compounds worldwide	N/A
Leading Developer Types	Majority are small firms based in North America	N/A
Partnership Agreements	>55% signed in past two years	N/A
Total Investment (since 2018)	~USD 4 billion from private and public sources	N/A
Intellectual Property Activity	660+ recently filed/granted patents	N/A
European and Asia Pacific Market Share	N/A	>75%

The concentration of development activity among small firms, coupled with substantial recent partnership activity and investment, suggests a dynamic but fragmented early-stage market [91]. The anticipated regional shift toward European and Asian markets by 2040 highlights the global nature of the opportunity and potential variations in regulatory and reimbursement approaches [91].

Core Economic and Industry Challenges

Regulatory Pathway Uncertainties

A fundamental barrier to gerotherapeutic development is the absence of clear regulatory pathways for therapies that target aging biology rather than specific diseases.

Classification Dilemma: Aging is not formally classified as a disease by major health authorities such as the WHO, FDA, or EMA, creating a fundamental regulatory challenge for gerotherapeutic approval [69] [10]. Without this classification, therapies that target fundamental aging processes cannot obtain regulatory approval despite evidence that they may delay multiple age-related conditions [69]. The International Classification of Diseases (ICD-11) now includes "aging-associated decline in intrinsic capacity" as a classification, replacing the previous term "old age," which may provide a potential regulatory foundation for future approvals [10]. However, consensus on specific endpoints and measurement approaches remains elusive [10].

Endpoint Validation Challenges: Regulatory agencies typically require disease-specific endpoints for drug approval, whereas gerotherapeutics aim to affect broader outcomes such as healthspan extension, multimorbidity reduction, and functional preservation [56] [69]. There is a critical need for validated biomarkers that can serve as surrogate endpoints in clinical trials, including measures of therapeutic mechanisms (e.g., senescent cell burden), biological age (e.g., epigenetic clocks), and functional capacity (e.g., gait speed) [69]. Initiatives like the TAME (Targeting Aging with MEtformin) trial attempt to circumvent these challenges by using composite endpoints that track the delay of several chronic diseases simultaneously [56] [69]. The TAME trial, which will investigate metformin's effect on delaying the onset of age-related diseases, has received FDA approval for its design, potentially serving as a regulatory proof-of-concept [56].

Economic Constraints and Market Barriers

The development of gerotherapeutics faces significant economic headwinds that impact investment decisions and commercial viability.

High Development Costs and Long Timelines: The systemic nature of aging necessitates longer trial durations to demonstrate meaningful clinical benefits, substantially increasing development costs [69] [10]. Traditional clinical trials typically last 3-5 years, whereas geroscience trials may require significantly longer durations to capture effects on healthspan and multimorbidity development [69]. The TAME trial, for example, is planned as a six-year study [56], which exceeds the duration of most conventional therapeutic trials.

Intellectual Property and Exclusivity Challenges: Repurposed drugs such as metformin and rapamycin constitute promising gerotherapeutic candidates but face limited patent exclusivity, reducing commercial incentives for further development [69]. For novel compounds, the high costs of development coupled with regulatory uncertainty create significant barriers to investment [10]. A comprehensive scoping review identified economic uncertainties—including high development costs and limited incentives due to unclear regulatory environments—as one of four major barriers to gerotherapeutic development [10].

Unclear Reimbursement Models: Payor acceptance represents a critical economic hurdle, as current reimbursement systems are designed for disease-specific treatments rather than preventive interventions that target aging biology [69]. Without clear pathways to reimbursement, even approved gerotherapeutics may face market adoption challenges [10]. The absence of established health economic models for gerotherapeutics further complicates value assessment and pricing decisions [10].

Experimental Methodologies in Geroscience Research

Clinical Trial Designs for Gerotherapeutic Evaluation

Innovative clinical trial methodologies are essential for evaluating gerotherapeutics, given the limitations of conventional disease-specific approaches.

Composite Endpoint Trials: The TAME trial exemplifies this approach with a primary endpoint defined as time to incidence of any of five major age-related conditions (myocardial infarction, stroke, cancer, heart failure, mild cognitive impairment/dementia) or death [56]. This design acknowledges that gerotherapeutics may simultaneously affect multiple age-related conditions rather than targeting a single disease entity [56]. The trial will enroll 3,000 participants aged 65-80 who either have reduced walking speed or an existing age-related condition, focusing on a population at elevated risk for multimorbidity [56].

Functional and Resilience Outcomes: Some trials target specific geriatric syndromes or functional measures that reflect overall health status. For example, a phase IIb trial of Lomecel-B (allogeneic mesenchymal stem cells) in frailty used the 6-minute walk test as a primary endpoint, along with inflammatory biomarkers such as TNF-α [56]. This approach evaluates interventions based on their ability to improve functional capacity and reverse biological markers of aging, rather than focusing on disease-specific parameters [56].

Biomarker-Driven Trial Designs: Incorporating validated aging biomarkers as secondary endpoints or enrichment strategies can provide mechanistic insights and potentially shorten trial duration [69]. Measures such as epigenetic aging clocks, senescent cell burden, and inflammatory markers may help establish proof-of-concept for biological activity before long-term clinical benefits manifest [69]. The development of "Gerodiagnostics" represents an active area of research aimed at identifying biomarkers that can predict or monitor responses to gerotherapeutic interventions [56] [90].

Preclinical Assessment of Gerotherapeutics

Robust preclinical models are essential for prioritizing gerotherapeutic candidates before human trials.

Mammalian Lifespan Studies: Rodent models remain the gold standard for initial assessment of potential healthspan-extending interventions. Caloric restriction, for example, increases mean lifespan in mice by 10% to 40% compared with ad libitum feeding and favorably affects multiple cellular pathways implicated in aging [93]. Similarly, rapamycin increased median lifespan in mice by 249 days in females and 154 days in males [93]. These studies typically require careful control of genetic background, diet, and environmental conditions to ensure reproducible results.

Functional Assessment in Animal Models: Beyond lifespan, comprehensive healthspan assessment in preclinical models includes measures of physical function (e.g., grip strength, endurance), cognitive performance, metabolic health, and organ function [93]. For example, reducing senescent cell burden in animal models improves physical function, including grip strength and mobility, as well as cardiac ejection fraction [93]. These functional outcomes may more closely reflect the goals of gerotherapeutic interventions in humans.

Non-Human Primate Studies: Translation to non-human primate models provides a bridge to human trials, given their closer physiological and aging-related similarities to humans. Studies in species such as rhesus macaques can assess effects on age-related conditions including metabolic syndrome, cognitive decline, and cardiovascular function [94]. For example, one study investigated long-term effects of dasatinib plus quercetin on aging outcomes and inflammation in non-human primates, providing insights for senolytic clinical trial design [94].

Signaling Pathways and Molecular Mechanisms

Key Geroscience Signaling Pathways

This diagram illustrates the primary biological pathways targeted by gerotherapeutic interventions. The nutrient sensing pathway (blue nodes), particularly mTOR and AMPK signaling, regulates protein synthesis and autophagy in response to metabolic cues [93]. The cellular senescence pathway (yellow nodes) represents the accumulation of senescent cells that resist apoptosis and release pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP) [56] [93]. The mitochondrial function pathway (green nodes) encompasses declining NAD+ levels, reduced mitochondrial efficiency, and increased oxidative stress [10]. Gerotherapeutics such as rapamycin, metformin, senolytics, and NAD+ boosters target these specific mechanisms to address fundamental aging processes [56] [93].

Research Reagent Solutions Toolkit

Table 3: Essential Research Reagents for Geroscience Investigation

Reagent Category	Specific Examples	Research Applications
Senescence Detection	SA-β-Gal staining, p16INK4a antibodies, SASP factor ELISAs	Identification and quantification of senescent cells in tissues and experimental models
Epigenetic Clocks	DNA methylation arrays (Illumina Epic Array), computational aging clocks	Assessment of biological age and evaluation of gerotherapeutic effects on aging rate
Metabolic Assays	NAD+ quantification kits, mitochondrial membrane potential dyes, OCR/ECAR analyzers	Evaluation of mitochondrial function and cellular metabolism in response to interventions
Inflammation Panels	Multiplex cytokine arrays (TNF-α, IL-6, CRP), NF-κB pathway activation assays	Measurement of inflammatory status and SASP-related secretion profiles
Compound Libraries	Senolytic compounds (dasatinib + quercetin, fisetin), mTOR inhibitors, AMPK activators	Screening and validation of gerotherapeutic candidates in model systems

This toolkit represents essential reagents and assays for investigating fundamental aging mechanisms and evaluating potential gerotherapeutic interventions [56] [94] [93]. The selection of appropriate reagents depends on specific research questions, model systems, and the particular hallmarks of aging under investigation.

Strategic Recommendations for Overcoming Development Challenges

Regulatory Pathway Innovation

Establishing clear regulatory pathways represents the most critical challenge for gerotherapeutic development. Several strategic approaches could help address current limitations:

Adapt Existing Regulatory Models: Precedents from oncology drug development offer potential models for gerotherapeutic approval [69]. The FDA's tissue-agnostic approval approach in oncology, which focuses on molecular targets rather than anatomical origin, could be adapted for gerotherapeutics that target specific aging mechanisms across multiple tissue types [69]. Similarly, the FDA's Accelerated Approval Program, which permits authorization based on surrogate endpoints, could be applied to gerotherapeutics using validated aging biomarkers [69].

International Harmonization Efforts: Given the global nature of both pharmaceutical development and aging populations, international regulatory alignment is essential [10]. Collaborative initiatives between the FDA, EMA, and other major regulatory agencies could establish consistent requirements for gerotherapeutic development, reducing uncertainty and duplication of effort [10]. The high concordance rate (91-98%) between FDA and EMA decisions on marketing approvals provides a foundation for such alignment [56].

Endpoint Validation and Biomarker Development: Concerted efforts to validate functional endpoints and biological aging biomarkers are essential for creating feasible regulatory pathways [69] [10]. Measures such as gait speed, grip strength, and cognitive function have demonstrated predictive value for health outcomes and could serve as acceptable endpoints for gerotherapeutic trials [69]. Similarly, accelerated development and validation of molecular aging biomarkers (e.g., epigenetic clocks, senescent cell burden) could provide surrogate endpoints that enable shorter trial durations [69].

Economic Model Innovation

Novel economic approaches are needed to address the financial barriers to gerotherapeutic development:

Incentive Structures Similar to Orphan Drugs: The Orphan Drug Act of 1983 created incentives for rare disease drug development through extended exclusivity, tax credits, and market protections [69]. Similar mechanisms could stimulate industry investment in gerotherapeutics by improving the risk-reward profile of development programs [69]. Given that aging affects everyone, such incentives would need careful design to balance innovation with affordability.

Integrated Development and Reimbursement Strategies: Early engagement with payors and health technology assessment bodies could help align development programs with evidence requirements for reimbursement [10]. Innovative payment models based on health economic value, including potential healthcare cost savings from reduced multimorbidity, could support appropriate pricing and market access for demonstrated gerotherapeutics [89].

Public-Private Partnerships and Non-Traditional Funding: Given the significant scientific and regulatory uncertainties, collaborative funding models that distribute risk across multiple stakeholders may accelerate development [10]. Venture capital, philanthropic organizations, and government agencies could form consortia to support high-quality translational research and proof-of-concept trials [91]. The approximately $4 billion invested in anti-aging therapeutics since 2018 indicates substantial private interest that could be leveraged through such partnerships [91].

Geroscience represents a paradigm shift in how we approach age-related disease, moving from reactive treatment of individual conditions to proactive targeting of shared biological aging processes. Despite compelling scientific rationale and promising preclinical evidence, gerotherapeutic development faces significant economic and industry challenges, including regulatory pathway uncertainties, high development costs, intellectual property constraints, and unclear reimbursement models.

Overcoming these barriers will require coordinated efforts across multiple stakeholders, including researchers, regulatory agencies, payors, and industry participants. Strategic approaches include adapting existing regulatory frameworks from other therapeutic areas, validating novel endpoints and biomarkers that reflect aging biology, creating economic incentives similar to those for orphan drugs, and fostering international harmonization of requirements.

The potential benefits of successful gerotherapeutic development—extended healthspan, reduced healthcare costs, and maintained quality of life in late age—justify the substantial effort required to address these challenges. As the global population continues to age, transforming geroscience from promise to practice represents both an urgent medical need and a significant opportunity to redefine healthy aging.

Evaluating Clinical Evidence and the Future Landscape of Longevity Medicine

Geroscience posits that targeting the biological mechanisms of aging can simultaneously delay the onset of multiple age-related chronic diseases, thereby extending human healthspan [69] [95]. This represents a paradigm shift from traditional disease-specific approaches to a holistic strategy focused on the root causes of age-related decline. The global clinical trials market, valued at $59 billion in 2024, reflects the growing emphasis on developing novel therapeutic interventions, with gerotherapeutics emerging as a transformative frontier [96]. Despite robust preclinical evidence, the translation of gerotherapeutic agents into clinical practice faces significant challenges, primarily due to the lack of formal regulatory frameworks that recognize aging as a treatable condition [69] [63]. This review synthesizes the current landscape of gerotherapeutic clinical trials, evaluating key agents, their outcomes, methodological approaches, and the evolving regulatory environment that will shape their future development.

Current Regulatory and Trial Design Landscape

The development of gerotherapeutics operates within a complex regulatory environment that has not yet formally recognized aging as a therapeutic target. A comprehensive scoping review of literature from 2014 to 2024 identified no specific regulatory frameworks for gerotherapeutics, highlighting a significant translational barrier [63]. Four major impediments were identified: (1) lack of recognition of biological aging as a legitimate target for medical intervention; (2) absence of clear regulatory pathways for aging-focused therapies; (3) economic uncertainties, including high development costs and limited incentives; and (4) insufficient public and policy engagement [63].

Evolving Regulatory Paradigms

Regulatory agencies are gradually adapting to accommodate geroscience principles. The U.S. Food and Drug Administration (FDA) has shown willingness to consider innovative trial designs, as evidenced by its approval of the TAME (Targeting Aging with Metformin) trial protocol [69] [95]. TAME represents a landmark study designed to test whether metformin can delay the onset of multiple age-related conditions (cardiovascular disease, cancer, dementia) using a composite endpoint, rather than targeting a single disease [95]. This approach could establish a precedent for future gerotherapeutic approval pathways.

Potential regulatory models are emerging from other therapeutic areas. The FDA's tissue-agnostic drug development framework in oncology, which approves therapies based on molecular biomarkers rather than anatomical origin, offers a promising model for gerotherapeutics that target fundamental aging processes across multiple tissue types [69]. Similarly, the Accelerated Approval Program, which utilizes surrogate endpoints, could substantially reduce the time required for gerotherapeutic development [69].

Table 1: Key Regulatory Challenges and Potential Solutions for Gerotherapeutic Development

Challenge	Current Status	Potential Solutions
Aging Classification	Not recognized as a disease by WHO or regulatory agencies [69]	Stepwise recognition as a modifiable risk factor; precedent set by TAME trial [69]
Regulatory Pathways	No formal pathways for aging interventions [63]	Adaptation of oncology models (tissue-agnostic approval); Accelerated Approval Program [69]
Clinical Trial Endpoints	Reliance on disease-specific outcomes [95]	Composite endpoints (multimorbidity-free survival); functional measures; biomarker validation [69] [95]
Economic Barriers	High development costs; unclear reimbursement [69]	Incentives modeled on Orphan Drug Act; real-world evidence platforms [69]

Innovative Trial Designs and Endpoints

Geroscience trials require novel methodologies that differ fundamentally from conventional disease-specific trials. Key innovations include:

• Composite Endpoints: The TAME trial utilizes time to first occurrence of any age-related chronic disease (cardiovascular event, cancer, dementia) or mortality as its primary endpoint, acknowledging the multidimensional nature of aging [95].
• Functional and Resilience Measures: Metrics such as gait speed, grip strength, and intrinsic capacity (mobility, cognition, sensory, psychological, vitality) are increasingly recognized as valid surrogate endpoints that predict health outcomes in older adults [69].
• Biomarker Development: Intensive efforts are underway to identify and validate biomarkers of biological aging, including DNA methylation clocks, senescent cell burden, and inflammatory markers [69] [97]. These "gerodiagnostics" could enable patient stratification and treatment monitoring [95].

Key Gerotherapeutic Agents and Clinical Outcomes

Several promising gerotherapeutic agents are currently under investigation, ranging from repurposed existing drugs to novel compounds. These agents target various hallmarks of aging through distinct mechanisms of action.

Established and Emerging Geroprotectors

Table 2: Key Gerotherapeutic Agents, Mechanisms, and Clinical Evidence

Agent	Molecular Target/Mechanism	Key Clinical Evidence/Outcomes	Current Status
Metformin	AMPK activation; mitochondrial complex I inhibition; reduces cellular senescence [98] [95]	TAME trial (ongoing): composite endpoint of time to cardiovascular disease, cancer, dementia, or mortality [69] [95]	Repurposed; scoring 11/12 on gerotherapeutic scale [98]
Rapamycin (Sirolimus)	mTORC1 inhibition [99]	Preclinical: Extends lifespan in mice (median 17.4% in females, 16.6% in males); human studies show enhanced immune response to influenza vaccine in elderly [99]	Repurposed; intermittent dosing improves metabolic parameters [99]
Trametinib	MEK1/2 inhibitor; Ras-MEK-ERK pathway suppression [99]	Preclinical: Extends mouse lifespan (7.2% females, 10.2% males); reduces liver/spleen tumors; attenuates brain inflammation [99]	FDA-approved for oncology; emerging geroprotector evidence
GLP-1 Receptor Agonists	GLP-1 receptor activation; weight loss; anti-inflammatory effects [98] [100]	Reduced cardiovascular events and all-cause mortality in high-risk populations; ongoing trials for Alzheimer's (evoke, evoke+) [100]	Approved for T2D/obesity; longevity potential under investigation
SGLT2 Inhibitors	Renal glucose reabsorption inhibition [98]	Reduced oxidative stress, inflammation; improved cardiovascular and kidney outcomes; potential dementia risk reduction [98]	Approved for T2D; scoring 12/12 on gerotherapeutic scale [98]
Bisphosphonates	Bone resorption inhibition [98]	Observational studies show 15% mortality reduction after 2.8-year follow-up [98]	Approved for osteoporosis; scoring 11/12 on gerotherapeutic scale [98]

Combination Therapies

Emerging evidence suggests that targeting multiple aging pathways simultaneously may yield superior results. A landmark 2025 study demonstrated that the combination of rapamycin and trametinib produces an additive lifespan extension in mice, greater than either drug alone [99]. The combination therapy significantly reduced liver tumors in both sexes, blocked age-related increases in brain glucose uptake, and strongly reduced inflammation in multiple tissues (brain, kidney, spleen, muscle) and circulating pro-inflammatory cytokines [99]. This approach mirrors combination strategies successfully employed in oncology and suggests that targeting the interconnected network of aging pathways may represent the future of gerotherapeutic intervention.

Experimental Models and Methodologies

Preclinical Models and Dosing Protocols

Robust preclinical models are essential for evaluating potential gerotherapeutics. The following diagram illustrates the experimental workflow from a recent combination therapy study:

The mouse model study employed careful dose optimization to balance efficacy with tolerability. Trametinib was initially tested at doses ranging from 0.29 to 11.52 mg per kg of diet over 4 weeks, with 1.44 mg/kg identified as the optimal dose that effectively inhibited MEK activity without adverse effects on body weight or organ function [99]. Rapamycin was administered intermittently (alternate weeks) at 42 mg/kg, a regimen shown to improve metabolic health parameters while maintaining lifespan extension efficacy [99]. This intermittent approach may mitigate potential side effects associated with continuous mTOR inhibition while preserving geroprotective benefits.

Signaling Pathways Targeted by Gerotherapeutics

Gerotherapeutic agents target evolutionarily conserved nutrient-sensing and stress-response pathways that regulate aging processes. The following diagram illustrates the key molecular pathways and their interactions:

The insulin-IGF-mTORC1-Ras network represents a central signaling hub targeted by multiple gerotherapeutic agents. This network integrates nutrient availability with cellular growth, metabolism, and stress responses, with hyperactivation driving multiple aging phenotypes [99]. The demonstrated additivity of rapamycin (mTORC1 inhibitor) and trametinib (MEK inhibitor) highlights the therapeutic potential of concurrently targeting multiple nodes within this network to achieve enhanced geroprotection [99].

Research Reagent Solutions

Table 3: Essential Research Reagents for Gerotherapeutic Investigations

Reagent/Category	Specific Examples	Research Application	Function in Geroscience
Small Molecule Inhibitors	Trametinib (MEK1/2 inhibitor), Rapamycin (mTOR inhibitor)	Pathway inhibition studies; lifespan intervention experiments [99]	Target specific aging-associated pathways; establish proof-of-concept
Biomarker Assays	DNA methylation clocks (e.g., Horvath, Hannum), Senescence-associated beta-galactosidase, Proteomic panels	Biological age assessment; intervention monitoring [69] [97]	Quantify biological aging; provide surrogate endpoints for clinical trials
Metabolic Tracers	18F-FDG (for PET imaging), Stable isotope-labeled metabolites	In vivo assessment of glucose metabolism; metabolic flux analysis [99]	Monitor age-related metabolic changes; evaluate intervention effects
Cytokine Panels	Multiplex assays for IL-6, TNF-α, CRP, other SASP factors	Inflammation and senescence assessment [99] [97]	Quantify "inflammaging"; monitor response to senolytics/senomorphics
Animal Models	C3B6F1 hybrid mice, Progeroid models (e.g., Werner syndrome)	Lifespan studies; mechanistic investigations [99] [95]	Preclinical evaluation of gerotherapeutics; study accelerated aging

The field of gerotherapeutic clinical trials stands at a pivotal juncture, with compelling preclinical evidence supporting the feasibility of targeting fundamental aging processes to extend healthspan. Key challenges remain, including the establishment of validated biomarkers, regulatory pathways for composite endpoints, and economic models that incentivize development. The ongoing TAME trial represents a critical proof-of-concept study that may establish a precedent for future gerotherapeutic approval pathways. As regulatory agencies increasingly engage with the geroscience community, and as biomarkers and surrogate endpoints continue to mature, the next decade promises to witness significant advances in the clinical translation of gerotherapeutics. The ultimate goal remains not merely the extension of lifespan, but the compression of morbidity, enabling longer periods of healthy, productive life.

Longevity clinics have emerged as a significant, yet controversial, force at the intersection of clinical practice and geroscience research. These facilities, which operate globally in centers such as the United States, Switzerland, and the United Arab Emirates, respond to a growing demand for personalized, preventive healthcare aimed at extending healthspan—the period of life spent in good health [101] [102]. Their core premise involves using advanced diagnostics to create customized interventions targeting the fundamental mechanisms of aging. Within the specific context of endocrine aging research, these clinics represent a dual-edged sword: they generate unprecedented volumes of longitudinal human data on hormone function, metabolic health, and inflammatory processes, yet they often do so outside the rigorous validation frameworks required for scientific acceptance [101] [102] [103]. This whitepaper analyzes the tension between the data collection potential of longevity clinics and the perils associated with their current lack of scientific integration, offering a roadmap for harnessing their output to advance geroscience, particularly in understanding and modulating the endocrine system's role in aging.

The Promise: Unprecedented Data Generation for Geroscience

Longevity clinics are positioned to become powerful engines for data generation in aging research. Their operational model naturally facilitates the collection of deep, longitudinal phenotyping data that is often logistically and financially prohibitive in traditional academic settings.

Depth and Breadth of Biodata Collection

A typical client engagement at a longevity clinic involves a comprehensive battery of diagnostics that provide a multi-dimensional view of the aging process. The core data streams include [101] [102]:

• Genomic sequencing to establish genetic predispositions and polygenic risk scores.
• Multi-omics profiling (including epigenomic, proteomic, and metabolomic analyses) to capture dynamic molecular changes.
• Advanced imaging (such as whole-body MRI and coronary CT scans) to assess organ-specific aging and subclinical disease.
• Immune system assessments and microbiome analyses to evaluate systemic inflammation and gut health.
• Epigenetic testing, including DNA methylation clocks, to estimate biological age.

This multi-modal diagnostic approach generates a rich, high-dimensional dataset that captures the heterogeneity of human aging across multiple physiological systems.

Longitudinal Engagement and Patient Phenotyping

Unlike traditional clinical trials, which are typically limited in duration and scope, longevity clinics engage with clients across years or even decades [101]. This long-term tracking enables the observation of aging trajectories and intervention effects over biologically relevant timescales. Furthermore, clients are typically highly engaged participants who actively track, monitor, and reflect on their health metrics, potentially improving data quality and adherence to interventions [102]. This continuous monitoring paradigm captures subtle shifts in health status that are often missed in conventional study designs, potentially revealing early biomarkers of decline and predictors of age-related diseases before clinical manifestation.

Table: Diagnostic Capabilities of Longevity Clinics and Their Research Applications

Diagnostic Modality	Specific Metrics Collected	Potential Research Application in Endocrine Aging
Epigenetic Profiling	DNA methylation age, epigenetic clock scores	Tracking pace of biological aging in response to hormone interventions
Multi-omics Profiling	Metabolites, proteins, transcriptomes	Identifying novel biomarkers of hormonal decline and tissue sensitivity
Advanced Imaging	Body composition, organ fat deposition, vascular calcification	Quantifying metabolic tissue health and cardiovascular aging
Hormone Panels	Cortisol, DHEA, testosterone, estrogen, IGF-1	Mapping endocrine axis changes and response to replacement therapies
Continuous Monitoring	Glucose levels, heart rate variability, activity, sleep	Capturing real-time physiological responses to interventions

The Peril: Validation Gaps and Ethical Concerns

Despite their potential for data generation, most longevity clinics operate with significant scientific and ethical limitations that undermine the validity and generalizability of their findings while presenting substantial risks to patients and the field of geroscience.

Lack of Scientific Integration and Standardization

A fundamental issue is that longevity clinics are "not yet embedded within mainstream medical practice" and lack strong connections to academic geroscience [101] [102]. This disconnection creates a validation gap where interventions are deployed without robust clinical testing or peer-reviewed evaluation. The field suffers from a critical absence of standardized protocols for both measurement and intervention, making it difficult to compare results across clinics or aggregate data for meaningful analysis [101] [102]. The tools frequently used, such as biological age calculators based on epigenetic or telomeric measurements, are often presented to clients as definitive scores despite ongoing debate about their precision, clinical utility, and interpretation [102]. This lack of methodological rigor extends to the interpretation of complex multi-omics profiles, which are frequently delivered to clients without clear, actionable, or scientifically-supported meaning, potentially leading to confusion and inappropriate health decisions [102].

Unvalidated Interventions and Direct Patient Risks

Many clinics offer expensive interventions that lack sufficient clinical validation, ranging from nutraceutical cocktails and hormone optimization programs to more experimental therapies like stem-cell infusions and peptide injections [101] [102]. The commercial incentives of the private clinic model can sometimes overcome scientific rationale, leading to the promotion of unproven or potentially risky therapies. A stark example cited during the DOC 2025 conference involved a patient who developed a ballooning meningioma after being placed on a complex regimen of supplements and hormones by a longevity practitioner; the tumor stopped growing only after all supplements were discontinued [103]. Further testing revealed that supposedly pure compounds purchased from clinics sometimes contain contaminants, including psychoactive substances and herbicides, highlighting serious quality control issues in an under-regulated market [103].

Ethical and Accessibility Challenges

The high cost of longevity clinic services—typically ranging from €10,000 to over €100,000 annually—creates significant healthcare inequity, limiting access to wealthy individuals while excluding populations most at risk for premature aging [101] [102]. This socioeconomic bias in data collection means the generated datasets may not represent the true heterogeneity of human aging, potentially limiting the generalizability of any findings. The regulatory landscape is equally problematic; many clinics position themselves as wellness providers rather than medical facilities, thereby escaping rigorous medical oversight [102] [103]. This "wellness grey zone" enables practices that might not withstand the scrutiny of institutional review boards or hospital ethics committees, creating accountability gaps [102].

Table: Risks and Limitations in Current Longevity Clinic Practices

Risk Category	Specific Limitations	Impact on Geroscience Research
Methodological	Non-standardized protocols, unvalidated biomarkers	Data incompatibility, irreproducible results
Clinical	Unproven interventions, inadequate practitioner training	Patient harm, discredits legitimate aging research
Ethical	High costs, regulatory arbitrage, lack of transparency	Exacerbates health inequities, creates biased datasets
Scientific	Disconnection from academic research, lack of controlled design	Inability to establish causality, limited publication value

Experimental Frameworks for Validation

To bridge the gap between data collection and scientific validation, longevity clinics must adopt more rigorous experimental frameworks that can generate clinically and scientifically meaningful evidence.

Methodologies for Biomarker Validation

The validation of aging biomarkers requires a systematic approach. Research from institutions like Northwestern University's Human Longevity Laboratory employs multi-system assessments that integrate epigenomic profiling with functional measures of cardiovascular, metabolic, and neurocognitive health [104]. A critical methodological consideration is the establishment of standardized operating procedures for sample collection, processing, and analysis to minimize technical variability. For epigenetic clocks, this includes consistent bisulfite conversion protocols, normalization methods, and pre-processing algorithms. Functional biomarkers, such as those assessing endocrine function, require strict adherence to timing of collection (e.g., cortisol awakening response) and standardized challenge tests (e.g., glucose tolerance tests) to ensure reliable data. Longitudinal tracking of these biomarkers alongside clinical endpoints allows for the determination of their predictive validity for age-related conditions and their responsiveness to interventions.

Evaluating NAD+ Boosting Interventions

Research on NAD+ boosters like NMN (Nicotinamide Mononucleotide) and Resveratrol exemplifies a more validated approach to longevity interventions. Recent clinical trials have employed randomized, placebo-controlled designs with specific dosing regimens (typically 100-1,250 mg daily for NMN) and objective outcome measures [104]. These studies track not only blood NAD+ levels but also functional endpoints including:

• Skeletal muscle metabolism assessed via insulin signaling assays
• Physical performance measured by 6-minute walk tests
• Patient-reported outcomes captured through standardized instruments like the SF-36 survey The synergy between NMN and Resveratrol has been quantified in murine models, showing NAD+ increases of 1.59x in heart tissue and 1.72x in skeletal muscle within six hours of administration [104]. This multi-level assessment strategy—from molecular biomarkers to functional outcomes—provides a template for how clinics could structure their intervention studies to generate scientifically valid evidence.

Diagram: Integration Pathway for Clinic Data and Academic Validation

Essential Research Reagents and Methodologies

To enhance the scientific rigor of longevity research, both clinics and academic institutions require standardized research reagents and methodologies. The following toolkit outlines essential resources for conducting validated aging research, with particular relevance to endocrine aging.

Table: Research Reagent Solutions for Endocrine Aging Research

Reagent/Category	Specific Examples	Research Application in Endocrine Aging
Epigenetic Clocks	HorvathClock, PhenoAge, GrimAge	Quantifying biological age acceleration relative to chronological age in hormone-sensitive tissues
Senescence Assays	SA-β-Galactosidase kit, p16INK4a immunohistochemistry, SASP cytokine panels	Detecting cellular senescence in endocrine tissues (e.g., pancreas, thyroid, gonads)
Metabolic Probes	Seahorse XF Analyzer reagents, stable isotope tracers, continuous glucose monitors	Assessing mitochondrial function and metabolic flexibility in response to hormone interventions
Hormone Assays	ELISA kits for cortisol, DHEA-S, IGF-1; LC-MS/MS for sex steroids	Precise quantification of hormone levels and circadian rhythmicity
Omics Platforms	DNA methylation arrays, RNA-seq kits, mass spectrometry panels	Multi-layer molecular profiling of endocrine aging pathways
Animal Models	Senescence-accelerated mice (SAMP), tissue-specific knockout models	Testing interventions targeting hormone signaling pathways in aging

Pathway to Integration: A Framework for Collaboration

For longevity clinics to fulfill their potential as contributors to geroscience, a deliberate pathway toward integration with academic research is essential. This requires structural changes in how clinics operate and how the research community engages with them.

Standardization and Methodological Harmonization

The single most important step toward integration is the development and adoption of standardized protocols for both measurement and intervention [101] [102]. This includes consensus on:

• Core biomarker panels that should be collected across all clinics and studies
• Standardized operating procedures for sample collection, processing, and analysis
• Common data elements and reporting frameworks to ensure interoperability
• Validated outcome measures for assessing healthspan interventions

Organizations like the Longevity Biotechnology Association are already working toward such standards, but broader adoption across the clinical ecosystem is needed [105]. Methodological harmonization would enable data pooling and meta-analyses, dramatically increasing statistical power for identifying subtle but meaningful effects.

Partnership Models and Data Sharing Frameworks

Productive collaboration between clinics and academic institutions requires formal partnership models that address incentives, data governance, and publication rights. Potential models include:

• Embedded research programs where academic researchers work within clinic settings
• Pragmatic clinical trials conducted through clinic networks with academic oversight
• Data trusts that facilitate secure, ethical sharing of anonymized clinic data with researchers

These partnerships should be structured to generate peer-reviewed publications that undergo rigorous scientific scrutiny, gradually building an evidence base for the most promising interventions [102]. The extensive, longitudinal datasets collected by clinics could be anonymized and shared with academic consortia, where advanced analytical approaches, including artificial intelligence and machine learning, could identify patterns of aging trajectories and intervention responses that would be impossible to detect in smaller, shorter-duration studies [101] [102].

Regulatory Clarity and Professional Training

The current "wellness grey zone" in which many clinics operate is unsustainable for credible scientific progress [102]. Clear regulatory frameworks distinguishing wellness services from medical interventions would help establish appropriate oversight mechanisms. Simultaneously, the development of accredited training programs in longevity medicine would help establish professional standards and ensure practitioners have the appropriate qualifications to interpret complex biomarkers and administer interventions [103]. Such programs would help address incidents like the one reported by Dr. Nicole Sirotin, who encountered a urologist interpreting cardiology tests at a longevity clinic [103].

Diagram: Integration Pathway From Data to Clinical Translation

Longevity clinics stand at a crossroads, representing both a significant opportunity and a substantial risk to the field of geroscience. Their ability to collect deep, longitudinal phenotyping data from motivated participants offers unprecedented potential to understand human aging, particularly the complex endocrine changes that occur throughout the lifespan. However, this potential remains largely unrealized due to methodological limitations, unvalidated interventions, and insufficient integration with the broader scientific community. The path forward requires a concerted effort to establish standards, foster collaboration, and create appropriate regulatory frameworks. By embracing these changes, longevity clinics could transition from their current peripheral status to become valuable contributors to the scientific understanding of aging, ultimately helping to translate basic research into interventions that extend healthspan for broader populations. For researchers focused on endocrine aging, engaged collaboration with rigorously conducted clinic-based research could provide the human data necessary to validate mechanistic findings from model systems and accelerate the development of interventions that preserve hormonal function and metabolic health throughout the lifespan.

Geroscience posits that targeting the biological hallmarks of aging can extend healthspan and reduce the burden of age-related chronic diseases. Geroprotectors are compounds that modulate these fundamental aging processes, offering a proactive, systemic approach to intervention rather than treating individual diseases reactively [78]. The societal impact of aging—the primary risk factor for major chronic conditions like cardiovascular disease, cancer, and neurodegenerative disorders—has accelerated research into these therapeutic candidates [78] [106].

This analysis provides a comprehensive technical assessment of geroprotector mechanisms and efficacy, framed within endocrine aging research. It examines computational discovery platforms, molecular pathways, combination therapies, and the evolving regulatory landscape to guide researchers and drug development professionals in advancing this transformative field.

Computational Approaches for Geroprotector Discovery

The chemical diversity and polypharmacological requirements of geroprotectors make computational screening essential for prioritizing candidates. Several machine learning platforms have emerged to systematically evaluate compounds targeting aging mechanisms.

PASS GERO Platform

The PASS GERO web application implements an in silico assessment of potential geroprotectors using an improved naïve Bayes classifier. The model predicts 117 aging-related biological activities with high accuracy (average Invariant Accuracy of Prediction = 0.967 under cross-validation) [78]. The system analyzes molecular structure through Multilevel Neighborhoods of Atoms (MNA) descriptors trained on over 1,482,930 compounds. Validation studies demonstrate strong concordance with known geroprotectors; for rapamycin, it correctly predicted mTOR inhibition and autophagy induction, while for metformin, it accurately identified AMPK activation [78].

Table 1: Performance Metrics of Computational Screening Platforms

Platform	Algorithm Type	Prediction Targets	Accuracy Metrics	Training Set Size
PASS GERO	Naïve Bayes classifier	117 aging-related activities	IAP: 0.967	1,482,930 compounds
Structure-based ML (COCONUT)	Decision Tree, SVM, KNN	Geroprotector classification	AUC: SVM 0.73, KNN 0.64, DT 0.62	206 known geroprotectors
AI-Driven Repurposing (MassAITC)	Recurrent neural networks, temporal convolutional networks	Biological age reduction from clinical data	Multi-modal biomarker integration	Mass General Brigham Biobank

Structure-Based Machine Learning Screening

Recent research has applied multiple machine learning classifiers to identify natural product candidates with geroprotective potential from the Collection of Open Natural Products (COCONUT) database containing 695,133 molecules [107]. Using 206 known geroprotectors for training, three models—Decision Tree (DT), Support Vector Machine (SVM), and K-Nearest Neighbours (KNN)—achieved modest accuracy with AUC values of 0.62, 0.73, and 0.64 respectively. The application of all three classifiers identified 1,488 candidate molecules meeting leadlikeness criteria, now available in a publicly accessible database [107].

Molecular Mechanisms and Signaling Pathways

Geroprotectors target conserved nutrient-sensing networks and aging hallmarks through multiple endocrine and metabolic pathways.

Insulin-IGF-mTORC1-Ras Network

The insulin-IGF-mTORC1-Ras nutrient-sensing network represents a central regulatory axis in aging, with extensive crosstalk between its branches [99]. Rapamycin (sirolimus), an established geroprotector, directly inhibits mTORC1 signaling, while trametinib (Mekinist) targets the Ras-MEK-ERK pathway. Recent preclinical evidence demonstrates that combined inhibition produces additive benefits for healthspan and lifespan extension in mice [99].

The endocrine hormone glucagon has emerged as another significant modulator of this network. Research led by Dr. Jennifer Stern at the University of Arizona revealed that glucagon signaling is critical for healthspan improvements stimulated by calorie restriction [24]. Mice lacking the glucagon receptor showed shortened lifespan and failed to benefit from calorie restriction. Notably, glucagon agonism robustly inhibits mTOR signaling, connecting this pancreatic hormone to conserved aging pathways [24].

Table 2: Key Geroprotector Mechanisms and Molecular Targets

Geroprotector Class	Representative Compounds	Primary Molecular Targets	Aging Hallmarks Addressed	Experimental Evidence
mTOR inhibitors	Rapamycin, everolimus	mTORC1 complex	Deregulated nutrient sensing, loss of proteostasis	Lifespan extension in mice (median 16-18%), improved immune function [99]
AMPK activators	Metformin, AICAR	AMP-activated protein kinase	Mitochondrial dysfunction, deregulated nutrient sensing	50% lifespan extension in C. elegans, TAME trial ongoing [78] [107]
Senolytics	Dasatinib + quercetin, fisetin	Senescent cell anti-apoptotic pathways	Cellular senescence, chronic inflammation	Improved cardiovascular function in aged mice [107]
Sirtuin activators	Resveratrol, NAD+ precursors	SIRT1-7 deacetylases	Epigenetic alterations, genomic instability	Activation of sirtuin pathways, improved metabolic health [78]
Ras-MEK-ERK inhibitors	Trametinib, selumetinib	MEK1/2 kinases	Deregulated nutrient sensing, genomic instability	Lifespan extension in mice (median 7-10%), reduced tumors [99]
Glucagon agonists	Retatrutide, Novo Nordisk analogs	Glucagon receptor	Deregulated nutrient sensing, mitochondrial dysfunction	mTOR pathway inhibition, metabolic improvements in mice [24]

Pathway Integration in Endocrine Aging

The interplay between geroprotectors and endocrine signaling represents a crucial mechanism in aging modulation. Calorie restriction, a non-pharmacological intervention that extends lifespan across species, works partly through glucagon signaling, which in turn inhibits mTOR pathway activity [24]. This connection positions glucagon-based therapies as promising geroprotective candidates, with several glucagon agonists already in clinical trials for metabolic diseases [24].

Experimental Models and Methodologies

Preclinical Efficacy Assessment

Rigorous preclinical models are essential for evaluating geroprotector efficacy before human translation. A recent landmark study published in Nature Aging systematically assessed the geroprotectors trametinib and rapamycin individually and in combination in C3B6F1 hybrid mice [99].

Experimental Protocol:

• Dose Optimization: Mice received trametinib at 0.29, 0.58, 1.44, 2.88, or 11.52 mg per kg diet for 4 weeks. Doses ≥1.44 mg/kg effectively inhibited Ras-MEK-ERK signaling without adverse effects, establishing the optimal dose for longevity studies [99].
• Lifespan Study Design: Treatment began at 6 months of age with continuous trametinib (1.44 mg/kg) and intermittent rapamycin (42 mg/kg in alternate weeks) either alone or in combination [99].
• Healthspan Metrics: Researchers assessed tumor incidence, brain glucose uptake (via FDG-PET), tissue inflammation (cytokine levels), and circulating inflammatory markers [99].

Key Findings:

• Trametinib alone extended median lifespan by 7.2% in females and 10.2% in males
• Rapamycin alone extended median lifespan by 17.4% in females and 16.6% in males
• Combination treatment produced additive effects, significantly outperforming either monotherapy
• Combination therapy reduced liver tumors in both sexes and spleen tumors in males
• Strong anti-inflammatory effects were observed across brain, kidney, spleen, and muscle tissues [99]

Research Reagent Solutions

Table 3: Essential Research Reagents for Geroprotector Investigation

Reagent/Category	Specific Examples	Research Application	Key Function in Experiments
MEK inhibitors	Trametinib (Mekinist)	Ras pathway inhibition	Specific MEK1/2 inhibition at 1.44 mg/kg diet in mice [99]
mTOR inhibitors	Rapamycin (sirolimus)	mTORC1 complex blockade	Intermittent dosing (42 mg/kg diet) extends lifespan [99]
Glucagon agonists	Novo Nordisk long-acting analogs, Retatrutide	Glucagon signaling studies	Testing mTOR inhibition and metabolic benefits [24]
Senescence markers	p16INK4a, p21, SA-β-gal	Senescent cell identification	Quantifying senolytic drug effects on tissue senescence [107]
Pathway activity assays	pERK1/2, pS6, pAMPK	Target engagement verification	Western blot analysis of liver, kidney, spleen tissues [99]
Metabolic tracers	18F-FDG	Brain glucose uptake measurement	PET imaging to assess age-related metabolic changes [99]
Inflammation panels	IL-6, TNF-α, IFN-γ multiplex assays	Systemic inflammation monitoring	Measuring age-related inflammation in plasma and tissues [99]

Regulatory Landscape and Translation Challenges

The development pathway for geroprotectors faces unique regulatory hurdles that distinguish them from conventional therapeutics.

Current Regulatory Environment

A comprehensive scoping review of regulatory environments for gerotherapeutics analyzed 3,780 publications but identified no specific regulatory frameworks for geroscience interventions [63] [108]. The review highlighted four major barriers:

• Lack of recognition of biological aging processes as legitimate targets for medical intervention
• Absence of clear regulatory pathways to evaluate aging-focused therapies
• Economic uncertainties, including high development costs and limited incentives in unclear regulatory environments
• Insufficient public and policy engagement to build support for aging interventions [63] [108]

Biomarker Development and Clinical Trial Design

The absence of validated biomarkers of aging presents a significant challenge for evaluating geroprotector efficacy in clinical trials. The TAME (Targeting Aging with Metformin) trial represents an innovative approach by using time to incidence of any age-related chronic disease as a composite endpoint [107]. Ongoing research aims to establish robust biomarkers including epigenetic clocks, proteomic profiles, and clinical biochemistry composites derived from routine laboratory measurements [106].

Future Directions and Clinical Translation

Combination Therapies

The additive benefits observed with trametinib and rapamycin combination therapy highlight the potential of targeting multiple aging pathways simultaneously [99]. This polypharmacological approach acknowledges the network nature of aging processes and may yield greater efficacy than single-target interventions.

Drug Repurposing Strategies

AI-driven drug repurposing initiatives, such as the MassAITC project analyzing the Mass General Brigham Biobank, aim to identify geroprotective effects in already-approved medications [106]. This approach offers substantial advantages by building on existing safety profiles and significantly reducing development timelines.

Integration with Endocrine Research

The emerging connection between glucagon signaling and aging pathways opens new avenues for geroprotector development [24]. As glucagon-based therapies advance for metabolic diseases, their potential application for healthy aging warrants dedicated investigation within endocrine aging research frameworks.

The comparative analysis of geroprotectors reveals a rapidly advancing field transitioning from single-target interventions to combination approaches that address the network complexity of aging. Computational screening platforms, validated preclinical models, and evolving biomarker development provide the essential toolkit for researchers targeting fundamental aging mechanisms. The integration of endocrine perspectives, particularly through glucagon signaling and its connection to conserved longevity pathways, offers promising directions for future therapeutic development. Overcoming regulatory challenges and establishing validated efficacy endpoints will be crucial for translating these findings into clinical applications that extend human healthspan.

Geroscience, the interdisciplinary field dedicated to understanding the biological mechanisms linking aging and age-related diseases (ARDs), presents a paradigm shift for modern medicine. Rather than treating individual diseases reactively, geroscience aims to target the fundamental hallmarks of aging to extend healthspan—the period of life spent in good health. The clinical application of this science, increasingly termed geromedicine, represents a transformative approach to healthcare [109]. This transition is becoming increasingly urgent as demographic shifts place unprecedented pressure on healthcare systems globally. By 2030, those aged 60 and over will constitute one-sixth of the global population, rising to one-fifth by 2050 [10]. Singapore, for example, is projected to achieve "super-aged" status by 2030, with over a quarter of its population being 65 or older [110]. This whitepaper delineates the pathways, challenges, and strategic frameworks for integrating geroscience into mainstream medical practice, with a specific focus on endocrine aging research.

Current Landscape and Regulatory Hurdles

A critical analysis of the current regulatory environment reveals significant barriers to the adoption of gerotherapeutics. A recent scoping review of 3,780 publications screened for inclusion found no existing regulatory frameworks specifically designed for gerotherapeutics [63] [10]. The analysis identified four major barriers:

• Lack of Recognition: The biological processes of aging are not universally recognized as valid targets for medical intervention [63] [10].
• Absence of Clear Pathways: There is a notable absence of clear regulatory pathways to evaluate therapies focused on aging itself, as opposed to specific diseases [63] [10].
• Economic Uncertainties: High development costs and limited incentives, exacerbated by unclear regulatory environments, create significant economic barriers [63] [10].
• Insufficient Engagement: Public and policy understanding and support for geroscience is currently insufficient [63] [10].

A pivotal challenge is that aging itself lacks formal disease status from major regulatory bodies like the FDA and EMA. However, a significant opening has emerged with the World Health Organization's International Classification of Diseases, 11th Revision (ICD-11), which now includes "ageing-associated decline in intrinsic capacity" (code MG2A) as a classified entity [10] [110]. This provides a potential foundation for regulatory approval of interventions aimed at mitigating age-related functional decline.

Table 1: Key Barriers to Geroscience Clinical Integration

Barrier Category	Specific Challenge	Potential Impact
Regulatory Status	Aging not classified as a disease	Prevents approval for "anti-aging" indications
	Lack of geroscience-specific pathways	Forces disease-specific development models
Methodological	Lack of validated biomarkers	Hinders measurement of therapeutic efficacy
	Need for novel clinical trial designs	Requires demonstration of multi-morbidity risk reduction
Economic & Policy	High development costs & uncertain ROI	Deters pharmaceutical investment
	Lack of public & policy engagement	Limits funding and healthcare system readiness

Foundational Pillars of Geromedicine

The emerging discipline of geromedicine is structured around three hierarchical objectives that distinguish it from traditional, disease-focused medical specialties [109]:

• Optimization: In ostensibly healthy individuals, geromedicine uses a systems biology approach—integrating gerodiagnostics—to model health trajectories and guide the application of gerotherapeutics to proactively slow, arrest, or reverse aging-related processes.
• Prevention: This focuses on identifying early, subtle disruptions (potential disease forerunners) within healthy populations to prevent progression to overt pathology.
• Interception: This emphasizes biomarker-based detection of subclinical abnormalities (e.g., latent infections, incipient atheroma, early-stage osteopenia) to allow timely interventions that intercept disease before it becomes clinically apparent.

This framework is operationalized through precision geromedicine, which entails the application of personalized, biomarker-driven strategies to optimize health and extend healthspan based on an individual’s unique genetic, molecular, clinical, and behavioral profile [109] [110].

Gerodiagnostics: Biomarkers and Aging Clocks

A cornerstone of precision geromedicine is gerodiagnostics, which involves quantifying the rate of biological aging. A genetics-based perspective on aging, utilizing genomic and epigenomic techniques, allows for the establishment of objective associations between genotype and aging phenotype [110]. This has led to the development of "epigenetic clocks," which analyze DNA methylation patterns to estimate biological age [110].

The value of these aging clocks is expanding from mere biomarker status to tools for therapeutic target discovery. Building on recently published aging clocks, researchers can reestablish a significant proportion of known drug targets by identifying clock-associated genes, highlighting their potential for target identification [111]. These clocks can also be applied in clinical trials for population stratification and treatment monitoring [111].

Table 2: Research Reagent Solutions for Geroscience Investigation

Research Reagent / Tool	Primary Function / Application in Geroscience
Senolytics (e.g., Dasatinib + Quercetin)	Selectively clear senescent cells; used in clinical trials for conditions like premature aging in childhood cancer survivors [112].
mTOR Inhibitors (e.g., Rapamycin)	Target altered nutrient sensing pathways; shown to extend lifespan in model organisms by inhibiting mTOR signaling [24].
Glucagon Receptor Agonists	Investigated for mimicking benefits of calorie restriction; shown to inhibit mTOR and improve metabolic function in aging mice [24].
NAD+ Boosters	Target mitochondrial dysfunction, a key hallmark of aging, to improve cellular energy metabolism [10].
Long-acting Hormone Therapies	Used to study mid-life hormonal shifts (menopause/andropause) and their impact on the biological aging clock [113] [114].
AI/Deep Learning Platforms	Identify novel drug targets and design potential therapeutics using large biological datasets; companies like Insilico Medicine pioneer this approach [112].

Experimental and Methodological Frameworks

Target Discovery and Validation

A promising strategy is the identification of dual-purpose targets that address both aging and age-related diseases simultaneously. This approach can mitigate risk and improve the time- and cost-efficiency of drug development [111]. The hallmarks of aging provide a conceptual framework for identifying such targets. For example, the hallmark "altered nutrient sensing" can be investigated by targeting pathways like mTOR.

Experimental Protocol: Evaluating Glucagon Agonism as a Gerotherapeutic

• Objective: To determine if a long-acting glucagon agonist can recapitulate the healthspan benefits of calorie restriction.
• Model System: Aging mice (e.g., C57BL/6 strain).
• Intervention: Treatment with a long-acting glucagon agonist (e.g., compounds from Novo Nordisk) vs. vehicle control.
• Methodology:
  • Administer the agonist via subcutaneous injection at a defined frequency.
  • Monitor metabolic parameters (e.g., glucose tolerance, energy expenditure) longitudinally.
  • Assess lifespan as a primary endpoint.
  • Analyze tissue samples post-mortem to measure activity in target pathways, such as mTOR signaling inhibition, via Western blot or immunohistochemistry [24].

Clinical Trial Design for Gerotherapeutics

Innovative trial designs are essential to demonstrate the efficacy of gerotherapeutics. Given that aging is a systemic process affecting multiple tissues, trial endpoints must move beyond single-disease outcomes.

Experimental Protocol: Combination Therapy for Endocrine Aging

• Objective: To evaluate the synergistic effects of tirzepatide (an obesity medication) and menopausal hormone therapy (MHT) on weight loss and metabolic health in postmenopausal women.
• Study Design: Real-world, retrospective cohort study using electronic medical records.
• Cohorts: Postmenopausal women using (1) tirzepatide plus MHT concurrently, and (2) tirzepatide alone.
• Primary Endpoint: Percentage of total body weight loss over a median duration of 18 months.
• Secondary Endpoints: Proportion of patients achieving at least 20% total body weight loss; changes in biomarkers of cardiometabolic health [114].

Signaling Pathways and Mechanisms

A key mechanistic insight in endocrine aging involves the relationship between mid-life hormonal changes, the gasotransmitter nitric oxide (NO), and vascular health. This network can be conceptualized as a "human biological aging clock" [113].

Diagram 1: The NO-Mediated Endocrine Aging Pathway. This diagram illustrates the proposed cascade where mid-life hormonal decline leads to a deficiency in Nitric Oxide, triggering a chain of events from microvascular dysfunction to systemic chronic inflammation and age-related disease [113].

The diagram above shows the cascade from mid-life hormonal shifts to systemic aging. This pathway is a prime target for interception. For instance, early sex hormone replacement therapies, aligned with the "timing hypothesis," have been correlated with reductions in all-cause mortality [113]. Furthermore, lifestyle interventions like exercise and dietary nitrate consumption can boost NO production, offering a non-pharmacological strategy to modulate this pathway [113].

Implementation Science and Healthcare Integration

Models of Care: Longevity Clinics and Public Health

A tangible manifestation of geroscience's clinical adoption is the rise of longevity clinics. These clinics, located in the US, Switzerland, UAE, and other countries, offer personalized, preventive health plans using advanced diagnostics like genomic testing and multi-omics profiling [101]. They represent a shift towards proactive healthcare. However, a significant issue is that they are "not yet embedded within mainstream medical practice," often operating outside conventional systems and lacking strong connections to academic geroscience [101]. This can lead to the marketing of expensive, unvalidated interventions, risking equity and public trust.

A more integrative model is exemplified by Singapore's Healthier SG initiative. This nationwide strategy empowers citizens to manage their health proactively through a network of private general practitioners who provide free screenings, vaccinations, and subsidized assessments aimed at preventing ARDs [110]. This public health framework creates an ideal platform for implementing evidence-based gerodiagnostics and gerotherapeutics at a population level.

Strategic Pathways for Adoption

To successfully integrate geroscience into mainstream medicine, a multi-pronged approach is essential:

• Regulatory Innovation: Stakeholders must collaborate to develop clear regulatory pathways. This could involve leveraging existing ICD-11 codes for "decline in intrinsic capacity" and creating new endpoints for clinical trials that measure multi-morbidity reduction or healthspan extension [63] [10] [110].
• Biomarker Standardization: Global efforts to validate and standardize biomarkers of aging, such as epigenetic clocks and measures of senescent cell burden, are critical for quantifying intervention efficacy [63] [111].
• Educational and Policy Reform: Building literacy in geroscience among clinicians, researchers, and the public is fundamental. Concurrently, policy support is needed to incentivize drug development and ensure equitable access to validated therapies [63] [10].
• Academic-Clinic Collaboration: Longevity clinics should be integrated with academic research centers to ensure that interventions are evidence-based and that collected data contributes to scientific discovery [101].

The integration of geroscience into mainstream medicine, while facing significant regulatory, methodological, and economic hurdles, is not only feasible but imperative. By embracing the pillars of precision geromedicine—optimization, prevention, and interception—and leveraging advances in gerodiagnostics and dual-purpose target discovery, the healthcare landscape can evolve from a reactive, disease-centric model to a proactive, health-preserving system. The journey requires concerted global collaboration among researchers, clinicians, regulators, and policymakers to build the necessary frameworks. Success in this endeavor promises to redefine healthcare for an aging global population, shifting the focus from merely extending lifespan to maximizing healthspan and functional vitality throughout the human life course.

The geroscience hypothesis posits that targeting the biological mechanisms of aging can simultaneously delay the onset and reduce the burden of multiple age-related diseases. While monotherapies have demonstrated promise in extending healthspan in model organisms, the inherent complexity and multifactorial nature of aging suggest that combinatorial approaches will be necessary for maximal therapeutic efficacy. Emerging evidence indicates that single genetic or pharmacological interventions are relatively inefficient at comprehensively addressing the pleiotropic processes driving aging [115]. The field is therefore transitioning toward combination therapies that simultaneously target multiple aging pathways, personalized approaches that account for individual biological and contextual factors, and systematic public health integration to translate these advances into population-wide impact. This evolution mirrors developments in other complex therapeutic areas like oncology and cardiometabolic disease, where combination regimens have yielded substantial improvements in patient outcomes. Within endocrine aging research, this paradigm shift offers particular promise for addressing the complex interplay between hormonal pathways, metabolic regulation, and aging processes.

Combination Therapies: Mechanisms and Evidence

Theoretical Frameworks for Intervention Interactions

The conceptual foundation for combination therapies in aging research rests on two complementary topographies for understanding aging manifestations [115]. The first builds a hierarchy from the perspective of high-throughput-omics, where tiers reflect the flow of biological information from genome to transcriptome, to proteome, to metabolome, and ultimately to the aging phenome. Within this framework, interventions can target multiple features either within the same level or across different levels. The second approach organizes hierarchy based on "manifestations of aging," including the established Hallmarks of Aging. In this view, aging originates from nonenzymatic interactions between transient metabolites and slow-turnover, information-dense macromolecules, which subsequently propagate to produce hallmark processes and ultimately physiological manifestations [115]. Combination interventions can target different elements within and between these levels, with the potential for additive, synergistic, or compensatory interactions.

Interaction analysis measures the phenotypic effects of two or more simultaneous aging interventions, with outcomes assessed through various manifestations of aging including molecular hallmarks, specific age-associated diseases, frailty, and mortality [115]. This approach not only identifies potentially effective combinations but also reveals mechanistic insights about relationships between aging pathways.

Experimental Evidence from Model Organisms

Substantial evidence supporting combination therapies has emerged from studies in C. elegans and D. melanogaster, where genetic and pharmacological interventions can be systematically combined. Research demonstrates that simultaneous manipulation of nutrient-sensing pathways can produce dramatic lifespan extensions exceeding what either intervention achieves independently [115].

Table 1: Selected Examples of Dual Intervention Lifespan Extension in C. elegans

Intervention I	Intervention I Pathway	% Lifespan Increase (I)	Intervention II	Intervention II Pathway	% Lifespan Increase (II)	% Lifespan Increase (Combination)
daf-2(e1370)	Deregulated nutrient sensing	169%	rsks-1(ok1255)	Deregulated nutrient sensing	20%	454%
daf-2(e1370)	Deregulated nutrient sensing	111%	Rapamycin	Deregulated nutrient sensing	26%	187%
cyc-2.1	Mitochondrial dysfunction	64%	daf-2	Deregulated nutrient sensing	114%	252%
DR (limiting bacterial food)	Deregulated nutrient sensing	37%	daf-2(e1370)	Deregulated nutrient sensing	105%	205%

These findings illustrate several important principles. First, combinations targeting different nodes within the same pathway (e.g., insulin/IGF-1 and TOR/S6K signaling) can produce strongly synergistic effects [115]. Second, interventions targeting distinct hallmarks (e.g., mitochondrial dysfunction combined with nutrient sensing manipulation) can also produce greater-than-additive benefits, suggesting interactions between different aging mechanisms [115]. The conservation of these pathways across species offers promise for translation to mammalian systems and eventually humans.

Signaling Pathway Interactions in Aging

The insulin/IGF-1 signaling (IIS) and TOR pathways represent central regulators of aging that interact through multiple nodes. Understanding these interactions provides a rationale for targeted combination approaches.

Diagram 1: IIS and TOR Pathway Interactions. This diagram illustrates the complex crosstalk between insulin/IGF-1 signaling (IIS) and TOR pathways, showing key regulatory nodes for potential combination interventions. Negative regulators are indicated with T-bar arrowheads.

The diagram illustrates several key interaction points that inform combination strategies. First, the negative feedback from S6K to IRS creates a compensatory mechanism that can limit the efficacy of single-pathway interventions [115]. Second, both pathways converge on functional outputs like autophagy, suggesting potential synergistic effects when targeted together. These interactions help explain why combining IIS and TOR manipulations often produces synergistic lifespan extension in model organisms.

Personalized Geroscience: From Population to Precision Medicine

The Precision Geromedicine Framework

Geromedicine represents an emerging discipline dedicated to enhancing health and extending healthspan by targeting fundamental biological processes of aging throughout the adult life course [90]. This field operates through three hierarchical objectives: optimization of health in apparently healthy individuals; prevention of disease by identifying early disruptions; and interception of subclinical abnormalities before they manifest as overt pathology [90]. The framework emphasizes that geromedicine should not focus solely on older or diseased populations but should encompass young adults, initiating interventions well before age-related disease onset.

Precision geromedicine applies personalized, biomarker-driven strategies to optimize health, extend healthspan, and prevent age-related diseases tailored to an individual's unique genetic, molecular, clinical, social, environmental, and behavioral profile [90]. This approach integrates multi-omics data, digital health monitoring, and systems biology to predict aging trajectories, detect early deviations from healthy aging, and implement gerotherapeutics that enhance resilience and promote longevity.

Gerodiagnostics and Biomarker Development

The implementation of precision geroscience depends critically on the development and validation of robust gerodiagnostics - biomarkers capable of quantifying biological aging processes and responses to interventions. These biomarkers span multiple levels of biological organization, from molecular to physiological to functional measures.

Table 2: Categories of Gerodiagnostics for Precision Aging Interventions

Category	Specific Biomarkers	Application in Precision Geroscience
Molecular Biomarkers	Epigenetic clocks, proteomic signatures, metabolomic profiles	Quantification of biological age, prediction of disease risk, monitoring intervention efficacy
Cellular Biomarkers	Senescence-associated beta-galactosidase, telomere length, mitochondrial function	Assessment of specific hallmarks of aging, target engagement for senolytics
Physiological Biomarkers	Cardiorespiratory fitness, vascular stiffness, cognitive function	Integrated measure of system-level aging, functional correlation with molecular changes
Digital Biomarkers	Physical activity patterns, sleep quality, cognitive performance	Continuous monitoring of health status, real-world assessment of interventions
Multi-omic Integration	Combined epigenetic, proteomic, metabolomic data	Comprehensive biological age estimation, personalized intervention targeting

The convergence of these biomarker approaches enables a systems biology perspective on aging, moving beyond single biomarkers to integrated signatures that more accurately reflect the multidimensional nature of aging processes [90].

Stratification Approaches for Personalized Interventions

Personalized geroscience requires frameworks for stratifying individuals according to their aging trajectory, vulnerability to specific aging-related conditions, and likely response to interventions. This stratification integrates multiple data types to guide intervention selection.

Diagram 2: Personalized Geroscience Workflow. This diagram outlines the integrated data collection and analysis pipeline for developing personalized aging interventions, from initial assessment through targeted implementation.

The workflow emphasizes several critical aspects of personalized geroscience. First, multi-modal data collection provides a comprehensive basis for assessment. Second, integrated analytics transform this data into actionable classifications of aging trajectory, dominant mechanisms, and specific risks. Finally, this analysis informs a personalized intervention plan that may include targeted therapies, precision lifestyle recommendations, and customized monitoring protocols [90].

Experimental Design and Methodological Considerations

Protocol for Combinatorial Intervention Testing

Rigorous evaluation of combination therapies requires standardized methodologies that can detect both efficacy and potential interactions between interventions. The following protocol outlines a systematic approach for testing combinatorial aging interventions:

• Single Intervention Dose-Response Characterization: Before combination testing, establish dose-response curves for individual interventions using appropriate metrics (e.g., lifespan, healthspan biomarkers, molecular endpoints). Identify submaximal doses for combination studies to avoid ceiling effects.

• Experimental Design Matrix: Implement a full factorial design that tests each intervention individually and in combination, plus appropriate controls. This design enables detection of synergistic, additive, or antagonistic interactions.

• Longitudinal Assessment Schedule: Implement regular assessment timepoints for molecular, physiological, and functional endpoints throughout the intervention period. Include baseline measurements before intervention initiation.

• Multi-level Endpoint Analysis: Assess outcomes across multiple biological levels:

  • Molecular: Omics analyses, target engagement biomarkers
  • Cellular: Senescence markers, mitochondrial function, stem cell activity
  • Physiological: Organ function, body composition, metabolic parameters
  • Functional: Physical performance, cognitive function, disease incidence
  • Overall: Lifespan, healthspan, compression of morbidity

• Interaction Analysis: Quantify interactions using appropriate statistical models (e.g., factorial ANOVA, response surface methodology). Distinguish between additive and synergistic effects through formal interaction terms.

This systematic approach enables comprehensive characterization of combination effects while controlling for potential confounders and identifying optimal intervention pairings.

Research Reagent Solutions for Geroscience Studies

The methodological advancement of geroscience depends on specialized research reagents and tools designed specifically for aging research applications.

Table 3: Essential Research Reagents for Combination Therapy Studies

Reagent Category	Specific Examples	Research Applications
Senescence Detection	SA-β-Gal staining, p16ᴵᴺᴷ⁴ᴀ reporters, SASP factor antibodies	Identification and quantification of senescent cells in tissues and cultures
Pathway Modulators	Rapamycin (TOR inhibitor), metformin (mitochondrial complex I inhibitor), STF-11843 (NAD+ booster)	Targeted manipulation of specific aging pathways for mechanistic studies
Genetic Tools	Tissue-specific inducible cre systems, RNAi libraries, CRISPR/Cas9 vectors	Spatiotemporal control of gene expression for pathway interrogation
Biosensors	FRET-based nutrient sensors, ROS detection probes, mitochondrial membrane potential dyes	Real-time monitoring of cellular parameters relevant to aging processes
Animal Models	Progeroid mice, senescence-accelerated models, tissue-specific aging models	Accelerated testing of interventions, tissue-specific aging mechanisms
Omics Platforms	Epigenetic clock assays, proteomic arrays, metabolomic profiling	Comprehensive molecular profiling for biological age assessment

These specialized reagents enable sophisticated interrogation of aging mechanisms and combination therapy effects across multiple biological scales, from molecular pathways to organismal outcomes.

Public Health Integration and Implementation Science

Frameworks for Health System Transformation

The translation of geroscience discoveries into population health impact requires systematic rethinking of healthcare delivery and public health infrastructure. A new healthcare paradigm proposes shifting from reactive disease management to proactive approaches targeting biological aging [116]. This transformation involves three progressive models: the existing system that reacts to disease after symptoms appear; intervening once age-related damage begins using new tools like senolytics and rapalogs; and preventing aging-related damage before it starts through continuous health maintenance [116].

The Public Health 4.0 framework specifically addresses healthy longevity through four domains of action [117]:

• Research: Calls for increased investment in geroscience, the exposome, social capital, and implementation science
• Education and Training: Encourages integration of aging and longevity into core curricula with interdisciplinary learning
• Practice: Advocates for redesigning prevention systems using life-course approaches and age-friendly environments
• Policy and Advocacy: Promotes shifting aging policy from burden-based models to proactive, asset-framed approaches

This comprehensive framework recognizes that extending healthspan requires coordinated action across multiple sectors and systems, with public health institutions playing a central convening and leadership role [117].

Longevity Clinics: Promise and Challenges

Longevity clinics have emerged as one potential delivery model for personalized aging interventions, offering advanced diagnostic services and customized intervention plans [101]. These clinics typically employ genomic testing, advanced imaging, and multi-omics profiling to develop personalized recommendations that may include lifestyle interventions, nutritional guidance, and in some cases, experimental therapies [101].

While these clinics represent an innovative approach to healthcare, several significant challenges remain. Most operate outside conventional medical systems and lack connections to academic geroscience, potentially leading to marketing of expensive interventions without sufficient clinical validation [101]. Program costs ranging from €10,000 to over €100,000 per year limit access to wealthy individuals, creating equity concerns [101]. Additionally, many clinics lack standardized protocols, and tools such as biological age calculators often lack demonstrated accuracy or clear clinical value [101].

Responsible integration of longevity clinics into mainstream healthcare would require greater collaboration with academic researchers, adoption of standardized protocols, increased transparency, regulatory clarity, and development of more scalable, affordable models [101].

Regulatory and Policy Considerations

The development of regulatory pathways for gerotherapeutics represents a critical barrier to clinical translation. Current regulatory frameworks are disease-based, while gerotherapeutics target fundamental aging processes that influence multiple conditions simultaneously [10]. This mismatch creates significant challenges for drug development and approval.

Recent developments offer potential pathways forward. The International Classification of Diseases (ICD-11) now includes "aging-associated decline in intrinsic capacity" (MG2A) as a classification, replacing the previous term "old age" [10]. This shift provides a potential regulatory foundation for future gerotherapeutic approvals by establishing a recognized target for interventions aimed at mitigating age-related declines. Similarly, sarcopenia has been assigned an ICD-10-CM code (M62.84), though consensus on measurement remains challenging [10].

Additional barriers identified through a comprehensive scoping review include [10]:

• Lack of recognition of biological aging processes as legitimate targets for medical intervention
• Absence of clear regulatory pathways to evaluate aging-focused therapies
• Economic uncertainties, including high development costs and limited incentives
• Insufficient public and policy engagement with geroscience

Addressing these barriers will require coordinated efforts among researchers, regulators, industry partners, and patient advocates to develop appropriate evaluation frameworks and reimbursement pathways.

The future of geroscience lies in successfully integrating combination therapies, personalized approaches, and public health implementation. Combination interventions targeting multiple aging mechanisms simultaneously offer the potential for greater efficacy than monotherapies, particularly given the interconnected nature of aging pathways. Personalized approaches recognize the substantial heterogeneity in aging trajectories and responses to interventions, requiring advanced diagnostics and stratification strategies. Public health integration ensures that scientific advances translate into broad population impact through reformed healthcare systems, evidence-based policies, and attention to equity considerations.

Realizing this integrated future will require addressing several critical challenges. Methodologically, the field needs standardized protocols for evaluating combination therapies and validated biomarkers for assessing biological aging. Translationally, regulatory pathways must adapt to accommodate interventions targeting aging processes rather than specific diseases. Implementationally, delivery models must balance innovation with evidence, accessibility with sustainability. Despite these challenges, the continued convergence of geroscience, precision medicine, and public health offers unprecedented potential to extend healthspan and transform the experience of aging.

Conclusion

The geroscience approach to endocrine aging represents a paradigm shift, moving from treating individual age-related diseases to targeting their shared biological underpinnings. Research has firmly established that endocrine pathways, such as those involving glucagon and reproductive hormones, are potent levers for extending healthspan. Promising gerotherapeutics are emerging, yet the field must overcome significant challenges—including the development of validated biomarkers, clear regulatory pathways, and inclusive clinical trial designs—to realize its full potential. Future success hinges on global collaboration, standardized methodologies, and a concerted effort to integrate these pioneering concepts into public health frameworks, ultimately aiming to increase human healthspan and reduce the burden of age-related disease.

References

• 1. From geroscience to precision geromedicine [https://www.sciencedirect.com/science/article/abs/pii/S0092867425002843]
• 2. Human Aging and Age-Related Diseases: From Underlying ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12221391/]
• 3. Targeting the hallmarks of aging: mechanisms and ... [https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1631578/full]
• 4. Aging and aging-related diseases: from molecular ... [https://www.nature.com/articles/s41392-022-01251-0]
• 5. The physiology of endocrine systems with ageing [https://pubmed.ncbi.nlm.nih.gov/30017799/]
• 6. and Endocrinology Aging [https://www.biomedcentral.com/collections/enag]
• 7. Hormones may have therapeutic potential to... | Endocrine Society [https://www.endocrine.org/news-and-advocacy/news-room/2025/hormones-may-have-therapeutic-potential-to-prevent-wrinkles-hair-graying]
• 8. Mapping Human Organ Aging: From Cellular Mechanism ... [https://www.genesispub.org/mapping-human-organ-aging-from-cellular-mechanism-to-clinical-applications-for-precision-medicine-in-healthspan-to-lifespan]
• 9. Targeting the hallmarks of aging: mechanisms and therapeutic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12259695/]
• 10. Advancing Geroscience Research – A Scoping Review of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12310402/]
• 11. The Nine Hallmarks of Aging: How Do They Affect Your ... [https://www.healthylongevity.clinic/blog/nine-hallmarks-of-aging]
• 12. Comprehensive human proteome profiles across a 50-year ... [https://www.sciencedirect.com/science/article/abs/pii/S0092867425007494]
• 13. Endocrine-exocrine miR-503-322 drives aging-associated ... [https://www.nature.com/articles/s41467-025-57615-x]
• 14. Metabolaging: a new geroscience perspective linking ... [https://www.sciencedirect.com/science/article/pii/S0026049525000277]
• 15. Endocrine Controls of Skin Aging [https://pubmed.ncbi.nlm.nih.gov/?term=KL+2900/3-1/DFG[Grants+and+Funding]&sort=date&sort_order=desc]
• 16. Defining an ageing-related pathology, disease or syndrome [https://link.springer.com/article/10.1007/s11357-024-01315-9]
• 17. Dietary restriction impacts health and lifespan of ... [https://www.nature.com/articles/s41586-024-08026-3]
• 18. Fasting-mimicking diet causes hepatic and blood markers ... [https://www.nature.com/articles/s41467-024-45260-9]
• 19. Fasting: Molecular Mechanisms and Clinical Applications - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3946160/]
• 20. 热量摄入而非食物摄入量是热量限制抗衰老作用的关键因素。 [https://suppr.wilddata.cn/browses/detail/pubmed/34493691]
• 21. Calorie restriction for enhanced longevity: The role of novel ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9036399/]
• 22. Effects of the periodic fasting-mimicking diet on health ... [https://pubmed.ncbi.nlm.nih.gov/38287649/]
• 23. 降低熱量攝取如何透過三種細胞訊息路徑達到抗老化功效 ... [https://coachdenys.com/anti-aging-with-calorie-restriction-cellular-pathways/]
• 24. University of Arizona scientist links calorie restriction ... [https://medicine.arizona.edu/news/2025/university-arizona-scientist-links-calorie-restriction-glucagon-and-healthy-aging]
• 25. U of A scientists link calorie restriction, glucagon, healthy aging [https://research.arizona.edu/news/u-scientists-link-calorie-restriction-glucagon-healthy-aging]
• 26. Glucagon Physiology - Endotext - NCBI Bookshelf - NIH [https://www.ncbi.nlm.nih.gov/books/NBK279127/]
• 27. Unlocking longevity with GLP-1: A key to turn back the clock? [https://www.sciencedirect.com/science/article/abs/pii/S0378512224001233]
• 28. Glucagon receptor signaling is indispensable for ... - PubMed [https://pubmed.ncbi.nlm.nih.gov/40993467/]
• 29. Glucagon receptor signaling is indispensable for the ... [https://link.springer.com/article/10.1007/s11357-025-01899-w]
• 30. Glucagon-like peptide-1 receptor: mechanisms ... - Nature [https://www.nature.com/articles/s41392-024-01931-z]
• 31. Postmortem tissue biomarkers of menopausal transition [https://www.nature.com/articles/s41380-025-03177-9]
• 32. Biomarkers of female reproductive aging in ... [https://www.sciencedirect.com/science/article/abs/pii/S1568163725002478]
• 33. Recapping TMS 2025: Evolving Insights and Future ... [https://www.pharmacytimes.com/view/recapping-tms-2025-evolving-insights-and-future-directions-in-menopause-care]
• 34. After Decades of Misunderstanding, Menopause is Finally ... [https://medicine.yale.edu/news-article/after-decades-of-misunderstanding-menopause-is-finally-having-its-moment/]
• 35. Artificial intelligence-derived retinal age gap as a marker ... [https://www.nature.com/articles/s41746-025-01699-8]
• 36. Biomarkers of female reproductive aging in ... [https://pubmed.ncbi.nlm.nih.gov/40998176/]
• 37. HHS Advances Women's Health, Removes Misleading ... [https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html]
• 38. Caloric Restriction and Aging: Studies in Mice and Monkeys [https://pmc.ncbi.nlm.nih.gov/articles/PMC3734859/]
• 39. Calorie Restriction in Mammals and Simple Model Organisms [https://pmc.ncbi.nlm.nih.gov/articles/PMC4026914/]
• 40. Modern animal models for biomedical research ... - STAT News [https://www.statnews.com/2025/11/07/animal-research-mice-models-invaluable-biomedical-discovery/]
• 41. Glucagon-like peptide 1 prevents reactive oxygen species- ... [https://pubmed.ncbi.nlm.nih.gov/20448207/]
• 42. Cell重磅综述：新增两个！衰老标志扩展到十四个 [https://news.bioon.com/article/66588e30279a.html]
• 43. Endocrine markers of aging [https://www.sciencedirect.com/science/article/abs/pii/053155658890040X]
• 44. Neuroendocrine ageing [https://pubmed.ncbi.nlm.nih.gov/7595179/]
• 45. An Expert Consensus Statement on Biomarkers of Aging for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11979094/]
• 46. 2025 Biomarkers of Aging Conference [https://www.agingconsortium.org/conference-home]
• 47. Biomarkers of Aging 2025 Conference [https://alamarbio.com/biomarkers-of-aging-2025-conference/]
• 48. 2025 Biomarkers of Aging Conference [https://biomodal.com/events/2025-biomarkers-of-aging-conference/]
• 49. ‐guided Geroscience of FDA‐approved drugs to target... repurposing [https://pmc.ncbi.nlm.nih.gov/articles/PMC9009114/]
• 50. Guided FDA-Approved Drugs Repurposed to Target Aging [https://esmed.org/MRA/mra/article/view/5138]
• 51. : update on mechanisms... | Nature Reviews Metformin Endocrinology [https://www.nature.com/articles/s41574-023-00833-4?error=cookies_not_supported&code=a0d3e0c4-f49f-4697-80ad-2261b74714d7]
• 52. Rapamycin for longevity: the pros, the cons, and future ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/]
• 53. Frontiers | A Critical Review of the Evidence That Metformin Is... [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.718942/full]
• 54. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists - ANA 2025 [https://2025.myana.org/cg_session/glucagon-like-peptide-1-glp-1-receptor-agonists-the-ultimate-antiaging-gateway-drug/]
• 55. What is the clinical evidence to support off-label rapamycin ... [https://www.aging-us.com/article/206300/text]
• 56. Challenges in developing Geroscience trials [https://www.nature.com/articles/s41467-023-39786-7]
• 57. Senolytic Interventions for Type 2 Diabetes [https://www.mdpi.com/2673-4540/6/6/48]
• 58. Coming of age: could obesity-related metabolic ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1622107/full]
• 59. Senolytics: Potential for Alleviating Diabetes and Its ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8234500/]
• 60. Could senolytics change the treatment landscape of age- ... [https://touchendocrinology.com/podcast/senolytics-age-related-diseases/]
• 61. Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI [https://www.ncbi.nlm.nih.gov/books/NBK551568/]
• 62. GLP-1 and GIP: Magic bullet for musculoskeletal diseases? [https://www.sciencedirect.com/science/article/pii/S2090123225006629]
• 63. Advancing Geroscience Research – A Scoping Review of ... [https://www.sciencedirect.com/science/article/pii/S1279770725001629]
• 64. Biomarkers of aging for the identification and evaluation ... [https://www.sciencedirect.com/science/article/pii/S0092867423008577]
• 65. Clinical Trials in Longevity Science: Where We Stand in 2025 [https://decodeage.com/en-ae/blogs/news-ageing/clinical-trials-in-longevity-science-where-we-stand-in-2025?srsltid=AfmBOoosUZD7QKV8NQgDOlRt_xuhVNQfsmGSVJkmhNyFyghtsRtcmtXO]
• 66. TAME - Targeting Aging with Metformin [https://www.afar.org/tame-trial]
• 67. Comparison of two data collection processes in clinical studies [https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-14-7]
• 68. Comparing categorical variables in clinical and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8992732/]
• 69. Overcoming the barriers to unlock gerotherapeutics - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12486172/]
• 70. Acting on ethics and governance of aging research [https://www.sciencedirect.com/science/article/abs/pii/S1471491423000643]
• 71. Validation of biomarkers of aging - PMC - PubMed Central - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC11090477/]
• 72. Ranking Biomarkers of Aging by Citation Profiling and ... [https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.686320/full]
• 73. Potential Noninvasive Biomarkers to Assess the Aging ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12558625/]
• 74. Patterns of Biomarkers Predict How Well People Age ... [https://www.bu.edu/sph/news/articles/2017/patterns-of-biomarkers-predict-how-well-people-age-risks-of-age-related-disease/]
• 75. Data Gaps that Bottleneck Aging Biomarker Discovery [https://norn.group/writing/data-gaps-that-bottleneck-aging-biomarker-discovery]
• 76. Clinical Trials in Longevity Science: Where We Stand in 2025 [https://decodeage.com/en-ae/blogs/news-ageing/clinical-trials-in-longevity-science-where-we-stand-in-2025?srsltid=AfmBOopllTBe_YIvpNSl4SBHJytKZIWAAS9sIXP1rHb-Lo8lLDs7Wmq2]
• 77. Comparative biology and non-traditional approaches for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11009194/]
• 78. In Silico Assessment of Potential Geroprotectors [https://pmc.ncbi.nlm.nih.gov/articles/PMC12470084/]
• 79. A scoping review of knowledge translation in strengthening ... [https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-025-01567-7]
• 80. Geroprotectors: A role in the treatment of frailty [https://www.sciencedirect.com/science/article/pii/S0047637419300363]
• 81. A new clinical age of aging research [https://www.sciencedirect.com/science/article/pii/S1043276024002236]
• 82. From precision interventions to precision health [https://www.nature.com/articles/s41467-025-60395-z]
• 83. Sex differences in biological aging with a focus on human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8118651/]
• 84. Workshop: Sex Differences Impacting Human Health Across ... [https://www.nia.nih.gov/research/dab/workshops/workshop-sex-differences-impacting-human-health-across-lifespan]
• 85. Sex-Specific Effects Found in New Anti-Aging Therapy for ... [https://www.aging-us.com/news-room/sex-specific-effects-found-in-new-anti-aging-therapy-for-elderly-mice]
• 86. Sex-specific insights into drug-induced lifespan extension ... [https://www.nature.com/articles/s41514-025-00229-w]
• 87. The physiology of endocrine systems with ageing - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC6089223/]
• 88. Quantitative measures of healthy aging and biological age [https://pmc.ncbi.nlm.nih.gov/articles/PMC4440677/]
• 89. What is Geroscience? [https://www.afar.org/what-is-geroscience-2]
• 90. Geromedicine: A new journal for the clinical application of ... [https://sciexplor.com/articles/Geromedicine.2025.0001]
• 91. Anti-Aging Drugs Market Industry Trends and Global ... [https://finance.yahoo.com/news/anti-aging-drugs-market-industry-112800435.html]
• 92. Global Geriatric Medicines Industry Outlook 2025-2029 [https://www.openpr.com/news/4279978/global-geriatric-medicines-industry-outlook-2025-2029-market]
• 93. Geroscience: A Translational Review [https://pubmed.ncbi.nlm.nih.gov/40773213/]
• 94. 2025 GeroScience Outstanding Publication Award Winners [https://link.springer.com/journal/11357/updates/27786122]
• 95. Challenges in developing Geroscience trials - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10439920/]
• 96. Отчет о размере и доле рынка клинических испытаний ... [https://www.gminsights.com/ru/industry-analysis/clinical-trials-market]
• 97. The Future of Aging Research [https://www.cedars-sinai.org/discoveries/the-future-of-aging-research.html]
• 98. Age Management Medicine News: June 2025 - #2 [https://agemed.org/e-journal/age-management-medicine-news-june-2025-2/]
• 99. The geroprotectors trametinib and rapamycin combine ... [https://www.nature.com/articles/s43587-025-00876-4]
• 100. Are GLP-1s the first longevity drugs? [https://www.nature.com/articles/s41587-025-02932-1]
• 101. The Rise of Longevity Clinics: Promise, Risk, and ... [https://www.aging-us.com/news-room/the-rise-of-longevity-clinics-promise-risk-and-the-future-of-aging]
• 102. Longevity clinics: between promise and peril - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12606959/]
• 103. DOC 2025 VIDEO: The High-Stakes Gamble of Longevity ... [https://doc.health/doc-2025-video-the-high-stakes-gamble-of-longevity-medicine-where-breakthrough-science-meets-the-wild-west/]
• 104. Clinical Trials in Longevity Science: Where We Stand in 2025 [https://decodeage.com/en-ae/blogs/news-ageing/clinical-trials-in-longevity-science-where-we-stand-in-2025?srsltid=AfmBOor0LC_rnJTwYDe_lRrzBcxNO3CcZ7s3AuDjDuoj_OT-7RkbT-iN]
• 105. Longevity Advances to Watch in 2025 [https://blog.a4m.com/20219-2/]
• 106. AI-Driven Drug Repurposing to Identify Potential ... [https://massaitc.org/2025/09/29/ai-driven-drug-repurposing-to-identify-potential-geroprotectors/]
• 107. Structure-based machine learning screening identifies natural ... [https://jcheminf.biomedcentral.com/articles/10.1186/s13321-025-01058-5]
• 108. Advancing Geroscience Research - A Scoping Review of ... [https://pubmed.ncbi.nlm.nih.gov/40706485/]
• 109. Geromedicine: A new journal for the clinical application of ... [https://www.sciexplor.com/articles/Geromedicine.2025.0001]
• 110. Towards Precision Geromedicine in Singapore [https://link.springer.com/article/10.1007/s11357-025-01686-7]
• 111. From clock to clock: Therapeutic target discovery for aging ... [https://www.sciencedirect.com/science/article/pii/S156816372500217X]
• 112. New aging research and drug discovery strategies in 2025 [https://aurahealth.ch/aging-research-drug-discovery/]
• 113. The human biological clock and aging—a comprehensive ... [https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1658952/full]
• 114. Combination of obesity medication tirzepatide and ... [https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/castaneda-press-release]
• 115. interventions in Combinatorial - PMC aging [https://pmc.ncbi.nlm.nih.gov/articles/PMC11194689/]
• 116. New Vision for Healthcare Focuses on Preventing Aging- ... [https://www.aging-us.com/news-room/new-vision-for-healthcare-focuses-on-preventing-aging-related-diseases]
• 117. Advancing Public Health 4.0: Introducing the Healthy ... [https://aspph.org/advancing-public-health-4-0-introducing-the-healthy-longevity-framework/]